EP1745800A1 - Novel blt2-mediated disease, and blt2 binding agent and compound - Google Patents
Novel blt2-mediated disease, and blt2 binding agent and compound Download PDFInfo
- Publication number
- EP1745800A1 EP1745800A1 EP05734600A EP05734600A EP1745800A1 EP 1745800 A1 EP1745800 A1 EP 1745800A1 EP 05734600 A EP05734600 A EP 05734600A EP 05734600 A EP05734600 A EP 05734600A EP 1745800 A1 EP1745800 A1 EP 1745800A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- blt2
- compound
- methyl
- biphenyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 202
- 201000010099 disease Diseases 0.000 title claims abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 29
- 230000001404 mediated effect Effects 0.000 title claims abstract description 20
- 239000011230 binding agent Substances 0.000 title claims description 11
- 101001017969 Homo sapiens Leukotriene B4 receptor 2 Proteins 0.000 claims abstract description 124
- 102100033375 Leukotriene B4 receptor 2 Human genes 0.000 claims abstract description 123
- 150000003839 salts Chemical class 0.000 claims abstract description 42
- 239000012453 solvate Substances 0.000 claims abstract description 39
- 229940002612 prodrug Drugs 0.000 claims abstract description 38
- 239000000651 prodrug Substances 0.000 claims abstract description 38
- 230000027455 binding Effects 0.000 claims abstract description 34
- 208000017520 skin disease Diseases 0.000 claims abstract description 28
- 230000002265 prevention Effects 0.000 claims abstract description 24
- 206010025323 Lymphomas Diseases 0.000 claims abstract description 12
- 208000026935 allergic disease Diseases 0.000 claims abstract description 11
- 208000015181 infectious disease Diseases 0.000 claims abstract description 11
- 208000028774 intestinal disease Diseases 0.000 claims abstract description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 9
- 206010061218 Inflammation Diseases 0.000 claims abstract description 9
- 230000004054 inflammatory process Effects 0.000 claims abstract description 9
- 208000009329 Graft vs Host Disease Diseases 0.000 claims abstract description 8
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 8
- 208000024908 graft versus host disease Diseases 0.000 claims abstract description 8
- 208000006454 hepatitis Diseases 0.000 claims abstract description 8
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 8
- 201000007270 liver cancer Diseases 0.000 claims abstract description 8
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 8
- 206010052779 Transplant rejections Diseases 0.000 claims abstract description 7
- -1 antibiotic Substances 0.000 claims description 163
- 238000000034 method Methods 0.000 claims description 50
- 239000003795 chemical substances by application Substances 0.000 claims description 45
- 239000003814 drug Substances 0.000 claims description 44
- 229940079593 drug Drugs 0.000 claims description 32
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 28
- 208000001126 Keratosis Diseases 0.000 claims description 28
- 239000000556 agonist Substances 0.000 claims description 20
- 201000004681 Psoriasis Diseases 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
- 239000005557 antagonist Substances 0.000 claims description 12
- 201000004624 Dermatitis Diseases 0.000 claims description 11
- 230000003042 antagnostic effect Effects 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 125000004429 atom Chemical group 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 230000002378 acidificating effect Effects 0.000 claims description 8
- 230000001270 agonistic effect Effects 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 239000000739 antihistaminic agent Substances 0.000 claims description 7
- 239000003018 immunosuppressive agent Substances 0.000 claims description 7
- 150000003431 steroids Chemical class 0.000 claims description 7
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims description 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 6
- 201000000849 skin cancer Diseases 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 5
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 5
- 230000001387 anti-histamine Effects 0.000 claims description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 5
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 5
- 150000003180 prostaglandins Chemical class 0.000 claims description 5
- 125000006850 spacer group Chemical group 0.000 claims description 5
- 101710170181 Metalloproteinase inhibitor Proteins 0.000 claims description 4
- 229940123950 Prostaglandin synthase inhibitor Drugs 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 4
- 230000001861 immunosuppressant effect Effects 0.000 claims description 4
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims description 4
- 229940126170 metalloproteinase inhibitor Drugs 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims description 4
- 229940122444 Chemokine receptor antagonist Drugs 0.000 claims description 3
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 claims description 3
- 101000693265 Homo sapiens Sphingosine 1-phosphate receptor 1 Proteins 0.000 claims description 3
- 229940124790 IL-6 inhibitor Drugs 0.000 claims description 3
- 229940123650 Interferon gamma agonist Drugs 0.000 claims description 3
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims description 3
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims description 3
- 229940124150 Lymphocyte inhibitor Drugs 0.000 claims description 3
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 210000000845 cartilage Anatomy 0.000 claims description 3
- 239000002559 chemokine receptor antagonist Substances 0.000 claims description 3
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims description 3
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims description 3
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims description 3
- 239000011251 protective drug Substances 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 abstract description 13
- 238000002560 therapeutic procedure Methods 0.000 abstract description 8
- 206010048768 Dermatosis Diseases 0.000 abstract description 7
- 201000011510 cancer Diseases 0.000 abstract description 7
- 208000031886 HIV Infections Diseases 0.000 abstract description 5
- 208000037357 HIV infectious disease Diseases 0.000 abstract description 5
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract description 5
- 208000030507 AIDS Diseases 0.000 abstract description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 4
- 229940126585 therapeutic drug Drugs 0.000 abstract description 4
- 206010073069 Hepatic cancer Diseases 0.000 abstract description 3
- 208000025865 Ulcer Diseases 0.000 abstract description 3
- 231100000397 ulcer Toxicity 0.000 abstract description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 120
- 230000014759 maintenance of location Effects 0.000 description 118
- 125000001424 substituent group Chemical group 0.000 description 97
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 69
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- 150000002430 hydrocarbons Chemical group 0.000 description 58
- 229930195733 hydrocarbon Natural products 0.000 description 52
- 239000004215 Carbon black (E152) Substances 0.000 description 50
- 235000002639 sodium chloride Nutrition 0.000 description 46
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 45
- 239000000243 solution Substances 0.000 description 40
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 29
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 26
- 238000002360 preparation method Methods 0.000 description 26
- 125000005843 halogen group Chemical group 0.000 description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 21
- 238000010511 deprotection reaction Methods 0.000 description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- 210000002510 keratinocyte Anatomy 0.000 description 20
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 19
- 239000002585 base Substances 0.000 description 18
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 18
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 17
- 239000011575 calcium Substances 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- 235000019441 ethanol Nutrition 0.000 description 17
- 230000003834 intracellular effect Effects 0.000 description 17
- 125000004093 cyano group Chemical group *C#N 0.000 description 16
- 125000000464 thioxo group Chemical group S=* 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 238000002347 injection Methods 0.000 description 15
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 15
- 229940083542 sodium Drugs 0.000 description 15
- 239000011734 sodium Substances 0.000 description 15
- 229910052708 sodium Inorganic materials 0.000 description 15
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 14
- 235000001465 calcium Nutrition 0.000 description 14
- 229960005069 calcium Drugs 0.000 description 14
- 229910052791 calcium Inorganic materials 0.000 description 14
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 14
- 229940090044 injection Drugs 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- 101100236208 Homo sapiens LTB4R gene Proteins 0.000 description 13
- 102100033374 Leukotriene B4 receptor 1 Human genes 0.000 description 13
- 238000005481 NMR spectroscopy Methods 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 125000000753 cycloalkyl group Chemical group 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 13
- 239000003960 organic solvent Substances 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- 238000004809 thin layer chromatography Methods 0.000 description 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 101100437750 Schizosaccharomyces pombe (strain 972 / ATCC 24843) blt1 gene Proteins 0.000 description 12
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000011347 resin Substances 0.000 description 12
- 229920005989 resin Polymers 0.000 description 12
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 11
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 11
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 125000000623 heterocyclic group Chemical group 0.000 description 11
- 125000006239 protecting group Chemical group 0.000 description 11
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 10
- 201000004384 Alopecia Diseases 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 10
- 231100000360 alopecia Toxicity 0.000 description 10
- 238000007796 conventional method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000003889 eye drop Substances 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 229940126062 Compound A Drugs 0.000 description 9
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 9
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 206010000496 acne Diseases 0.000 description 9
- 239000012190 activator Substances 0.000 description 9
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 9
- 239000003242 anti bacterial agent Substances 0.000 description 9
- 229940088710 antibiotic agent Drugs 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- 206010059313 Anogenital warts Diseases 0.000 description 8
- 206010012438 Dermatitis atopic Diseases 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 229910019142 PO4 Inorganic materials 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 8
- 208000000260 Warts Diseases 0.000 description 8
- 201000008937 atopic dermatitis Diseases 0.000 description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 8
- 208000034557 congenital alopecia Diseases 0.000 description 8
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 239000010452 phosphate Substances 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 230000002335 preservative effect Effects 0.000 description 8
- 201000010153 skin papilloma Diseases 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 125000003396 thiol group Chemical class [H]S* 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 7
- 208000002874 Acne Vulgaris Diseases 0.000 description 7
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 7
- 229940022663 acetate Drugs 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 239000002260 anti-inflammatory agent Substances 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 229960003957 dexamethasone Drugs 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 229960000890 hydrocortisone Drugs 0.000 description 7
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 description 7
- 238000007911 parenteral administration Methods 0.000 description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 208000009608 Papillomavirus Infections Diseases 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 6
- 229960002537 betamethasone Drugs 0.000 description 6
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 150000004820 halides Chemical class 0.000 description 6
- 208000021145 human papilloma virus infection Diseases 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 125000004585 polycyclic heterocycle group Chemical group 0.000 description 6
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 6
- 229960002477 riboflavin Drugs 0.000 description 6
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 239000008247 solid mixture Substances 0.000 description 6
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 239000003470 adrenal cortex hormone Substances 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 5
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 206010025135 lupus erythematosus Diseases 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229960004584 methylprednisolone Drugs 0.000 description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 5
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 5
- 229960005205 prednisolone Drugs 0.000 description 5
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 125000000213 sulfino group Chemical group [H]OS(*)=O 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 5
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 4
- 206010001764 Alopecia scarring Diseases 0.000 description 4
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 206010012442 Dermatitis contact Diseases 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 208000003794 Follicular Mucinosis Diseases 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- FOGXJPFPZOHSQS-AYVLZSQQSA-N Hydrocortisone butyrate propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O FOGXJPFPZOHSQS-AYVLZSQQSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 206010027145 Melanocytic naevus Diseases 0.000 description 4
- 208000003351 Melanosis Diseases 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- 208000007256 Nevus Diseases 0.000 description 4
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 4
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 4
- HVRLZEKDTUEKQH-NOILCQHBSA-N Olopatadine hydrochloride Chemical compound Cl.C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 HVRLZEKDTUEKQH-NOILCQHBSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 4
- 206010037575 Pustular psoriasis Diseases 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 4
- 208000028990 Skin injury Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 206010041303 Solar dermatitis Diseases 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 229940124532 absorption promoter Drugs 0.000 description 4
- 208000009621 actinic keratosis Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 208000004631 alopecia areata Diseases 0.000 description 4
- 208000010640 alopecia mucinosa Diseases 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229940124599 anti-inflammatory drug Drugs 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 239000000043 antiallergic agent Substances 0.000 description 4
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 4
- 229950000210 beclometasone dipropionate Drugs 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 125000001626 borono group Chemical group [H]OB([*])O[H] 0.000 description 4
- 206010009887 colitis Diseases 0.000 description 4
- 229940000425 combination drug Drugs 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 208000010247 contact dermatitis Diseases 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 4
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 4
- 229940012356 eye drops Drugs 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000003325 follicular Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 206010018797 guttate psoriasis Diseases 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 208000002741 leukoplakia Diseases 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 4
- 208000008588 molluscum contagiosum Diseases 0.000 description 4
- 229960002744 mometasone furoate Drugs 0.000 description 4
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 229940060184 oil ingredients Drugs 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229960003139 olopatadine hydrochloride Drugs 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229960004063 propylene glycol Drugs 0.000 description 4
- 235000013772 propylene glycol Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 235000019192 riboflavin Nutrition 0.000 description 4
- 239000002151 riboflavin Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 description 4
- 150000003385 sodium Chemical class 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 229960005294 triamcinolone Drugs 0.000 description 4
- 229940070710 valerate Drugs 0.000 description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 4
- 235000019158 vitamin B6 Nutrition 0.000 description 4
- 239000011726 vitamin B6 Substances 0.000 description 4
- 229940011671 vitamin b6 Drugs 0.000 description 4
- 239000011787 zinc oxide Substances 0.000 description 4
- 235000014692 zinc oxide Nutrition 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 241000725101 Clea Species 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- DRSFVGQMPYTGJY-GNSLJVCWSA-N Deprodone propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CC)[C@@]1(C)C[C@@H]2O DRSFVGQMPYTGJY-GNSLJVCWSA-N 0.000 description 3
- RRJFVPUCXDGFJB-UHFFFAOYSA-N Fexofenadine hydrochloride Chemical compound Cl.C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RRJFVPUCXDGFJB-UHFFFAOYSA-N 0.000 description 3
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 101001056472 Mus musculus Keratin, type II cytoskeletal 5 Proteins 0.000 description 3
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 102000015433 Prostaglandin Receptors Human genes 0.000 description 3
- 108010050183 Prostaglandin Receptors Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 229930003471 Vitamin B2 Natural products 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 239000003875 Wang resin Substances 0.000 description 3
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 3
- IUJTVDNJFPZYBL-UHFFFAOYSA-N [1,1'-biphenyl]-2-carboxylic acid, 4'-[[(1-oxopentyl)phenylamino]methyl]- Chemical compound C=1C=CC=CC=1N(C(=O)CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O IUJTVDNJFPZYBL-UHFFFAOYSA-N 0.000 description 3
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 3
- MGVGMXLGOKTYKP-ZFOBEOMCSA-N acetic acid;(6s,8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound CC(O)=O.C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 MGVGMXLGOKTYKP-ZFOBEOMCSA-N 0.000 description 3
- 150000008065 acid anhydrides Chemical class 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 229960003099 amcinonide Drugs 0.000 description 3
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 3
- 238000007112 amidation reaction Methods 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 239000003908 antipruritic agent Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- UDGHXQPQKQPSBB-UHFFFAOYSA-N benzenesulfonic acid;4-[4-[(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1.C1CN(CCCC(=O)O)CCC1OC(C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 UDGHXQPQKQPSBB-UHFFFAOYSA-N 0.000 description 3
- 229940049706 benzodiazepine Drugs 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 229960001105 bepotastine besilate Drugs 0.000 description 3
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 3
- 229960004311 betamethasone valerate Drugs 0.000 description 3
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 3
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960004703 clobetasol propionate Drugs 0.000 description 3
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 3
- 150000004696 coordination complex Chemical class 0.000 description 3
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 229960003596 cyproheptadine hydrochloride Drugs 0.000 description 3
- ZPMVNZLARAEGHB-UHFFFAOYSA-N cyproheptadine hydrochloride (anhydrous) Chemical compound Cl.C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 ZPMVNZLARAEGHB-UHFFFAOYSA-N 0.000 description 3
- 229960003657 dexamethasone acetate Drugs 0.000 description 3
- CIWBQSYVNNPZIQ-PKWREOPISA-N dexamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-PKWREOPISA-N 0.000 description 3
- 229950000250 dexamethasone dipropionate Drugs 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 229960000520 diphenhydramine Drugs 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 229960000354 fexofenadine hydrochloride Drugs 0.000 description 3
- 229960001347 fluocinolone acetonide Drugs 0.000 description 3
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 3
- 229960000785 fluocinonide Drugs 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 229960001067 hydrocortisone acetate Drugs 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 125000001841 imino group Chemical group [H]N=* 0.000 description 3
- 229940124589 immunosuppressive drug Drugs 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 3
- 229960000991 ketoprofen Drugs 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 229960001293 methylprednisolone acetate Drugs 0.000 description 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 3
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 3
- 229960002702 piroxicam Drugs 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- FKKAEMQFOIDZNY-CODXZCKSSA-M prednisolone sodium succinate Chemical compound [Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC([O-])=O)[C@@H]4[C@@H]3CCC2=C1 FKKAEMQFOIDZNY-CODXZCKSSA-M 0.000 description 3
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 229960001940 sulfasalazine Drugs 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 229960002117 triamcinolone acetonide Drugs 0.000 description 3
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 235000019164 vitamin B2 Nutrition 0.000 description 3
- 239000011716 vitamin B2 Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 2
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 2
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 description 2
- FWLKKPKZQYVAFR-LVEZLNDCSA-N (e)-but-2-enedioic acid;1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 FWLKKPKZQYVAFR-LVEZLNDCSA-N 0.000 description 2
- RXBYRTSOWREATF-UHFFFAOYSA-N 1,2,3,4-tetrahydroacridine Chemical compound C1=CC=C2C=C(CCCC3)C3=NC2=C1 RXBYRTSOWREATF-UHFFFAOYSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 2
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- LITNEAPWQHVPOK-FFSVYQOJSA-N 2(1h)-pyrimidinone, 5-[3-[(1s,2s,4r)-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl]tetrahydro- Chemical compound C1=C(O[C@@H]2[C@H]3CC[C@H](C3)C2)C(OC)=CC=C1C1CNC(=O)NC1 LITNEAPWQHVPOK-FFSVYQOJSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- QMEQBOSUJUOXMX-UHFFFAOYSA-N 2h-oxadiazine Chemical compound N1OC=CC=N1 QMEQBOSUJUOXMX-UHFFFAOYSA-N 0.000 description 2
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- LUXXPXJGDQNGIG-UHFFFAOYSA-N 4-[4-[[benzyl(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CC=1C=CC=CC=1)CCCC1=CC=CC=C1 LUXXPXJGDQNGIG-UHFFFAOYSA-N 0.000 description 2
- QTQGHKVYLQBJLO-UHFFFAOYSA-N 4-methylbenzenesulfonate;(4-methyl-1-oxo-1-phenylmethoxypentan-2-yl)azanium Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)CC(N)C(=O)OCC1=CC=CC=C1 QTQGHKVYLQBJLO-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 2
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 2
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 2
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 2
- 102000009410 Chemokine receptor Human genes 0.000 description 2
- 108050000299 Chemokine receptor Proteins 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000000907 Condylomata Acuminata Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 229940122010 Corticotropin releasing factor antagonist Drugs 0.000 description 2
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- HHJIUUAMYGBVSD-YTFFSALGSA-N Diflucortolone valerate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)CCCC)[C@@]2(C)C[C@@H]1O HHJIUUAMYGBVSD-YTFFSALGSA-N 0.000 description 2
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 229940122858 Elastase inhibitor Drugs 0.000 description 2
- 206010015278 Erythrodermic psoriasis Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 2
- 102000004300 GABA-A Receptors Human genes 0.000 description 2
- 108090000839 GABA-A Receptors Proteins 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000007746 Immunologic Deficiency Syndromes Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 229940122801 Interleukin 8 antagonist Drugs 0.000 description 2
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 2
- 102000002791 Interleukin-8B Receptors Human genes 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000003680 Leukotriene B4 receptors Human genes 0.000 description 2
- 108090000093 Leukotriene B4 receptors Proteins 0.000 description 2
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 102000044589 Mitogen-Activated Protein Kinase 1 Human genes 0.000 description 2
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 2
- HYRKAAMZBDSJFJ-LFDBJOOHSA-N Paramethasone acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]2(C)C[C@@H]1O HYRKAAMZBDSJFJ-LFDBJOOHSA-N 0.000 description 2
- 229910002666 PdCl2 Inorganic materials 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 2
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 2
- 102000009389 Prostaglandin D receptors Human genes 0.000 description 2
- 108050000258 Prostaglandin D receptors Proteins 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 229910006069 SO3H Inorganic materials 0.000 description 2
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 2
- 206010039796 Seborrhoeic keratosis Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- JDLSRXWHEBFHNC-UHFFFAOYSA-N Ufenamate Chemical compound CCCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 JDLSRXWHEBFHNC-UHFFFAOYSA-N 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 241000934136 Verruca Species 0.000 description 2
- MUXFZBHBYYYLTH-UHFFFAOYSA-N Zaltoprofen Chemical compound O=C1CC2=CC(C(C(O)=O)C)=CC=C2SC2=CC=CC=C21 MUXFZBHBYYYLTH-UHFFFAOYSA-N 0.000 description 2
- FBRAWBYQGRLCEK-UHFFFAOYSA-N [17-(2-chloroacetyl)-9-fluoro-10,13,16-trimethyl-3,11-dioxo-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CCl)(OC(=O)CCC)C1(C)CC2=O FBRAWBYQGRLCEK-UHFFFAOYSA-N 0.000 description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 125000004419 alkynylene group Chemical group 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 2
- 201000004201 anogenital venereal wart Diseases 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000003092 anti-cytokine Effects 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 2
- 229960005207 auranofin Drugs 0.000 description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229960001102 betamethasone dipropionate Drugs 0.000 description 2
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 2
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 description 2
- 229960005354 betamethasone sodium phosphate Drugs 0.000 description 2
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- MXJWRABVEGLYDG-UHFFFAOYSA-N bufexamac Chemical compound CCCCOC1=CC=C(CC(=O)NO)C=C1 MXJWRABVEGLYDG-UHFFFAOYSA-N 0.000 description 2
- 229960000962 bufexamac Drugs 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 229960002079 calcium pantothenate Drugs 0.000 description 2
- 239000003556 cannabinoid 2 receptor agonist Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229960005465 clobetasone butyrate Drugs 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002769 corticotropin releasing factor antagonist Substances 0.000 description 2
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 2
- 229960003290 cortisone acetate Drugs 0.000 description 2
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 2
- 229960003338 crotamiton Drugs 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 2
- 125000006638 cyclopentyl carbonyl group Chemical group 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 2
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 2
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 2
- IYYZUPMFVPLQIF-UHFFFAOYSA-N dibenzothiophene Chemical compound C1=CC=C2C3=CC=CC=C3SC2=C1 IYYZUPMFVPLQIF-UHFFFAOYSA-N 0.000 description 2
- 229960003970 diflucortolone valerate Drugs 0.000 description 2
- 229960004875 difluprednate Drugs 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- 108010007093 dispase Proteins 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003602 elastase inhibitor Substances 0.000 description 2
- 229960000325 emedastine Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229960002549 enoxacin Drugs 0.000 description 2
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 2
- 229960003720 enoxolone Drugs 0.000 description 2
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 2
- 229960002548 epinastine hydrochloride Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 229960004511 fludroxycortide Drugs 0.000 description 2
- JWRMHDSINXPDHB-OJAGFMMFSA-N flumethasone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(=O)C(C)(C)C)(O)[C@@]2(C)C[C@@H]1O JWRMHDSINXPDHB-OJAGFMMFSA-N 0.000 description 2
- 229940042902 flumethasone pivalate Drugs 0.000 description 2
- 229960002390 flurbiprofen Drugs 0.000 description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 229960002383 halcinonide Drugs 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000000938 histamine H1 antagonist Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 2
- 229960001401 hydrocortisone sodium succinate Drugs 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 2
- 229960003630 ketotifen fumarate Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 201000011486 lichen planus Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229960002373 loxoprofen Drugs 0.000 description 2
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000010841 mRNA extraction Methods 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000001055 magnesium Nutrition 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
- 229960004963 mesalazine Drugs 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- DZNKOAWEHDKBEP-UHFFFAOYSA-N methyl 2-[6-[bis(2-methoxy-2-oxoethyl)amino]-5-[2-[2-[bis(2-methoxy-2-oxoethyl)amino]-5-methylphenoxy]ethoxy]-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylate Chemical compound COC(=O)CN(CC(=O)OC)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OC)CC(=O)OC)=CC2=C1OC(C=1OC(=CN=1)C(=O)OC)=C2 DZNKOAWEHDKBEP-UHFFFAOYSA-N 0.000 description 2
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 2
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- NPGREARFJMFTDF-UHFFFAOYSA-N n-(3,5-dichloro-1-hydroxypyridin-4-ylidene)-8-methoxy-2-(trifluoromethyl)quinoline-5-carboxamide Chemical compound C12=CC=C(C(F)(F)F)N=C2C(OC)=CC=C1C(=O)N=C1C(Cl)=CN(O)C=C1Cl NPGREARFJMFTDF-UHFFFAOYSA-N 0.000 description 2
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- DTHHUAXKOMWYBI-UHFFFAOYSA-N oxadiazolidine Chemical compound C1CONN1 DTHHUAXKOMWYBI-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229960002739 oxaprozin Drugs 0.000 description 2
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 2
- 229960002698 oxatomide Drugs 0.000 description 2
- BAINIUMDFURPJM-UHFFFAOYSA-N oxatomide Chemical compound O=C1NC2=CC=CC=C2N1CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BAINIUMDFURPJM-UHFFFAOYSA-N 0.000 description 2
- 230000033116 oxidation-reduction process Effects 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- 229960000865 paramethasone acetate Drugs 0.000 description 2
- XGISHOFUAFNYQF-UHFFFAOYSA-N pentanoyl chloride Chemical compound CCCCC(Cl)=O XGISHOFUAFNYQF-UHFFFAOYSA-N 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 229950000688 phenothiazine Drugs 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 229960003101 pranoprofen Drugs 0.000 description 2
- DGYSDXLCLKPUBR-SLPNHVECSA-N prednisolone valerate acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(C)=O)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O DGYSDXLCLKPUBR-SLPNHVECSA-N 0.000 description 2
- 229950008480 prednisolone valerate acetate Drugs 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 2
- 229960001327 pyridoxal phosphate Drugs 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 2
- QFTLJRFNJYIISH-UHFFFAOYSA-N pyrrolo[2,3-b]pyridine Chemical compound C1=C[N]C2=NC=CC2=C1 QFTLJRFNJYIISH-UHFFFAOYSA-N 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 201000003385 seborrheic keratosis Diseases 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 239000003723 serotonin 1A agonist Substances 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- KHCLTYBPOCIPHE-UHFFFAOYSA-M sodium;3-[3-[[(4-methoxybenzoyl)-(4-phenylbutyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(OC)=CC=C1C(=O)N(CC=1C=C(C=CC=1)C=1C=C(C=CC=1)C([O-])=O)CCCCC1=CC=CC=C1 KHCLTYBPOCIPHE-UHFFFAOYSA-M 0.000 description 2
- JNZZMJWKTIVKEI-UHFFFAOYSA-M sodium;4-[4-[[(4-methoxybenzoyl)-(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(OC)=CC=C1C(=O)N(CC=1C=CC(=CC=1)C=1C=CC(=CC=1)C([O-])=O)CCCC1=CC=CC=C1 JNZZMJWKTIVKEI-UHFFFAOYSA-M 0.000 description 2
- YNEHXQGCTHFUQY-UHFFFAOYSA-M sodium;4-[4-[[cyclopentanecarbonyl(2-phenylethyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C(=O)C1CCCC1)CCC1=CC=CC=C1 YNEHXQGCTHFUQY-UHFFFAOYSA-M 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 229960004492 suprofen Drugs 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000011269 tar Substances 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- RLTPJVKHGBFGQA-UHFFFAOYSA-N thiadiazolidine Chemical compound C1CSNN1 RLTPJVKHGBFGQA-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229960005342 tranilast Drugs 0.000 description 2
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 229950010121 ufenamate Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229950004227 zaltoprofen Drugs 0.000 description 2
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 2
- GBLRQXKSCRCLBZ-AJSYEDJNSA-N (1S,2R,1'S,2'R)-doxacurium Chemical compound COC1=C(OC)C(OC)=CC(C[C@@H]2[N@@+](CCC3=C2C(=C(OC)C(OC)=C3)OC)(C)CCCOC(=O)CCC(=O)OCCC[N@+]2(C)[C@H](C3=C(OC)C(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=C(OC)C=2)=C1 GBLRQXKSCRCLBZ-AJSYEDJNSA-N 0.000 description 1
- RRKODOZNUZCUBN-CCAGOZQPSA-N (1z,3z)-cycloocta-1,3-diene Chemical group C1CC\C=C/C=C\C1 RRKODOZNUZCUBN-CCAGOZQPSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 description 1
- AJZJIYUOOJLBAU-CEAXSRTFSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;n,n,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1.C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 AJZJIYUOOJLBAU-CEAXSRTFSA-N 0.000 description 1
- AZXZMCQMDWVCDF-SCEXVKQTSA-N (2r,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(1r,2r,3s,4r,6s)-4,6-diamino-2-[(2s,3r,4s,5r)-4-[(2r,3r,4r,5s,6s)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol;2-butoxy-n-[2 Chemical group C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21.O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO AZXZMCQMDWVCDF-SCEXVKQTSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- KRDCGZGYWRCHNN-NAWJVIAPSA-N (2s)-2-(6-methoxynaphthalen-2-yl)propanoic acid;piperazine Chemical compound C1CNCCN1.C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21.C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 KRDCGZGYWRCHNN-NAWJVIAPSA-N 0.000 description 1
- VUAFHZCUKUDDBC-SCSAIBSYSA-N (2s)-2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid Chemical compound CC(C)(S)C(=O)N[C@H](CS)C(O)=O VUAFHZCUKUDDBC-SCSAIBSYSA-N 0.000 description 1
- JJBWFKJWSAKJTP-QHCPKHFHSA-N (2s)-3-[(2-methylpropan-2-yl)oxy]-2-[[pentyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]carbamoyl]amino]propanoic acid Chemical compound C1=CC(CN(CCCCC)C(=O)N[C@@H](COC(C)(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 JJBWFKJWSAKJTP-QHCPKHFHSA-N 0.000 description 1
- XTPMKUKWAMGWIQ-FQEVSTJZSA-N (2s)-3-hydroxy-2-[[pentyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]carbamoyl]amino]propanoic acid Chemical compound C1=CC(CN(CCCCC)C(=O)N[C@@H](CO)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 XTPMKUKWAMGWIQ-FQEVSTJZSA-N 0.000 description 1
- IDQMDQWHGOWMKX-KBBWGOFYSA-N (2s,3r,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-c Chemical compound NCC(O)=O.SC[C@H](N)C(O)=O.CSCC[C@H](N)C(O)=O.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O IDQMDQWHGOWMKX-KBBWGOFYSA-N 0.000 description 1
- KMEGBUCIGMEPME-LQYKFRDPSA-N (2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(1r,4s)-3,3-dimethyl-2,2,6-trioxo-2$l^{6}-thiabicyclo[3.2.0]heptane-4-carboxylic acid Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)C2C(=O)C[C@H]21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 KMEGBUCIGMEPME-LQYKFRDPSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- SVSFIELZISOJDT-XRZFDKQNSA-N (6r,7r)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-[2-(dimethylamino)ethyl]tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrochloride Chemical compound Cl.CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 SVSFIELZISOJDT-XRZFDKQNSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- PMGQWSIVQFOFOQ-BDUVBVHRSA-N (e)-but-2-enedioic acid;(2r)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCOC(C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-BDUVBVHRSA-N 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N 1,1'-Carbonyldiimidazole Substances C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- AEBWATHAIVJLTA-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropentalene Chemical compound C1CCC2CCCC21 AEBWATHAIVJLTA-UHFFFAOYSA-N 0.000 description 1
- ODJQFZXHKPCJMD-UHFFFAOYSA-N 1,2,3,3a,4,5,6,7,8,8a-decahydroazulene Chemical compound C1CCCCC2CCCC21 ODJQFZXHKPCJMD-UHFFFAOYSA-N 0.000 description 1
- IXTPCSZJZAKJTO-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a,9,9a,10,10a-tetradecahydroacridine Chemical compound N1C2CCCCC2CC2C1CCCC2 IXTPCSZJZAKJTO-UHFFFAOYSA-N 0.000 description 1
- PIHAUZGWAXLKCA-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydro-1,8-naphthyridine Chemical compound N1CCCC2CCCNC21 PIHAUZGWAXLKCA-UHFFFAOYSA-N 0.000 description 1
- VKJHANNFFHMLBB-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydrocinnoline Chemical compound N1NCCC2CCCCC21 VKJHANNFFHMLBB-UHFFFAOYSA-N 0.000 description 1
- NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical compound C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 description 1
- AEBKORRYDYKJLT-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydrophthalazine Chemical compound C1NNCC2CCCCC21 AEBKORRYDYKJLT-UHFFFAOYSA-N 0.000 description 1
- HZNXIPDYYIWDNM-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinazoline Chemical compound N1CNCC2CCCCC21 HZNXIPDYYIWDNM-UHFFFAOYSA-N 0.000 description 1
- POTIYWUALSJREP-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline Chemical compound N1CCCC2CCCCC21 POTIYWUALSJREP-UHFFFAOYSA-N 0.000 description 1
- MDEXMBGPIZUUBI-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoxaline Chemical compound N1CCNC2CCCCC21 MDEXMBGPIZUUBI-UHFFFAOYSA-N 0.000 description 1
- XTDNMGZRUWMVLT-UHFFFAOYSA-N 1,2,3,4,4a,5a,6,7,8,9,9a,9b-dodecahydrodibenzofuran Chemical compound C1CCCC2C3CCCCC3OC21 XTDNMGZRUWMVLT-UHFFFAOYSA-N 0.000 description 1
- XMJFSCXZDZSDJS-UHFFFAOYSA-N 1,2,3,4,4a,5a,6,7,8,9,9a,9b-dodecahydrodibenzothiophene Chemical compound C1CCCC2C3CCCCC3SC21 XMJFSCXZDZSDJS-UHFFFAOYSA-N 0.000 description 1
- LOWDSHXWDYULHF-UHFFFAOYSA-N 1,2,3,4,5,5a,6,7,8,9,10,10a-dodecahydroheptalene Chemical compound C1CCCCC2CCCCCC21 LOWDSHXWDYULHF-UHFFFAOYSA-N 0.000 description 1
- ZCZVGQCBSJLDDS-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridine Chemical compound C1=CC=C2CCCNC2=N1 ZCZVGQCBSJLDDS-UHFFFAOYSA-N 0.000 description 1
- WXRSSOIHEAVYLL-UHFFFAOYSA-N 1,2,3,4-tetrahydrocinnoline Chemical compound C1=CC=C2NNCCC2=C1 WXRSSOIHEAVYLL-UHFFFAOYSA-N 0.000 description 1
- LREHXNMBUBVFHA-UHFFFAOYSA-N 1,2,3,4-tetrahydrodibenzofuran Chemical compound O1C2=CC=CC=C2C2=C1CCCC2 LREHXNMBUBVFHA-UHFFFAOYSA-N 0.000 description 1
- JCLPOPNXITXHOR-UHFFFAOYSA-N 1,2,3,4-tetrahydrodibenzothiophene Chemical compound S1C2=CC=CC=C2C2=C1CCCC2 JCLPOPNXITXHOR-UHFFFAOYSA-N 0.000 description 1
- STIWEDICJHIFJT-UHFFFAOYSA-N 1,2,3,4-tetrahydrophthalazine Chemical compound C1=CC=C2CNNCC2=C1 STIWEDICJHIFJT-UHFFFAOYSA-N 0.000 description 1
- OQJVXNHMUWQQEW-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrazine Chemical compound C1CNC=CN1 OQJVXNHMUWQQEW-UHFFFAOYSA-N 0.000 description 1
- JQIZHNLEFQMDCQ-UHFFFAOYSA-N 1,2,3,4-tetrahydropyridazine Chemical compound C1CC=CNN1 JQIZHNLEFQMDCQ-UHFFFAOYSA-N 0.000 description 1
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical compound C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 description 1
- PKORYTIUMAOPED-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinazoline Chemical compound C1=CC=C2NCNCC2=C1 PKORYTIUMAOPED-UHFFFAOYSA-N 0.000 description 1
- HORKYAIEVBUXGM-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoxaline Chemical compound C1=CC=C2NCCNC2=C1 HORKYAIEVBUXGM-UHFFFAOYSA-N 0.000 description 1
- FIDRAVVQGKNYQK-UHFFFAOYSA-N 1,2,3,4-tetrahydrotriazine Chemical compound C1NNNC=C1 FIDRAVVQGKNYQK-UHFFFAOYSA-N 0.000 description 1
- KAOYLRLQZXRRBD-UHFFFAOYSA-N 1,2,3-benzothiadiazepine Chemical compound S1N=NC=CC2=CC=CC=C12 KAOYLRLQZXRRBD-UHFFFAOYSA-N 0.000 description 1
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 1
- DMTVEFFTCXZRHY-UHFFFAOYSA-N 1,2,3-benzoxadiazepine Chemical compound O1N=NC=CC2=CC=CC=C12 DMTVEFFTCXZRHY-UHFFFAOYSA-N 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical group C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- UUZJJNBYJDFQHL-UHFFFAOYSA-N 1,2,3-triazolidine Chemical compound C1CNNN1 UUZJJNBYJDFQHL-UHFFFAOYSA-N 0.000 description 1
- AGSHYIAAUGKFEA-UHFFFAOYSA-N 1,2,5-oxadiazolidine Chemical compound C1CNON1 AGSHYIAAUGKFEA-UHFFFAOYSA-N 0.000 description 1
- FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical compound S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 description 1
- ZCXLTWVZYXBHJS-UHFFFAOYSA-N 1,2-benzoxazepine Chemical compound O1N=CC=CC2=CC=CC=C12 ZCXLTWVZYXBHJS-UHFFFAOYSA-N 0.000 description 1
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- XEYKWYIXHMEQGM-UHFFFAOYSA-N 1,2-dihydro-1,8-naphthyridine Chemical compound C1=CC=C2C=CCNC2=N1 XEYKWYIXHMEQGM-UHFFFAOYSA-N 0.000 description 1
- UXJHQQLYKUVLIE-UHFFFAOYSA-N 1,2-dihydroacridine Chemical compound C1=CC=C2N=C(C=CCC3)C3=CC2=C1 UXJHQQLYKUVLIE-UHFFFAOYSA-N 0.000 description 1
- QRDNXAYNXUKMOO-UHFFFAOYSA-N 1,2-dihydrocinnoline Chemical compound C1=CC=C2C=CNNC2=C1 QRDNXAYNXUKMOO-UHFFFAOYSA-N 0.000 description 1
- AYMOVGCUZMUZSI-UHFFFAOYSA-N 1,2-dihydrodibenzothiophene Chemical compound S1C2=CC=CC=C2C2=C1C=CCC2 AYMOVGCUZMUZSI-UHFFFAOYSA-N 0.000 description 1
- IOEPOEDBBPRAEI-UHFFFAOYSA-N 1,2-dihydroisoquinoline Chemical compound C1=CC=C2CNC=CC2=C1 IOEPOEDBBPRAEI-UHFFFAOYSA-N 0.000 description 1
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical compound C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1
- QYMGRIFMUQCAJW-UHFFFAOYSA-N 1,2-dihydropyrazine Chemical compound C1NC=CN=C1 QYMGRIFMUQCAJW-UHFFFAOYSA-N 0.000 description 1
- WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical compound C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 description 1
- IRFSXVIRXMYULF-UHFFFAOYSA-N 1,2-dihydroquinoline Chemical compound C1=CC=C2C=CCNC2=C1 IRFSXVIRXMYULF-UHFFFAOYSA-N 0.000 description 1
- XXBQLHATYQHJQC-UHFFFAOYSA-N 1,2-dihydroquinoxaline Chemical compound C1=CC=C2N=CCNC2=C1 XXBQLHATYQHJQC-UHFFFAOYSA-N 0.000 description 1
- PXGILEVFPBXLEB-UHFFFAOYSA-N 1,2-dimethyl-3-propan-2-ylazulene Chemical compound C1=CC=CC=C2C(C(C)C)=C(C)C(C)=C21 PXGILEVFPBXLEB-UHFFFAOYSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical group C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- HGQBCKVFVUCIML-UHFFFAOYSA-N 1,3,3a,4,5,6,7,7a-octahydro-2-benzofuran Chemical compound C1CCCC2COCC21 HGQBCKVFVUCIML-UHFFFAOYSA-N 0.000 description 1
- SJXUGVWKLLOJDR-UHFFFAOYSA-N 1,3,3a,4,5,6,7,7a-octahydro-2-benzothiophene Chemical compound C1CCCC2CSCC21 SJXUGVWKLLOJDR-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- GWYPDXLJACEENP-UHFFFAOYSA-N 1,3-cycloheptadiene Chemical compound C1CC=CC=CC1 GWYPDXLJACEENP-UHFFFAOYSA-N 0.000 description 1
- DKYBVKMIZODYKL-UHFFFAOYSA-N 1,3-diazinane Chemical compound C1CNCNC1 DKYBVKMIZODYKL-UHFFFAOYSA-N 0.000 description 1
- NETOFWKJBRGPAG-UHFFFAOYSA-N 1,3-dibutyl-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C1=CC(CN(CCCC)C(=O)NCCCC)=CC=C1C1=CC=CC=C1C1=NN=NN1 NETOFWKJBRGPAG-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- BDIJPBVLZALCFW-UHFFFAOYSA-N 1-[(4-chlorophenyl)-phenylmethyl]-4-methyl-1,4-diazepan-4-ium;chloride Chemical compound [Cl-].C1C[NH+](C)CCCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 BDIJPBVLZALCFW-UHFFFAOYSA-N 0.000 description 1
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 1
- NIGNBCLEMMGDQP-UHFFFAOYSA-N 1-benzothiepine Chemical compound S1C=CC=CC2=CC=CC=C12 NIGNBCLEMMGDQP-UHFFFAOYSA-N 0.000 description 1
- LWZYUACNWRVDDJ-UHFFFAOYSA-N 1-benzoxepine Chemical compound O1C=CC=CC2=CC=CC=C12 LWZYUACNWRVDDJ-UHFFFAOYSA-N 0.000 description 1
- ZWTHOJQGPPRVII-UHFFFAOYSA-N 1-butyl-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-3-[4-(trifluoromethoxy)phenyl]urea Chemical compound C=1C=C(OC(F)(F)F)C=CC=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 ZWTHOJQGPPRVII-UHFFFAOYSA-N 0.000 description 1
- IHUSOJYDTMEDRP-UHFFFAOYSA-N 1-butyl-3-(2,2-diphenylethyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CNC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 IHUSOJYDTMEDRP-UHFFFAOYSA-N 0.000 description 1
- CXLCPLGBCQNHCO-UHFFFAOYSA-N 1-butyl-3-(2-ethoxyphenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC=C(OCC)C=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 CXLCPLGBCQNHCO-UHFFFAOYSA-N 0.000 description 1
- MKWUMTAKQNXEGR-UHFFFAOYSA-N 1-butyl-3-(2-hydroxyphenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC=C(O)C=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 MKWUMTAKQNXEGR-UHFFFAOYSA-N 0.000 description 1
- MCPYYQBZYTUZLU-UHFFFAOYSA-N 1-butyl-3-(2-methylsulfanylphenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC=C(SC)C=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 MCPYYQBZYTUZLU-UHFFFAOYSA-N 0.000 description 1
- YVSRBMLOEHNZCG-UHFFFAOYSA-N 1-butyl-3-(2-morpholin-4-ylethyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C1COCCN1CCNC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 YVSRBMLOEHNZCG-UHFFFAOYSA-N 0.000 description 1
- DYCANSCKTVMTOU-UHFFFAOYSA-N 1-butyl-3-(2-nitrophenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC=C([N+]([O-])=O)C=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 DYCANSCKTVMTOU-UHFFFAOYSA-N 0.000 description 1
- SRUYVNNMBGRVTB-UHFFFAOYSA-N 1-butyl-3-(2-phenylethyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC=CC=1CCNC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 SRUYVNNMBGRVTB-UHFFFAOYSA-N 0.000 description 1
- XLNIEFRTPCKACT-UHFFFAOYSA-N 1-butyl-3-(2-phenylphenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC=C(C=2C=CC=CC=2)C=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 XLNIEFRTPCKACT-UHFFFAOYSA-N 0.000 description 1
- DTCSZZPFIGHOEX-UHFFFAOYSA-N 1-butyl-3-(3,4-difluorophenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=C(F)C(F)=CC=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 DTCSZZPFIGHOEX-UHFFFAOYSA-N 0.000 description 1
- CKMZPJSROIEWCS-UHFFFAOYSA-N 1-butyl-3-(3-ethylphenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC(CC)=CC=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 CKMZPJSROIEWCS-UHFFFAOYSA-N 0.000 description 1
- JQTYXJWWAKAROD-UHFFFAOYSA-N 1-butyl-3-(3-methoxyphenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC(OC)=CC=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 JQTYXJWWAKAROD-UHFFFAOYSA-N 0.000 description 1
- RYTVKHWRXNIOOQ-UHFFFAOYSA-N 1-butyl-3-(4-ethylphenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=C(CC)C=CC=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 RYTVKHWRXNIOOQ-UHFFFAOYSA-N 0.000 description 1
- ODUPPJOVFXSOLC-UHFFFAOYSA-N 1-butyl-3-(4-methoxyphenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=C(OC)C=CC=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 ODUPPJOVFXSOLC-UHFFFAOYSA-N 0.000 description 1
- CWWOJBNJIJARNX-UHFFFAOYSA-N 1-butyl-3-(4-methyl-2-nitrophenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=C(C)C=C([N+]([O-])=O)C=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 CWWOJBNJIJARNX-UHFFFAOYSA-N 0.000 description 1
- HIZKJJLBSIFQDB-UHFFFAOYSA-N 1-butyl-3-(oxolan-2-ylmethyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C1CCOC1CNC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 HIZKJJLBSIFQDB-UHFFFAOYSA-N 0.000 description 1
- XLCUOPXYQHEUNL-HXUWFJFHSA-N 1-butyl-3-[(1r)-1-phenylethyl]-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound N([C@H](C)C=1C=CC=CC=1)C(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 XLCUOPXYQHEUNL-HXUWFJFHSA-N 0.000 description 1
- XLCUOPXYQHEUNL-FQEVSTJZSA-N 1-butyl-3-[(1s)-1-phenylethyl]-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 XLCUOPXYQHEUNL-FQEVSTJZSA-N 0.000 description 1
- PFJJROMLQFHIPR-UHFFFAOYSA-N 1-butyl-3-[2,6-di(propan-2-yl)phenyl]-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound CC(C)C=1C=CC=C(C(C)C)C=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 PFJJROMLQFHIPR-UHFFFAOYSA-N 0.000 description 1
- UVTKWWZXRSYBCI-UHFFFAOYSA-N 1-butyl-3-[2-(3-prop-1-en-2-ylphenyl)propan-2-yl]-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC(C(C)=C)=CC=1C(C)(C)NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 UVTKWWZXRSYBCI-UHFFFAOYSA-N 0.000 description 1
- WXMWQAXZQJKXKG-UHFFFAOYSA-N 1-butyl-3-[2-(4-hydroxyphenyl)ethyl]-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=C(O)C=CC=1CCNC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 WXMWQAXZQJKXKG-UHFFFAOYSA-N 0.000 description 1
- YUQOINNACFOQFK-UHFFFAOYSA-N 1-butyl-3-cyclohexyl-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C1CCCCC1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 YUQOINNACFOQFK-UHFFFAOYSA-N 0.000 description 1
- PRLZJYZHZRFPHM-UHFFFAOYSA-N 1-butyl-3-phenyl-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC=CC=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 PRLZJYZHZRFPHM-UHFFFAOYSA-N 0.000 description 1
- WBJOGFVHYTZWJT-UHFFFAOYSA-N 1-butyl-3-propan-2-yl-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C1=CC(CN(CCCC)C(=O)NC(C)C)=CC=C1C1=CC=CC=C1C1=NN=NN1 WBJOGFVHYTZWJT-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2,2'-azo-bis-isobutyronitrile Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- OGHHATWOTABYKY-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1,3-benzothiazole Chemical compound C1CCCC2SCNC21 OGHHATWOTABYKY-UHFFFAOYSA-N 0.000 description 1
- XLRZZUUFKAXBGZ-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1,3-benzoxazole Chemical compound C1CCCC2OCNC21 XLRZZUUFKAXBGZ-UHFFFAOYSA-N 0.000 description 1
- DNZWAKVIOXCEHH-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1-benzofuran Chemical compound C1CCCC2OCCC21 DNZWAKVIOXCEHH-UHFFFAOYSA-N 0.000 description 1
- NZOBCFVNZQYCCZ-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1-benzothiophene Chemical compound C1CCCC2SCCC21 NZOBCFVNZQYCCZ-UHFFFAOYSA-N 0.000 description 1
- MDNGXAFGRWQHNZ-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-benzimidazole Chemical compound C1CCCC2NCNC21 MDNGXAFGRWQHNZ-UHFFFAOYSA-N 0.000 description 1
- LVJPACZOEKXFAY-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-indazole Chemical compound C1CCCC2CNNC21 LVJPACZOEKXFAY-UHFFFAOYSA-N 0.000 description 1
- SBVSDAFTZIVQEI-UHFFFAOYSA-N 2,3,4,4a,4b,5,6,7,8,8a,9,9a-dodecahydro-1h-carbazole Chemical compound C1CCCC2C3CCCCC3NC21 SBVSDAFTZIVQEI-UHFFFAOYSA-N 0.000 description 1
- LOPOBSRXDVBTHH-UHFFFAOYSA-N 2,3,4,4a,4b,5,6,7,8,8a,9,9a-dodecahydro-1h-pyrido[3,4-b]indole Chemical compound C1NCCC2C3CCCCC3NC21 LOPOBSRXDVBTHH-UHFFFAOYSA-N 0.000 description 1
- UDMSIVPAVKUOKF-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1,2-benzoxazepine Chemical compound C1CCNOC2=CC=CC=C21 UDMSIVPAVKUOKF-UHFFFAOYSA-N 0.000 description 1
- QEYQSYAGLRIYBE-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-1,2-benzodiazepine Chemical compound C1CCNNC2=CC=CC=C21 QEYQSYAGLRIYBE-UHFFFAOYSA-N 0.000 description 1
- MZBVNYACSSGXID-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-1-benzazepine Chemical compound N1CCCCC2=CC=CC=C21 MZBVNYACSSGXID-UHFFFAOYSA-N 0.000 description 1
- SCEIUGQQBYRBPP-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-azepine Chemical compound C1CCC=CNC1 SCEIUGQQBYRBPP-UHFFFAOYSA-N 0.000 description 1
- YYVKQFQZKSLYFN-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-diazepine Chemical compound C1CNNC=CC1 YYVKQFQZKSLYFN-UHFFFAOYSA-N 0.000 description 1
- GLCYMVDVOVIDBB-UHFFFAOYSA-N 2,3,4,5-tetrahydrooxadiazepine Chemical compound C1CC=CONN1 GLCYMVDVOVIDBB-UHFFFAOYSA-N 0.000 description 1
- ABQOPHYTASMWLA-UHFFFAOYSA-N 2,3,4,5-tetrahydrooxazepine Chemical compound C1CNOC=CC1 ABQOPHYTASMWLA-UHFFFAOYSA-N 0.000 description 1
- SOHIYESEPVZKHS-UHFFFAOYSA-N 2,3,4,5-tetrahydrooxepine Chemical compound C1CCC=COC1 SOHIYESEPVZKHS-UHFFFAOYSA-N 0.000 description 1
- WHUAPUGLAGYTQS-UHFFFAOYSA-N 2,3,4,5-tetrahydrothiadiazepine Chemical compound C1CC=CSNN1 WHUAPUGLAGYTQS-UHFFFAOYSA-N 0.000 description 1
- IFPKIMVCYSSDDJ-UHFFFAOYSA-N 2,3,4,5-tetrahydrothiazepine Chemical compound C1CNSC=CC1 IFPKIMVCYSSDDJ-UHFFFAOYSA-N 0.000 description 1
- VRKPANGTGANDRQ-UHFFFAOYSA-N 2,3,4,5-tetrahydrothiepine Chemical compound C1CCC=CSC1 VRKPANGTGANDRQ-UHFFFAOYSA-N 0.000 description 1
- CFTOTSJVQRFXOF-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CNCC2 CFTOTSJVQRFXOF-UHFFFAOYSA-N 0.000 description 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical compound C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 description 1
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 description 1
- YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical compound C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 description 1
- ZWWWYOKRVNYQHF-UHFFFAOYSA-N 2,3-dihydro-1h-1,2-benzodiazepine Chemical compound C1=CCNNC2=CC=CC=C21 ZWWWYOKRVNYQHF-UHFFFAOYSA-N 0.000 description 1
- BEWVAZNECYSPMT-UHFFFAOYSA-N 2,3-dihydro-1h-azepine Chemical compound C1CC=CC=CN1 BEWVAZNECYSPMT-UHFFFAOYSA-N 0.000 description 1
- QHYXWSXPPUTDRA-UHFFFAOYSA-N 2,3-dihydro-1h-diazepine Chemical compound C1NNC=CC=C1 QHYXWSXPPUTDRA-UHFFFAOYSA-N 0.000 description 1
- QDKGOMZIPXGDDJ-UHFFFAOYSA-N 2,3-dihydro-1h-indazole Chemical compound C1=CC=C2CNNC2=C1 QDKGOMZIPXGDDJ-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- WLGQUBABAPAJNB-UHFFFAOYSA-N 2,3-dihydrooxepine Chemical compound C1CC=CC=CO1 WLGQUBABAPAJNB-UHFFFAOYSA-N 0.000 description 1
- IZEOXCXHDBQQAP-UHFFFAOYSA-N 2,3-dihydrothiazepine Chemical compound C1NSC=CC=C1 IZEOXCXHDBQQAP-UHFFFAOYSA-N 0.000 description 1
- QSZUTAPGRWXHEO-UHFFFAOYSA-N 2,3-dihydrothiepine Chemical compound C1CC=CC=CS1 QSZUTAPGRWXHEO-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- PZJFUNZDCRKXPZ-UHFFFAOYSA-N 2,5-dihydro-1h-tetrazole Chemical compound C1NNN=N1 PZJFUNZDCRKXPZ-UHFFFAOYSA-N 0.000 description 1
- ZECQLHQEHJJSAN-UHFFFAOYSA-N 2,9-dihydro-1h-carbazole Chemical compound N1C2=CC=CC=C2C2=C1CCC=C2 ZECQLHQEHJJSAN-UHFFFAOYSA-N 0.000 description 1
- BIAPMJDDPWPHOP-UHFFFAOYSA-N 2,9-dihydro-1h-pyrido[3,4-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CNC=C2 BIAPMJDDPWPHOP-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- WWJBDSBGLBEFSH-UHFFFAOYSA-N 2-(4-methoxyphenyl)azepane Chemical compound C1=CC(OC)=CC=C1C1NCCCCC1 WWJBDSBGLBEFSH-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- WYUYEJNGHIOFOC-VVTVMFAVSA-N 2-[(z)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C\CN1CCCC1 WYUYEJNGHIOFOC-VVTVMFAVSA-N 0.000 description 1
- DGAHJUDAVWYUDW-UHFFFAOYSA-N 2-[3-[[benzyl-[(4-chlorophenyl)methyl]amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C1=CC=CC=C1C1=CC=CC(CN(CC=2C=CC=CC=2)CC=2C=CC(Cl)=CC=2)=C1 DGAHJUDAVWYUDW-UHFFFAOYSA-N 0.000 description 1
- VJKIXGAMLUFKII-UHFFFAOYSA-N 2-[4-[[(2-phenylacetyl)amino]methyl]phenyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)CC1=CC=CC=C1 VJKIXGAMLUFKII-UHFFFAOYSA-N 0.000 description 1
- CPSBQDRGXXXNBX-UHFFFAOYSA-N 2-[4-[[(4-cyanophenyl)methyl-heptan-4-ylamino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=C(C=2C(=CC=CC=2)C(O)=O)C=CC=1CN(C(CCC)CCC)CC1=CC=C(C#N)C=C1 CPSBQDRGXXXNBX-UHFFFAOYSA-N 0.000 description 1
- JXUWHKKVGRWWCB-UHFFFAOYSA-N 2-[4-[[benzyl(pentanoyl)amino]methyl]phenyl]benzoic acid Chemical compound C=1C=C(C=2C(=CC=CC=2)C(O)=O)C=CC=1CN(C(=O)CCCC)CC1=CC=CC=C1 JXUWHKKVGRWWCB-UHFFFAOYSA-N 0.000 description 1
- VXYDHPDQMSVQCU-UHFFFAOYSA-N 2-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)piperidin-1-yl]-n-hydroxyacetamide Chemical compound COC1=CC=C(C2(CCN(CC(=O)NO)CC2)C#N)C=C1OC1CCCC1 VXYDHPDQMSVQCU-UHFFFAOYSA-N 0.000 description 1
- KJYYQILGVKQZHT-UHFFFAOYSA-N 2-[[butyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]carbamoyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylic acid Chemical compound S1C=2CCCCC=2C(C(O)=O)=C1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 KJYYQILGVKQZHT-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- LYTMVABTDYMBQK-UHFFFAOYSA-N 2-benzothiophene Chemical compound C1=CC=CC2=CSC=C21 LYTMVABTDYMBQK-UHFFFAOYSA-N 0.000 description 1
- XULHFMYCBKQGEE-UHFFFAOYSA-N 2-hexyl-1-Decanol Chemical compound CCCCCCCCC(CO)CCCCCC XULHFMYCBKQGEE-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- CJNZAXGUTKBIHP-UHFFFAOYSA-N 2-iodobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- FGLBSLMDCBOPQK-UHFFFAOYSA-N 2-nitropropane Chemical compound CC(C)[N+]([O-])=O FGLBSLMDCBOPQK-UHFFFAOYSA-N 0.000 description 1
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 1
- FSUYMKXZLQOFQY-UHFFFAOYSA-N 3,4-dihydro-1,2-benzodithiine Chemical compound C1=CC=C2SSCCC2=C1 FSUYMKXZLQOFQY-UHFFFAOYSA-N 0.000 description 1
- NTOIMCSZPGZTND-UHFFFAOYSA-N 3,4-dihydro-1,2-benzoxathiine Chemical compound C1=CC=C2OSCCC2=C1 NTOIMCSZPGZTND-UHFFFAOYSA-N 0.000 description 1
- IDUSJBBWEKNWAK-UHFFFAOYSA-N 3,4-dihydro-2h-1,2-benzothiazine Chemical compound C1=CC=C2SNCCC2=C1 IDUSJBBWEKNWAK-UHFFFAOYSA-N 0.000 description 1
- BOLMDIXLULGTBD-UHFFFAOYSA-N 3,4-dihydro-2h-oxazine Chemical compound C1CC=CON1 BOLMDIXLULGTBD-UHFFFAOYSA-N 0.000 description 1
- NDTSIDOTKVWMRI-UHFFFAOYSA-N 3,4-dihydro-2h-pyrazino[2,3-b][1,4]oxazine Chemical compound C1=CN=C2NCCOC2=N1 NDTSIDOTKVWMRI-UHFFFAOYSA-N 0.000 description 1
- NWWJFMCCTZLKNT-UHFFFAOYSA-N 3,4-dihydro-2h-thiazine Chemical compound C1CC=CSN1 NWWJFMCCTZLKNT-UHFFFAOYSA-N 0.000 description 1
- ATVJJNGVPSKBGO-UHFFFAOYSA-N 3,4-dihydro-2h-thiopyran Chemical compound C1CSC=CC1 ATVJJNGVPSKBGO-UHFFFAOYSA-N 0.000 description 1
- ICHMVLMXGWNBOX-UHFFFAOYSA-N 3-(2-bromophenyl)-1-butyl-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC=C(Br)C=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 ICHMVLMXGWNBOX-UHFFFAOYSA-N 0.000 description 1
- KLPQJJKXRIDASJ-UHFFFAOYSA-N 3-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]-N-ethyl-8-propan-2-yl-7H-purin-6-imine Chemical compound CCN=C1C2=C(N=C(N2)C(C)C)N(C=N1)CC3=CC(=C(C=C3)OC)OC4CCCC4 KLPQJJKXRIDASJ-UHFFFAOYSA-N 0.000 description 1
- DOTGLEDGHCUFJJ-UHFFFAOYSA-N 3-[2-[(dibenzylamino)methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C1=CC=CC(C=2C(=CC=CC=2)CN(CC=2C=CC=CC=2)CC=2C=CC=CC=2)=C1 DOTGLEDGHCUFJJ-UHFFFAOYSA-N 0.000 description 1
- TWKYRKLMXPHFRJ-UHFFFAOYSA-N 3-[2-[[(4-chlorophenyl)methyl-(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C1=CC=CC(C=2C(=CC=CC=2)CN(CCCC=2C=CC=CC=2)CC=2C=CC(Cl)=CC=2)=C1 TWKYRKLMXPHFRJ-UHFFFAOYSA-N 0.000 description 1
- JCVLKIANADXUDG-UHFFFAOYSA-N 3-[2-[[2-phenylethyl(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C1=CC=CC(C=2C(=CC=CC=2)CN(CCCC=2C=CC=CC=2)CCC=2C=CC=CC=2)=C1 JCVLKIANADXUDG-UHFFFAOYSA-N 0.000 description 1
- MTEBKCOVNYANFQ-UHFFFAOYSA-N 3-[2-[[benzyl(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C1=CC=CC(C=2C(=CC=CC=2)CN(CCCC=2C=CC=CC=2)CC=2C=CC=CC=2)=C1 MTEBKCOVNYANFQ-UHFFFAOYSA-N 0.000 description 1
- JDDXIQVQFKUVEK-UHFFFAOYSA-N 3-[3-[[(4-cyanophenyl)methyl-(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C1=CC=CC(C=2C=C(CN(CCCC=3C=CC=CC=3)CC=3C=CC(=CC=3)C#N)C=CC=2)=C1 JDDXIQVQFKUVEK-UHFFFAOYSA-N 0.000 description 1
- XKXMITTZVZSHJW-UHFFFAOYSA-N 3-[3-[[benzyl(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C1=CC=CC(C=2C=C(CN(CCCC=3C=CC=CC=3)CC=3C=CC=CC=3)C=CC=2)=C1 XKXMITTZVZSHJW-UHFFFAOYSA-N 0.000 description 1
- UOHAJGACJGSUHU-UHFFFAOYSA-N 3-[3-[[bis(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C1=CC=CC(C=2C=C(CN(CCCC=3C=CC=CC=3)CCCC=3C=CC=CC=3)C=CC=2)=C1 UOHAJGACJGSUHU-UHFFFAOYSA-N 0.000 description 1
- CTTKTXWEBLACQG-UHFFFAOYSA-N 3-[4-[[(4-methoxyphenyl)methyl-(2-phenylethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(OC)=CC=C1CN(CC=1C=CC(=CC=1)C=1C=C(C=CC=1)C(O)=O)CCC1=CC=CC=C1 CTTKTXWEBLACQG-UHFFFAOYSA-N 0.000 description 1
- XPHKMYWUKNOIMH-UHFFFAOYSA-N 3-benzyl-1-butyl-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC=CC=1CNC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 XPHKMYWUKNOIMH-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- WHGMHGPIJZTKTI-UHFFFAOYSA-N 3h-1,2-benzodithiole Chemical compound C1=CC=C2CSSC2=C1 WHGMHGPIJZTKTI-UHFFFAOYSA-N 0.000 description 1
- GPYDBWWOYRNOBL-UHFFFAOYSA-N 4,5-dihydro-3h-1,2-benzodioxepine Chemical compound C1CCOOC2=CC=CC=C21 GPYDBWWOYRNOBL-UHFFFAOYSA-N 0.000 description 1
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 description 1
- MNHXYNNKDDXKNP-UHFFFAOYSA-N 4-(3-chlorophenyl)-1,7-diethyl-2-pyrido[2,3-d]pyrimidinone Chemical compound N=1C(=O)N(CC)C2=NC(CC)=CC=C2C=1C1=CC=CC(Cl)=C1 MNHXYNNKDDXKNP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 description 1
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 description 1
- KHWIDEDSLKUQDL-UHFFFAOYSA-N 4-[2-[[(4-chlorophenyl)methyl-(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1CN(CC=1C=CC(Cl)=CC=1)CCCC1=CC=CC=C1 KHWIDEDSLKUQDL-UHFFFAOYSA-N 0.000 description 1
- HUMPLPIFUFNHHU-UHFFFAOYSA-N 4-[2-[[(4-cyanophenyl)methyl-(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1CN(CC=1C=CC(=CC=1)C#N)CCCC1=CC=CC=C1 HUMPLPIFUFNHHU-UHFFFAOYSA-N 0.000 description 1
- OTPVIQLCLXGYBE-UHFFFAOYSA-N 4-[2-[[benzyl(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1CN(CC=1C=CC=CC=1)CCCC1=CC=CC=C1 OTPVIQLCLXGYBE-UHFFFAOYSA-N 0.000 description 1
- JHNRQBUYGDTRRM-UHFFFAOYSA-N 4-[2-[[benzyl(cyclohexylmethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1CN(CC=1C=CC=CC=1)CC1CCCCC1 JHNRQBUYGDTRRM-UHFFFAOYSA-N 0.000 description 1
- KNHKYWIDKHSYTF-UHFFFAOYSA-N 4-[2-[[bis(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1CN(CCCC=1C=CC=CC=1)CCCC1=CC=CC=C1 KNHKYWIDKHSYTF-UHFFFAOYSA-N 0.000 description 1
- NTRDEDPJUXFFSV-UHFFFAOYSA-N 4-[2-[[butyl-[(4-chlorophenyl)methyl]amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=C(C=2C=CC(=CC=2)C(O)=O)C=1CN(CCCC)CC1=CC=C(Cl)C=C1 NTRDEDPJUXFFSV-UHFFFAOYSA-N 0.000 description 1
- LEPUFWKHCHNHLL-UHFFFAOYSA-N 4-[3-[[(4-cyanophenyl)methyl-(2-phenylethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C1=CC=CC(CN(CCC=2C=CC=CC=2)CC=2C=CC(=CC=2)C#N)=C1 LEPUFWKHCHNHLL-UHFFFAOYSA-N 0.000 description 1
- QGIMNLYFHRTOEG-UHFFFAOYSA-N 4-[3-[[benzyl(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C1=CC=CC(CN(CCCC=2C=CC=CC=2)CC=2C=CC=CC=2)=C1 QGIMNLYFHRTOEG-UHFFFAOYSA-N 0.000 description 1
- HNINTMWCLKRSHV-UHFFFAOYSA-N 4-[3-[[cyclohexylmethyl(2-phenylethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C1=CC=CC(CN(CCC=2C=CC=CC=2)CC2CCCCC2)=C1 HNINTMWCLKRSHV-UHFFFAOYSA-N 0.000 description 1
- QJHYDKZHEUEGEE-UHFFFAOYSA-N 4-[4-[(dibenzylamino)methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CC=1C=CC=CC=1)CC1=CC=CC=C1 QJHYDKZHEUEGEE-UHFFFAOYSA-N 0.000 description 1
- WTHKSDWVQOFUHX-UHFFFAOYSA-N 4-[4-[[(4-chlorophenyl)methyl-(2-methoxyethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=C(C=2C=CC(=CC=2)C(O)=O)C=CC=1CN(CCOC)CC1=CC=C(Cl)C=C1 WTHKSDWVQOFUHX-UHFFFAOYSA-N 0.000 description 1
- PUVVWYCEOUKMID-UHFFFAOYSA-N 4-[4-[[(4-chlorophenyl)methyl-(2-phenylethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CC=1C=CC(Cl)=CC=1)CCC1=CC=CC=C1 PUVVWYCEOUKMID-UHFFFAOYSA-N 0.000 description 1
- WMWLZMTZEPAUQV-UHFFFAOYSA-N 4-[4-[[(4-chlorophenyl)methyl-(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CC=1C=CC(Cl)=CC=1)CCCC1=CC=CC=C1 WMWLZMTZEPAUQV-UHFFFAOYSA-N 0.000 description 1
- VTFLMXUZXCXBDS-UHFFFAOYSA-N 4-[4-[[(4-cyanophenyl)methyl-(2-phenylethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CC=1C=CC(=CC=1)C#N)CCC1=CC=CC=C1 VTFLMXUZXCXBDS-UHFFFAOYSA-N 0.000 description 1
- SAMUKQGBKBIDKZ-UHFFFAOYSA-N 4-[4-[[(4-cyanophenyl)methyl-(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CC=1C=CC(=CC=1)C#N)CCCC1=CC=CC=C1 SAMUKQGBKBIDKZ-UHFFFAOYSA-N 0.000 description 1
- AQNIQEACTGAWFN-UHFFFAOYSA-N 4-[4-[[(4-methoxyphenyl)methyl-(2-phenylethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(OC)=CC=C1CN(CC=1C=CC(=CC=1)C=1C=CC(=CC=1)C(O)=O)CCC1=CC=CC=C1 AQNIQEACTGAWFN-UHFFFAOYSA-N 0.000 description 1
- SUSHMFOTSVWABK-UHFFFAOYSA-N 4-[4-[[(4-methoxyphenyl)methyl-(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(OC)=CC=C1CN(CC=1C=CC(=CC=1)C=1C=CC(=CC=1)C(O)=O)CCCC1=CC=CC=C1 SUSHMFOTSVWABK-UHFFFAOYSA-N 0.000 description 1
- RSXPTGRUWIBIKJ-UHFFFAOYSA-N 4-[4-[[2-phenylethyl(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CCC=1C=CC=CC=1)CCCC1=CC=CC=C1 RSXPTGRUWIBIKJ-UHFFFAOYSA-N 0.000 description 1
- BZELGTSDMWRDCK-UHFFFAOYSA-N 4-[4-[[3-phenylpropyl(pyridin-2-ylmethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CC=1N=CC=CC=1)CCCC1=CC=CC=C1 BZELGTSDMWRDCK-UHFFFAOYSA-N 0.000 description 1
- FITUDDDMFJILPF-UHFFFAOYSA-N 4-[4-[[benzyl(butyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=C(C=2C=CC(=CC=2)C(O)=O)C=CC=1CN(CCCC)CC1=CC=CC=C1 FITUDDDMFJILPF-UHFFFAOYSA-N 0.000 description 1
- RWSJWDKLNJGNCM-UHFFFAOYSA-N 4-[4-[[benzyl(cyclohexylmethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CC=1C=CC=CC=1)CC1CCCCC1 RWSJWDKLNJGNCM-UHFFFAOYSA-N 0.000 description 1
- PJNNYIKMCFMVSF-UHFFFAOYSA-N 4-[4-[[benzyl(pentyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=C(C=2C=CC(=CC=2)C(O)=O)C=CC=1CN(CCCCC)CC1=CC=CC=C1 PJNNYIKMCFMVSF-UHFFFAOYSA-N 0.000 description 1
- MCTGINWQHVYQRI-UHFFFAOYSA-N 4-[4-[[bis(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CCCC=1C=CC=CC=1)CCCC1=CC=CC=C1 MCTGINWQHVYQRI-UHFFFAOYSA-N 0.000 description 1
- VEAIWPADBYMFOB-UHFFFAOYSA-N 4-[4-[[butyl(cyclohexylmethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=C(C=2C=CC(=CC=2)C(O)=O)C=CC=1CN(CCCC)CC1CCCCC1 VEAIWPADBYMFOB-UHFFFAOYSA-N 0.000 description 1
- SHWVCXXXTFBFCJ-UHFFFAOYSA-N 4-[4-[[butyl-[(4-chlorophenyl)methyl]amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=C(C=2C=CC(=CC=2)C(O)=O)C=CC=1CN(CCCC)CC1=CC=C(Cl)C=C1 SHWVCXXXTFBFCJ-UHFFFAOYSA-N 0.000 description 1
- GMRDUBKTXKGLRK-UHFFFAOYSA-N 4-[4-[[butyl-[(4-cyanophenyl)methyl]amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=C(C=2C=CC(=CC=2)C(O)=O)C=CC=1CN(CCCC)CC1=CC=C(C#N)C=C1 GMRDUBKTXKGLRK-UHFFFAOYSA-N 0.000 description 1
- CLUNYRKDAODAMW-UHFFFAOYSA-N 4-[4-[[cyclohexylmethyl(2-phenylethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CC1CCCCC1)CCC1=CC=CC=C1 CLUNYRKDAODAMW-UHFFFAOYSA-N 0.000 description 1
- XOAONLBLHYLGGM-UHFFFAOYSA-N 4-[4-[[heptan-4-yl(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=C(C=2C=CC(=CC=2)C(O)=O)C=CC=1CN(C(CCC)CCC)CCCC1=CC=CC=C1 XOAONLBLHYLGGM-UHFFFAOYSA-N 0.000 description 1
- PVYMYYGMZPFMPA-UHFFFAOYSA-N 4-[4-[[pentyl(2-phenylethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=C(C=2C=CC(=CC=2)C(O)=O)C=CC=1CN(CCCCC)CCC1=CC=CC=C1 PVYMYYGMZPFMPA-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- RKETZVBQTUSNLM-UHFFFAOYSA-N 6-(3-bromophenyl)-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole Chemical compound BrC1=CC=CC(C2N=C3SCCN3C2)=C1 RKETZVBQTUSNLM-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- WUWFMDMBOJLQIV-UHFFFAOYSA-N 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid Chemical compound C1C(N)CCN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F WUWFMDMBOJLQIV-UHFFFAOYSA-N 0.000 description 1
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 239000005964 Acibenzolar-S-methyl Substances 0.000 description 1
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- MROJXXOCABQVEF-UHFFFAOYSA-N Actarit Chemical compound CC(=O)NC1=CC=C(CC(O)=O)C=C1 MROJXXOCABQVEF-UHFFFAOYSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- LGPXEPJBSCUEHI-UHFFFAOYSA-N C(C)OC(NC(=O)N(CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)CCCC)=O Chemical compound C(C)OC(NC(=O)N(CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)CCCC)=O LGPXEPJBSCUEHI-UHFFFAOYSA-N 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 108010017312 CCR2 Receptors Proteins 0.000 description 1
- 108010017316 CCR3 Receptors Proteins 0.000 description 1
- 108010017317 CCR4 Receptors Proteins 0.000 description 1
- 108010017088 CCR5 Receptors Proteins 0.000 description 1
- 108010061300 CXCR3 Receptors Proteins 0.000 description 1
- 102000011963 CXCR3 Receptors Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 102000001326 Chemokine CCL4 Human genes 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- NTURVSFTOYPGON-UHFFFAOYSA-N Dihydroquinazoline Chemical compound C1=CC=C2C=NCNC2=C1 NTURVSFTOYPGON-UHFFFAOYSA-N 0.000 description 1
- 102100031107 Disintegrin and metalloproteinase domain-containing protein 11 Human genes 0.000 description 1
- 101710121366 Disintegrin and metalloproteinase domain-containing protein 11 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- URJQOOISAKEBKW-UHFFFAOYSA-N Emorfazone Chemical compound C1=NN(C)C(=O)C(OCC)=C1N1CCOCC1 URJQOOISAKEBKW-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- RHAXSHUQNIEUEY-UHFFFAOYSA-N Epirizole Chemical compound COC1=CC(C)=NN1C1=NC(C)=CC(OC)=N1 RHAXSHUQNIEUEY-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001293 FEMA 3089 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VWWQXMAJTJZDQX-UHFFFAOYSA-N Flavine adenine dinucleotide Natural products C1=NC2=C(N)N=CN=C2N1C(C(O)C1O)OC1COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UHFFFAOYSA-N 0.000 description 1
- APQPGQGAWABJLN-UHFFFAOYSA-N Floctafenine Chemical compound OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=C(C(F)(F)F)C=CC=C12 APQPGQGAWABJLN-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- ALIVXCSEERJYHU-UHFFFAOYSA-N Flurbiprofen axetil Chemical compound FC1=CC(C(C)C(=O)OC(OC(C)=O)C)=CC=C1C1=CC=CC=C1 ALIVXCSEERJYHU-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229940033332 HIV-1 vaccine Drugs 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- YCISZOVUHXIOFY-HKXOFBAYSA-N Halopredone acetate Chemical compound C1([C@H](F)C2)=CC(=O)C(Br)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@](OC(C)=O)(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O YCISZOVUHXIOFY-HKXOFBAYSA-N 0.000 description 1
- 229920001499 Heparinoid Polymers 0.000 description 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000864393 Homo sapiens Protein BUD31 homolog Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- ACEWLPOYLGNNHV-UHFFFAOYSA-N Ibuprofen piconol Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OCC1=CC=CC=N1 ACEWLPOYLGNNHV-UHFFFAOYSA-N 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 108010018976 Interleukin-8A Receptors Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- QPJBONAWFAURGB-UHFFFAOYSA-L Lobenzarit disodium Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1NC1=CC(Cl)=CC=C1C([O-])=O QPJBONAWFAURGB-UHFFFAOYSA-L 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- DTXXSJZBSTYZKE-ZDQKKZTESA-N Maxacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](OCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C DTXXSJZBSTYZKE-ZDQKKZTESA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 102000046795 Mitogen-Activated Protein Kinase 3 Human genes 0.000 description 1
- 108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100236212 Mus musculus Ltb4r2 gene Proteins 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- HUMXXHTVHHLNRO-KAJVQRHHSA-N Prednisolone tebutate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC(C)(C)C)(O)[C@@]1(C)C[C@@H]2O HUMXXHTVHHLNRO-KAJVQRHHSA-N 0.000 description 1
- YWYQTGBBEZQBGO-BERLURQNSA-N Pregnanediol Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](O)C)[C@@]2(C)CC1 YWYQTGBBEZQBGO-BERLURQNSA-N 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 102100026476 Prostacyclin receptor Human genes 0.000 description 1
- 101710170814 Prostacyclin receptor Proteins 0.000 description 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 1
- 102000000471 Prostaglandin F receptors Human genes 0.000 description 1
- 108050008995 Prostaglandin F receptors Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100030160 Protein BUD31 homolog Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VYWWNRMSAPEJLS-MDWYKHENSA-N Rokitamycin Chemical compound C1[C@](OC(=O)CC)(C)[C@@H](OC(=O)CCC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](O)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C VYWWNRMSAPEJLS-MDWYKHENSA-N 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 239000004163 Spermaceti wax Substances 0.000 description 1
- 108010086613 Streptodornase and Streptokinase Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- JZFICWYCTCCINF-UHFFFAOYSA-N Thiadiazin Chemical compound S=C1SC(C)NC(C)N1CCN1C(=S)SC(C)NC1C JZFICWYCTCCINF-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- XGMPVBXKDAHORN-RBWIMXSLSA-N Triamcinolone diacetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](OC(C)=O)[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O XGMPVBXKDAHORN-RBWIMXSLSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- YWYQTGBBEZQBGO-UHFFFAOYSA-N UC1011 Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(O)C)C1(C)CC2 YWYQTGBBEZQBGO-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- FXXSETTYJSGMCR-GLCLSGQWSA-N Valacillin (TN) Chemical compound [Cl-].O1C(=O)OC(COC(=O)[C@H]2C(S[C@H]3[NH+]2C([C@H]3NC(=O)[C@H](N)C=2C=CC=CC=2)=O)(C)C)=C1C FXXSETTYJSGMCR-GLCLSGQWSA-N 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- NTCYWJCEOILKNG-ROLPUNSJSA-N [(1r,2s)-1-hydroxy-1-phenylpropan-2-yl]-dimethylazanium;chloride Chemical compound Cl.CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 NTCYWJCEOILKNG-ROLPUNSJSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- RYVJQEZJUFRANT-UHFFFAOYSA-N [3-[4-(3-ethoxy-2-hydroxypropoxy)anilino]-3-oxopropyl]-dimethylsulfanium;4-methylbenzenesulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CCOCC(O)COC1=CC=C(NC(=O)CC[S+](C)C)C=C1 RYVJQEZJUFRANT-UHFFFAOYSA-N 0.000 description 1
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 description 1
- PVQATPQSBYNMGE-UHFFFAOYSA-N [benzhydryloxy(phenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)OC(C=1C=CC=CC=1)C1=CC=CC=C1 PVQATPQSBYNMGE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 1
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
- 229960004266 acetylcholine chloride Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229950003218 actarit Drugs 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229960004229 alclometasone dipropionate Drugs 0.000 description 1
- DJHCCTTVDRAMEH-DUUJBDRPSA-N alclometasone dipropionate Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O DJHCCTTVDRAMEH-DUUJBDRPSA-N 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- OSQHGAXCVAYZPZ-UHFFFAOYSA-K aluminum;2-[3-(trifluoromethyl)anilino]benzoate Chemical compound [Al+3].[O-]C(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1.[O-]C(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1.[O-]C(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 OSQHGAXCVAYZPZ-UHFFFAOYSA-K 0.000 description 1
- QZNJPJDUBTYMRS-UHFFFAOYSA-M amfenac sodium hydrate Chemical compound O.[Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=CC=C1 QZNJPJDUBTYMRS-UHFFFAOYSA-M 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229940126574 aminoglycoside antibiotic Drugs 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 108010074587 aminooxypentane-RANTES Proteins 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- LSNWBKACGXCGAJ-UHFFFAOYSA-N ampiroxicam Chemical compound CN1S(=O)(=O)C2=CC=CC=C2C(OC(C)OC(=O)OCC)=C1C(=O)NC1=CC=CC=N1 LSNWBKACGXCGAJ-UHFFFAOYSA-N 0.000 description 1
- 229950011249 ampiroxicam Drugs 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 125000005577 anthracene group Chemical group 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000002787 antisense oligonuctleotide Substances 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229940114078 arachidonate Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical compound C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229950006944 atizoram Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960001799 aurothioglucose Drugs 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- MVXVYAKCVDQRLW-UHFFFAOYSA-N azain Natural products C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960004335 azelastine hydrochloride Drugs 0.000 description 1
- YEJAJYAHJQIWNU-UHFFFAOYSA-N azelastine hydrochloride Chemical compound Cl.C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 YEJAJYAHJQIWNU-UHFFFAOYSA-N 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960005149 bendazac Drugs 0.000 description 1
- BYFMCKSPFYVMOU-UHFFFAOYSA-N bendazac Chemical compound C12=CC=CC=C2C(OCC(=O)O)=NN1CC1=CC=CC=C1 BYFMCKSPFYVMOU-UHFFFAOYSA-N 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 description 1
- 229960004648 betamethasone acetate Drugs 0.000 description 1
- VXOWJCTXWVWLLC-REGDIAEZSA-N betamethasone butyrate propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O VXOWJCTXWVWLLC-REGDIAEZSA-N 0.000 description 1
- 229950008408 betamethasone butyrate propionate Drugs 0.000 description 1
- 229950006991 betamethasone phosphate Drugs 0.000 description 1
- VIQRCOQXIHFJND-UHFFFAOYSA-N bicyclo[2.2.2]oct-2-ene Chemical group C1CC2CCC1C=C2 VIQRCOQXIHFJND-UHFFFAOYSA-N 0.000 description 1
- DEVHXDJLQMAWLM-UHFFFAOYSA-N bicyclo[3.1.1]hept-3-ene Chemical compound C1C2CC1CC=C2 DEVHXDJLQMAWLM-UHFFFAOYSA-N 0.000 description 1
- SHOMMGQAMRXRRK-UHFFFAOYSA-N bicyclo[3.1.1]heptane Chemical compound C1C2CC1CCC2 SHOMMGQAMRXRRK-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 229960004272 bucillamine Drugs 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- GRADOOOISCPIDG-UHFFFAOYSA-N buta-1,3-diyne Chemical group [C]#CC#C GRADOOOISCPIDG-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229940105847 calamine Drugs 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
- 229950003631 carpronium chloride Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229950010227 cefotiam hexetil Drugs 0.000 description 1
- LTINZAODLRIQIX-FBXRGJNPSA-N cefpodoxime proxetil Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(=O)OC(C)OC(=O)OC(C)C)C(=O)C(=N/OC)\C1=CSC(N)=N1 LTINZAODLRIQIX-FBXRGJNPSA-N 0.000 description 1
- 229960004797 cefpodoxime proxetil Drugs 0.000 description 1
- 229960002620 cefuroxime axetil Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 description 1
- 150000001782 cephems Chemical class 0.000 description 1
- 229960004342 cetirizine hydrochloride Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- SFHUSLFRIKHKPE-UHFFFAOYSA-L chloro-[(2,5-dioxoimidazolidin-4-yl)carbamoylamino]aluminum;hydrate Chemical compound O.NC(=O)NC1NC(=O)N([Al]Cl)C1=O SFHUSLFRIKHKPE-UHFFFAOYSA-L 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 239000003766 cholecystokinin A receptor antagonist Substances 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229950001653 cilomilast Drugs 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- GPUVGQIASQNZET-CCEZHUSRSA-N cinnoxicam Chemical compound C=1C=CC=CC=1/C=C/C(=O)OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 GPUVGQIASQNZET-CCEZHUSRSA-N 0.000 description 1
- KSPYMJJKQMWWNB-UHFFFAOYSA-N cipamfylline Chemical compound O=C1N(CC2CC2)C(=O)C=2NC(N)=NC=2N1CC1CC1 KSPYMJJKQMWWNB-UHFFFAOYSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002689 clemastine fumarate Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 150000001925 cycloalkenes Chemical class 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- LMGZGXSXHCMSAA-UHFFFAOYSA-N cyclodecane Chemical compound C1CCCCCCCCC1 LMGZGXSXHCMSAA-UHFFFAOYSA-N 0.000 description 1
- DDTBPAQBQHZRDW-UHFFFAOYSA-N cyclododecane Chemical compound C1CCCCCCCCCCC1 DDTBPAQBQHZRDW-UHFFFAOYSA-N 0.000 description 1
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- GPTJTTCOVDDHER-UHFFFAOYSA-N cyclononane Chemical compound C1CCCCCCCC1 GPTJTTCOVDDHER-UHFFFAOYSA-N 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- URYYVOIYTNXXBN-UPHRSURJSA-N cyclooctene Chemical compound C1CCC\C=C/CC1 URYYVOIYTNXXBN-UPHRSURJSA-N 0.000 description 1
- 239000004913 cyclooctene Substances 0.000 description 1
- KFGVRWGDTLZAAO-UHFFFAOYSA-N cyclopenta-1,3-diene dicyclohexyl(cyclopenta-1,3-dien-1-yl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.C1CCC(CC1)P(C1CCCCC1)c1ccc[cH-]1 KFGVRWGDTLZAAO-UHFFFAOYSA-N 0.000 description 1
- SRONXYPFSAKOGH-UHFFFAOYSA-N cyclopentadecane Chemical group C1CCCCCCCCCCCCCC1 SRONXYPFSAKOGH-UHFFFAOYSA-N 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- KATXJJSCAPBIOB-UHFFFAOYSA-N cyclotetradecane Chemical compound C1CCCCCCCCCCCCC1 KATXJJSCAPBIOB-UHFFFAOYSA-N 0.000 description 1
- UEVXKGPJXXDGCX-UHFFFAOYSA-N cyclotridecane Chemical compound C1CCCCCCCCCCCC1 UEVXKGPJXXDGCX-UHFFFAOYSA-N 0.000 description 1
- KYTNZWVKKKJXFS-UHFFFAOYSA-N cycloundecane Chemical compound C1CCCCCCCCCC1 KYTNZWVKKKJXFS-UHFFFAOYSA-N 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- MTZXHKAPOZYPCQ-NHVFNMKISA-N d05511 Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1.OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1.OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO.OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO.OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO.OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO.OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO MTZXHKAPOZYPCQ-NHVFNMKISA-N 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- AJOXHJPWFCGMBU-DHUJRADRSA-N decyl (2s)-2-[[butyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]carbamoyl]amino]-3-(4-hydroxyphenyl)propanoate Chemical compound C([C@@H](C(=O)OCCCCCCCCCC)NC(=O)N(CCCC)CC=1C=CC(=CC=1)C=1C(=CC=CC=1)C=1NN=NN=1)C1=CC=C(O)C=C1 AJOXHJPWFCGMBU-DHUJRADRSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229950000812 dexamethasone palmitate Drugs 0.000 description 1
- RPBJOYICBFNIMN-RDWMNNCQSA-M dexamethasone sodium m-sulfobenzoate Chemical compound [Na+].O=C([C@]1(O)[C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)COC(=O)C1=CC=CC(S([O-])(=O)=O)=C1 RPBJOYICBFNIMN-RDWMNNCQSA-M 0.000 description 1
- 229960005372 dexchlorpheniramine maleate Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical compound C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 description 1
- HTFFABIIOAKIBH-UHFFFAOYSA-N diazinane Chemical compound C1CCNNC1 HTFFABIIOAKIBH-UHFFFAOYSA-N 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- XCFZLSYVIQYSJT-UHFFFAOYSA-N diethyl 2-[[butyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]carbamoyl]amino]-2-(2-cyanoethyl)propanedioate Chemical compound C1=CC(CN(CCCC)C(=O)NC(CCC#N)(C(=O)OCC)C(=O)OCC)=CC=C1C1=CC=CC=C1C1=NN=NN1 XCFZLSYVIQYSJT-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- BADXJIPKFRBFOT-UHFFFAOYSA-N dimedone Chemical compound CC1(C)CC(=O)CC(=O)C1 BADXJIPKFRBFOT-UHFFFAOYSA-N 0.000 description 1
- JGKVKXPDDVRUKC-UHFFFAOYSA-N dimethothiazine mesylate Chemical compound CS(O)(=O)=O.C1=C(S(=O)(=O)N(C)C)C=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 JGKVKXPDDVRUKC-UHFFFAOYSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 229960004646 diphenhydramine tannate Drugs 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- OWQUZNMMYNAXSL-UHFFFAOYSA-N diphenylpyraline Chemical compound C1CN(C)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 OWQUZNMMYNAXSL-UHFFFAOYSA-N 0.000 description 1
- 229960000879 diphenylpyraline Drugs 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- VXIHRIQNJCRFQX-UHFFFAOYSA-K disodium aurothiomalate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O VXIHRIQNJCRFQX-UHFFFAOYSA-K 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- MOGICMVNWAUWMK-HIXRZVNASA-L disodium;(5r,6s)-6-[(1r)-1-hydroxyethyl]-7-oxo-3-[(2r)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate;pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].S([C@@H]1[C@H](C(N1C=1C([O-])=O)=O)[C@H](O)C)C=1[C@H]1CCCO1.S([C@@H]1[C@H](C(N1C=1C([O-])=O)=O)[C@H](O)C)C=1[C@H]1CCCO1 MOGICMVNWAUWMK-HIXRZVNASA-L 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940073563 dl- methylephedrine hydrochloride Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229960004082 doxycycline hydrochloride Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- KYFWUBJMTHVBIF-QFIPXVFZSA-N dsstox_cid_27248 Chemical compound N([C@@H]1N=C(C=2C=3N(C1=O)CCC=3C=C(C=2)C)C=1C=CC=CC=1)C(=O)C1=CC=NC=C1 KYFWUBJMTHVBIF-QFIPXVFZSA-N 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229960001971 ebastine Drugs 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 229950010243 emorfazone Drugs 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 239000003248 enzyme activator Substances 0.000 description 1
- 229950003801 epirizole Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- DXIDZJKAMMFMDK-XIFFEERXSA-N ethyl (2S)-2-[[butyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]carbamoyl]oxy-ethylamino]-3-(4-hydroxyphenyl)-2-methylpropanoate Chemical compound C(CCC)N(C(=O)ON([C@@](CC1=CC=C(C=C1)O)(C(=O)OCC)C)CC)CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1 DXIDZJKAMMFMDK-XIFFEERXSA-N 0.000 description 1
- QJIQPLMVMPPAAL-UHFFFAOYSA-N ethyl 2-[[butyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]carbamoyl]amino]-4-nitrobenzoate Chemical compound C=1C([N+]([O-])=O)=CC=C(C(=O)OCC)C=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 QJIQPLMVMPPAAL-UHFFFAOYSA-N 0.000 description 1
- XEYRVAQJYPIGER-UHFFFAOYSA-N ethyl 2-[[butyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]carbamoyl]amino]benzoate Chemical compound C=1C=CC=C(C(=O)OCC)C=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 XEYRVAQJYPIGER-UHFFFAOYSA-N 0.000 description 1
- KXOULIGNWPZRGB-UHFFFAOYSA-N ethyl 2-[benzyl-[butyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]carbamoyl]amino]acetate Chemical compound C=1C=CC=CC=1CN(CC(=O)OCC)C(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 KXOULIGNWPZRGB-UHFFFAOYSA-N 0.000 description 1
- STOLVIATJQKTJX-UHFFFAOYSA-N ethyl 3-[[butyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]carbamoyl]amino]benzoate Chemical compound C=1C=CC(C(=O)OCC)=CC=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 STOLVIATJQKTJX-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 229960000379 faropenem Drugs 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 229960003306 fleroxacin Drugs 0.000 description 1
- XBJBPGROQZJDOJ-UHFFFAOYSA-N fleroxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F XBJBPGROQZJDOJ-UHFFFAOYSA-N 0.000 description 1
- 229960003240 floctafenine Drugs 0.000 description 1
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960001321 flunoxaprofen Drugs 0.000 description 1
- ARPYQKTVRGFPIS-VIFPVBQESA-N flunoxaprofen Chemical compound N=1C2=CC([C@@H](C(O)=O)C)=CC=C2OC=1C1=CC=C(F)C=C1 ARPYQKTVRGFPIS-VIFPVBQESA-N 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960003336 fluorocortisol acetate Drugs 0.000 description 1
- 229950005941 flurbiprofen axetil Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- VPSRLGDRGCKUTK-UHFFFAOYSA-N fura-2-acetoxymethyl ester Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=CC2=C1OC(C=1OC(=CN=1)C(=O)OCOC(C)=O)=C2 VPSRLGDRGCKUTK-UHFFFAOYSA-N 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 229940083579 fusidate sodium Drugs 0.000 description 1
- 229940125777 fusion inhibitor Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 229950004611 halopredone acetate Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 229910052864 hemimorphite Inorganic materials 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 239000002554 heparinoid Substances 0.000 description 1
- POOYFSLWYLDQMD-UHFFFAOYSA-N heptacalcium;zinc Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Zn+2] POOYFSLWYLDQMD-UHFFFAOYSA-N 0.000 description 1
- DDTGNKBZWQHIEH-UHFFFAOYSA-N heptalene Chemical compound C1=CC=CC=C2C=CC=CC=C21 DDTGNKBZWQHIEH-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 102000043426 human LTB4R2 Human genes 0.000 description 1
- BNRNAKTVFSZAFA-UHFFFAOYSA-N hydrindane Chemical compound C1CCCC2CCCC21 BNRNAKTVFSZAFA-UHFFFAOYSA-N 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960003220 hydroxyzine hydrochloride Drugs 0.000 description 1
- 229960001560 hydroxyzine pamoate Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229950005954 ibuprofen piconol Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 229960003517 isothipendyl Drugs 0.000 description 1
- OQJBSDFFQWMKBQ-UHFFFAOYSA-N isothipendyl Chemical compound C1=CN=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 OQJBSDFFQWMKBQ-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 1
- 229960004144 josamycin Drugs 0.000 description 1
- 239000009428 kamisyoyo san Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960000194 kebuzone Drugs 0.000 description 1
- LGYTZKPVOAIUKX-UHFFFAOYSA-N kebuzone Chemical compound O=C1C(CCC(=O)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 LGYTZKPVOAIUKX-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 229950005831 lenampicillin Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960003814 lomefloxacin hydrochloride Drugs 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000010169 makyokansekito Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229950006319 maxacalcitol Drugs 0.000 description 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 229960005042 mequitazine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 108010086335 methionine stromal cell-derived factor-1beta Proteins 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- MNUSHZDUHWBMSZ-UHFFFAOYSA-N methyl 2-(4-formylphenyl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1=CC=C(C=O)C=C1 MNUSHZDUHWBMSZ-UHFFFAOYSA-N 0.000 description 1
- OHHITJYTTZWFBQ-UHFFFAOYSA-N methyl 2-[4-(aminomethyl)phenyl]benzoate;hydrochloride Chemical compound Cl.COC(=O)C1=CC=CC=C1C1=CC=C(CN)C=C1 OHHITJYTTZWFBQ-UHFFFAOYSA-N 0.000 description 1
- UOLMZWZSLYSILW-UHFFFAOYSA-N methyl 2-[4-(azidomethyl)phenyl]benzoate Chemical compound COC(=O)C1=CC=CC=C1C1=CC=C(CN=[N+]=[N-])C=C1 UOLMZWZSLYSILW-UHFFFAOYSA-N 0.000 description 1
- RMXGTMRDXKUUDJ-UHFFFAOYSA-N methyl 2-[4-(bromomethyl)phenyl]benzoate Chemical compound COC(=O)C1=CC=CC=C1C1=CC=C(CBr)C=C1 RMXGTMRDXKUUDJ-UHFFFAOYSA-N 0.000 description 1
- HCRFHWQUDDECED-UHFFFAOYSA-N methyl 2-[4-(hydroxymethyl)phenyl]benzoate Chemical compound COC(=O)C1=CC=CC=C1C1=CC=C(CO)C=C1 HCRFHWQUDDECED-UHFFFAOYSA-N 0.000 description 1
- DGKCKKBEEQHWSX-UHFFFAOYSA-N methyl 2-[4-[(benzylamino)methyl]phenyl]benzoate Chemical compound COC(=O)C1=CC=CC=C1C(C=C1)=CC=C1CNCC1=CC=CC=C1 DGKCKKBEEQHWSX-UHFFFAOYSA-N 0.000 description 1
- ZRAYQYYGRUJUBO-UHFFFAOYSA-N methyl 2-[4-[[benzyl(pentanoyl)amino]methyl]phenyl]benzoate Chemical compound C=1C=C(C=2C(=CC=CC=2)C(=O)OC)C=CC=1CN(C(=O)CCCC)CC1=CC=CC=C1 ZRAYQYYGRUJUBO-UHFFFAOYSA-N 0.000 description 1
- YAPPSBSJBWVSKM-UHFFFAOYSA-N methyl 2-[[butyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]carbamothioyl]amino]acetate Chemical compound C1=CC(CN(CCCC)C(=S)NCC(=O)OC)=CC=C1C1=CC=CC=C1C1=NN=NN1 YAPPSBSJBWVSKM-UHFFFAOYSA-N 0.000 description 1
- GSSOPTGQOVHMEA-UHFFFAOYSA-N methyl 2-[[butyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]carbamoyl]-(cyclohexylmethyl)amino]acetate Chemical compound C1CCCCC1CN(CC(=O)OC)C(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 GSSOPTGQOVHMEA-UHFFFAOYSA-N 0.000 description 1
- SGBSKUMYIRZGCO-UHFFFAOYSA-N methyl 2-[butyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]carbamoyl]oxy-3-phenylpropanoate Chemical compound C=1C=CC=CC=1CC(C(=O)OC)OC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 SGBSKUMYIRZGCO-UHFFFAOYSA-N 0.000 description 1
- FFGHEXHKQXVIMF-UHFFFAOYSA-N methyl 3-[[butyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]carbamoyl]amino]thiophene-2-carboxylate Chemical compound C1=CSC(C(=O)OC)=C1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 FFGHEXHKQXVIMF-UHFFFAOYSA-N 0.000 description 1
- 125000006261 methyl amino sulfonyl group Chemical group [H]N(C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960002421 minocycline hydrochloride Drugs 0.000 description 1
- REOJLIXKJWXUGB-UHFFFAOYSA-N mofebutazone Chemical compound O=C1C(CCCC)C(=O)NN1C1=CC=CC=C1 REOJLIXKJWXUGB-UHFFFAOYSA-N 0.000 description 1
- 229960005285 mofebutazone Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229940126403 monoamine reuptake inhibitor Drugs 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- YKQOSKADJPQZHB-RGYSVOEGSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(6r,9s,12r,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydr Chemical compound CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)C([C@@H](C)O)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O YKQOSKADJPQZHB-RGYSVOEGSA-N 0.000 description 1
- YDTNDBLWQKZYMO-UHFFFAOYSA-N n-butyl-n-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-3,4-dihydro-2h-quinoline-1-carboxamide Chemical compound C1CCC2=CC=CC=C2N1C(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 YDTNDBLWQKZYMO-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229960003808 nadifloxacin Drugs 0.000 description 1
- JYJTVFIEFKZWCJ-UHFFFAOYSA-N nadifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)CCC3=C1N1CCC(O)CC1 JYJTVFIEFKZWCJ-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002746 neurokinin 2 receptor antagonist Substances 0.000 description 1
- 239000004082 neurotensin receptor antagonist Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- JFNLZVQOOSMTJK-UHFFFAOYSA-N norbornene Chemical compound C1C2CCC1C=C2 JFNLZVQOOSMTJK-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- NIEHEMAZEULEKB-UHFFFAOYSA-N ortho-ethylanisole Natural products CCC1=CC=CC=C1OC NIEHEMAZEULEKB-UHFFFAOYSA-N 0.000 description 1
- OTLYTKRAADUASA-UHFFFAOYSA-N oxadiazepane Chemical compound C1CCONNC1 OTLYTKRAADUASA-UHFFFAOYSA-N 0.000 description 1
- RYDICHIKLKVOEJ-UHFFFAOYSA-N oxadiazepine Chemical compound O1C=CC=CN=N1 RYDICHIKLKVOEJ-UHFFFAOYSA-N 0.000 description 1
- XCRJTRCPEJKXLR-UHFFFAOYSA-N oxadiazinane Chemical compound C1CNNOC1 XCRJTRCPEJKXLR-UHFFFAOYSA-N 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- IVMHDOBGNQOUHO-UHFFFAOYSA-N oxathiane Chemical compound C1CCSOC1 IVMHDOBGNQOUHO-UHFFFAOYSA-N 0.000 description 1
- AQNQGBUEVCAVML-UHFFFAOYSA-N oxazepane Chemical compound C1CCNOCC1 AQNQGBUEVCAVML-UHFFFAOYSA-N 0.000 description 1
- SFJGCXYXEFWEBK-UHFFFAOYSA-N oxazepine Chemical compound O1C=CC=CC=N1 SFJGCXYXEFWEBK-UHFFFAOYSA-N 0.000 description 1
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 1
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 229960004368 oxytetracycline hydrochloride Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 1
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 1
- 229960000903 pantethine Drugs 0.000 description 1
- 235000008975 pantethine Nutrition 0.000 description 1
- 239000011581 pantethine Substances 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 229940127242 parasympathomimetic drug Drugs 0.000 description 1
- 229940069533 paregoric Drugs 0.000 description 1
- 239000008414 paregoric Substances 0.000 description 1
- DXHYQIJBUNRPJT-UHFFFAOYSA-N parsalmide Chemical compound CCCCNC(=O)C1=CC(N)=CC=C1OCC#C DXHYQIJBUNRPJT-UHFFFAOYSA-N 0.000 description 1
- HHXMXAQDOUCLDN-RXMQYKEDSA-N penem Chemical compound S1C=CN2C(=O)C[C@H]21 HHXMXAQDOUCLDN-RXMQYKEDSA-N 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- XDJOIMJURHQYDW-UHFFFAOYSA-N phenalene Chemical compound C1=CC(CC=C2)=C3C2=CC=CC3=C1 XDJOIMJURHQYDW-UHFFFAOYSA-N 0.000 description 1
- GJSGGHOYGKMUPT-UHFFFAOYSA-N phenoxathiine Chemical compound C1=CC=C2OC3=CC=CC=C3SC2=C1 GJSGGHOYGKMUPT-UHFFFAOYSA-N 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- SFLGSKRGOWRGBR-UHFFFAOYSA-N phthalane Chemical compound C1=CC=C2COCC2=C1 SFLGSKRGOWRGBR-UHFFFAOYSA-N 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011297 pine tar Substances 0.000 description 1
- 229940068124 pine tar Drugs 0.000 description 1
- 229960001369 piroxicam cinnamate Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- NFOHLBHARAZXFQ-UHFFFAOYSA-L platinum(2+);dihydroxide Chemical compound O[Pt]O NFOHLBHARAZXFQ-UHFFFAOYSA-L 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- ZUFQCVZBBNZMKD-UHFFFAOYSA-M potassium 2-ethylhexanoate Chemical compound [K+].CCCCC(CC)C([O-])=O ZUFQCVZBBNZMKD-UHFFFAOYSA-M 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 description 1
- 229960002943 prednisolone sodium phosphate Drugs 0.000 description 1
- 229960002176 prednisolone sodium succinate Drugs 0.000 description 1
- 229960004259 prednisolone tebutate Drugs 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229960000825 proglumetacin Drugs 0.000 description 1
- MKFWBVKQDGNXDW-SPIKMXEPSA-N proglumetacin dimaleate Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C=1C=CC=CC=1C(=O)NC(C(=O)N(CCC)CCC)CCC(=O)OCCCN(CC1)CCN1CCOC(=O)CC(C1=CC(OC)=CC=C11)=C(C)N1C(=O)C1=CC=C(Cl)C=C1 MKFWBVKQDGNXDW-SPIKMXEPSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- NSETWVJZUWGCKE-UHFFFAOYSA-N propylphosphonic acid Chemical compound CCCP(O)(O)=O NSETWVJZUWGCKE-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- QBERHIJABFXGRZ-UHFFFAOYSA-M rhodium;triphenylphosphane;chloride Chemical compound [Cl-].[Rh].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QBERHIJABFXGRZ-UHFFFAOYSA-M 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 150000003287 riboflavins Chemical class 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- 229960001170 rokitamycin Drugs 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- WEMQMWWWCBYPOV-UHFFFAOYSA-N s-indacene Chemical compound C=1C2=CC=CC2=CC2=CC=CC2=1 WEMQMWWWCBYPOV-UHFFFAOYSA-N 0.000 description 1
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003523 serotonin 4 antagonist Substances 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 239000000387 serotonin 5-HT4 receptor agonist Substances 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 229950000112 serrapeptase Drugs 0.000 description 1
- 108010038132 serratiopeptidase Proteins 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- IMOLVSPMDGCLMB-UHFFFAOYSA-N simetride Chemical compound COC1=CC(CCC)=CC=C1OCC(=O)N1CCN(C(=O)COC=2C(=CC(CCC)=CC=2)OC)CC1 IMOLVSPMDGCLMB-UHFFFAOYSA-N 0.000 description 1
- 229950007670 simetride Drugs 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229960001315 sodium aurothiomalate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 1
- DOZOPSLNCNXCNU-UHFFFAOYSA-M sodium;2-[2-[(n-(4-chlorobenzoyl)anilino)methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1C1=CC=CC=C1CN(C=1C=CC=CC=1)C(=O)C1=CC=C(Cl)C=C1 DOZOPSLNCNXCNU-UHFFFAOYSA-M 0.000 description 1
- ICVAGEPSSOEGIU-UHFFFAOYSA-M sodium;2-[2-[[(2-phenylacetyl)-(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1C1=CC=CC=C1CN(C(=O)CC=1C=CC=CC=1)CCCC1=CC=CC=C1 ICVAGEPSSOEGIU-UHFFFAOYSA-M 0.000 description 1
- SDXNLHDLHJHBEF-UHFFFAOYSA-M sodium;2-[2-[[(4-chlorobenzoyl)-(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1C1=CC=CC=C1CN(C(=O)C=1C=CC(Cl)=CC=1)CCCC1=CC=CC=C1 SDXNLHDLHJHBEF-UHFFFAOYSA-M 0.000 description 1
- ZJWSOEPJXDCINV-UHFFFAOYSA-M sodium;2-[2-[[(4-chlorobenzoyl)-heptan-4-ylamino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=C(Cl)C=CC=1C(=O)N(C(CCC)CCC)CC1=CC=CC=C1C1=CC=CC=C1C([O-])=O ZJWSOEPJXDCINV-UHFFFAOYSA-M 0.000 description 1
- UAWFWHBPAVGFTI-UHFFFAOYSA-M sodium;2-[2-[[(4-methoxybenzoyl)-(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(OC)=CC=C1C(=O)N(CC=1C(=CC=CC=1)C=1C(=CC=CC=1)C([O-])=O)CCCC1=CC=CC=C1 UAWFWHBPAVGFTI-UHFFFAOYSA-M 0.000 description 1
- VVGPPHWFPYYGPQ-UHFFFAOYSA-M sodium;2-[2-[[3-phenylpropanoyl(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1C1=CC=CC=C1CN(C(=O)CCC=1C=CC=CC=1)CCCC1=CC=CC=C1 VVGPPHWFPYYGPQ-UHFFFAOYSA-M 0.000 description 1
- GEQJMINZRKCRPI-UHFFFAOYSA-M sodium;2-[2-[[benzyl-(2-phenylacetyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1C1=CC=CC=C1CN(C(=O)CC=1C=CC=CC=1)CC1=CC=CC=C1 GEQJMINZRKCRPI-UHFFFAOYSA-M 0.000 description 1
- NPULVZXNNSGOQW-UHFFFAOYSA-M sodium;2-[2-[[heptan-4-yl(3-phenylpropanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=CC=CC=1CCC(=O)N(C(CCC)CCC)CC1=CC=CC=C1C1=CC=CC=C1C([O-])=O NPULVZXNNSGOQW-UHFFFAOYSA-M 0.000 description 1
- DHFRPTLPJUVNCU-UHFFFAOYSA-M sodium;2-[2-[[n-(3-phenylpropanoyl)anilino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1C1=CC=CC=C1CN(C=1C=CC=CC=1)C(=O)CCC1=CC=CC=C1 DHFRPTLPJUVNCU-UHFFFAOYSA-M 0.000 description 1
- YUZHNKYPBOXLKX-UHFFFAOYSA-M sodium;2-[3-[(n-(2-phenylacetyl)anilino)methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1C1=CC=CC(CN(C(=O)CC=2C=CC=CC=2)C=2C=CC=CC=2)=C1 YUZHNKYPBOXLKX-UHFFFAOYSA-M 0.000 description 1
- VYPDUQYOLCLEGS-UHFFFAOYSA-M sodium;2-ethylhexanoate Chemical compound [Na+].CCCCC(CC)C([O-])=O VYPDUQYOLCLEGS-UHFFFAOYSA-M 0.000 description 1
- KFQKMWJWANIVIB-UHFFFAOYSA-M sodium;3-[3-[(n-(4-chlorobenzoyl)anilino)methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC(C=2C=C(CN(C(=O)C=3C=CC(Cl)=CC=3)C=3C=CC=CC=3)C=CC=2)=C1 KFQKMWJWANIVIB-UHFFFAOYSA-M 0.000 description 1
- ZIFMLRFJFTZAFM-UHFFFAOYSA-M sodium;3-[3-[(n-(4-methoxybenzoyl)anilino)methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(OC)=CC=C1C(=O)N(C=1C=CC=CC=1)CC1=CC=CC(C=2C=C(C=CC=2)C([O-])=O)=C1 ZIFMLRFJFTZAFM-UHFFFAOYSA-M 0.000 description 1
- KTZZAPBDUAYMTO-UHFFFAOYSA-M sodium;3-[3-[[(4-chlorobenzoyl)-(2-phenylethyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC(C=2C=C(CN(CCC=3C=CC=CC=3)C(=O)C=3C=CC(Cl)=CC=3)C=CC=2)=C1 KTZZAPBDUAYMTO-UHFFFAOYSA-M 0.000 description 1
- LESOVJYQZKRPBC-UHFFFAOYSA-M sodium;3-[3-[[2-phenylethyl(3-phenylpropanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC(C=2C=C(CN(CCC=3C=CC=CC=3)C(=O)CCC=3C=CC=CC=3)C=CC=2)=C1 LESOVJYQZKRPBC-UHFFFAOYSA-M 0.000 description 1
- JKIQWLJVUPNYAC-UHFFFAOYSA-M sodium;3-[3-[[3-phenylpropanoyl(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC(C=2C=C(CN(CCCC=3C=CC=CC=3)C(=O)CCC=3C=CC=CC=3)C=CC=2)=C1 JKIQWLJVUPNYAC-UHFFFAOYSA-M 0.000 description 1
- JXDLUXUDUPQFLX-UHFFFAOYSA-M sodium;3-[3-[[benzyl(3-phenylpropanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC(C=2C=C(CN(CC=3C=CC=CC=3)C(=O)CCC=3C=CC=CC=3)C=CC=2)=C1 JXDLUXUDUPQFLX-UHFFFAOYSA-M 0.000 description 1
- FVFIGZLXUQHPSC-UHFFFAOYSA-M sodium;3-[3-[[benzyl-(4-chlorobenzoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC(C=2C=C(CN(CC=3C=CC=CC=3)C(=O)C=3C=CC(Cl)=CC=3)C=CC=2)=C1 FVFIGZLXUQHPSC-UHFFFAOYSA-M 0.000 description 1
- YANQFBCURKPYAU-UHFFFAOYSA-M sodium;3-[3-[[butyl(3-phenylpropanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=CC=CC=1CCC(=O)N(CCCC)CC(C=1)=CC=CC=1C1=CC=CC(C([O-])=O)=C1 YANQFBCURKPYAU-UHFFFAOYSA-M 0.000 description 1
- YBQFXXQZMTWXEC-UHFFFAOYSA-M sodium;3-[3-[[heptan-4-yl(3-phenylpropanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=CC=CC=1CCC(=O)N(C(CCC)CCC)CC(C=1)=CC=CC=1C1=CC=CC(C([O-])=O)=C1 YBQFXXQZMTWXEC-UHFFFAOYSA-M 0.000 description 1
- NDMPTGTXJABWOT-UHFFFAOYSA-M sodium;3-[3-[[heptan-4-yl-(2-phenylacetyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=CC=CC=1CC(=O)N(C(CCC)CCC)CC(C=1)=CC=CC=1C1=CC=CC(C([O-])=O)=C1 NDMPTGTXJABWOT-UHFFFAOYSA-M 0.000 description 1
- HTOYRHNYJROOTH-UHFFFAOYSA-M sodium;3-[3-[[n-(3-phenylpropanoyl)anilino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC(C=2C=C(CN(C(=O)CCC=3C=CC=CC=3)C=3C=CC=CC=3)C=CC=2)=C1 HTOYRHNYJROOTH-UHFFFAOYSA-M 0.000 description 1
- FPVVBJSQCHPXMN-UHFFFAOYSA-M sodium;3-[3-[[pentanoyl(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=CC(C=2C=C(C=CC=2)C([O-])=O)=CC=1CN(C(=O)CCCC)CCCC1=CC=CC=C1 FPVVBJSQCHPXMN-UHFFFAOYSA-M 0.000 description 1
- PCOOCQPSMCUVMG-UHFFFAOYSA-M sodium;4-[3-[[(2-phenylacetyl)-(2-phenylethyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(CCC=2C=CC=CC=2)C(=O)CC=2C=CC=CC=2)=C1 PCOOCQPSMCUVMG-UHFFFAOYSA-M 0.000 description 1
- MKSRIDMJKRFMEL-UHFFFAOYSA-M sodium;4-[3-[[(2-phenylacetyl)-(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(CCCC=2C=CC=CC=2)C(=O)CC=2C=CC=CC=2)=C1 MKSRIDMJKRFMEL-UHFFFAOYSA-M 0.000 description 1
- BEPNMMPKARZBCK-UHFFFAOYSA-M sodium;4-[3-[[(4-chlorobenzoyl)-(2-phenylethyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(CCC=2C=CC=CC=2)C(=O)C=2C=CC(Cl)=CC=2)=C1 BEPNMMPKARZBCK-UHFFFAOYSA-M 0.000 description 1
- FAKMOHWQPIWFBS-UHFFFAOYSA-M sodium;4-[3-[[(4-chlorobenzoyl)-(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(CCCC=2C=CC=CC=2)C(=O)C=2C=CC(Cl)=CC=2)=C1 FAKMOHWQPIWFBS-UHFFFAOYSA-M 0.000 description 1
- NARFFMGCFNOHIB-UHFFFAOYSA-M sodium;4-[3-[[(4-methoxybenzoyl)-(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(OC)=CC=C1C(=O)N(CC=1C=C(C=CC=1)C=1C=CC(=CC=1)C([O-])=O)CCCC1=CC=CC=C1 NARFFMGCFNOHIB-UHFFFAOYSA-M 0.000 description 1
- CHTUOEPWLUGYLD-UHFFFAOYSA-M sodium;4-[3-[[2-phenylethyl(3-phenylpropanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(CCC=2C=CC=CC=2)C(=O)CCC=2C=CC=CC=2)=C1 CHTUOEPWLUGYLD-UHFFFAOYSA-M 0.000 description 1
- QKBHILJEJZFXKD-UHFFFAOYSA-M sodium;4-[3-[[3-phenylpropanoyl(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(CCCC=2C=CC=CC=2)C(=O)CCC=2C=CC=CC=2)=C1 QKBHILJEJZFXKD-UHFFFAOYSA-M 0.000 description 1
- YBPLIAYNOKDIMO-UHFFFAOYSA-M sodium;4-[3-[[benzyl(3-phenylpropanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(CC=2C=CC=CC=2)C(=O)CCC=2C=CC=CC=2)=C1 YBPLIAYNOKDIMO-UHFFFAOYSA-M 0.000 description 1
- KSGKDGWTSFRIEI-UHFFFAOYSA-M sodium;4-[3-[[benzyl(cyclopentanecarbonyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(CC=2C=CC=CC=2)C(=O)C2CCCC2)=C1 KSGKDGWTSFRIEI-UHFFFAOYSA-M 0.000 description 1
- YFMYBQJXAKKRKQ-UHFFFAOYSA-M sodium;4-[3-[[benzyl-(2-phenylacetyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(CC=2C=CC=CC=2)C(=O)CC=2C=CC=CC=2)=C1 YFMYBQJXAKKRKQ-UHFFFAOYSA-M 0.000 description 1
- MBBHVBMDXHESRZ-UHFFFAOYSA-M sodium;4-[3-[[benzyl-(4-chlorobenzoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(CC=2C=CC=CC=2)C(=O)C=2C=CC(Cl)=CC=2)=C1 MBBHVBMDXHESRZ-UHFFFAOYSA-M 0.000 description 1
- UHAUAYHTAWYTEU-UHFFFAOYSA-M sodium;4-[3-[[benzyl-(4-methoxybenzoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(OC)=CC=C1C(=O)N(CC=1C=C(C=CC=1)C=1C=CC(=CC=1)C([O-])=O)CC1=CC=CC=C1 UHAUAYHTAWYTEU-UHFFFAOYSA-M 0.000 description 1
- BGQHZRNMUUCJRV-UHFFFAOYSA-M sodium;4-[3-[[cyclopentanecarbonyl(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(CCCC=2C=CC=CC=2)C(=O)C2CCCC2)=C1 BGQHZRNMUUCJRV-UHFFFAOYSA-M 0.000 description 1
- BTRSWYFRGJTPDO-UHFFFAOYSA-M sodium;4-[3-[[heptan-4-yl-(2-phenylacetyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=CC=CC=1CC(=O)N(C(CCC)CCC)CC(C=1)=CC=CC=1C1=CC=C(C([O-])=O)C=C1 BTRSWYFRGJTPDO-UHFFFAOYSA-M 0.000 description 1
- NTTYWQYCTXXTII-UHFFFAOYSA-M sodium;4-[3-[[n-(3-phenylpropanoyl)anilino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(C(=O)CCC=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NTTYWQYCTXXTII-UHFFFAOYSA-M 0.000 description 1
- LZZGUCRXLKFNMO-UHFFFAOYSA-M sodium;4-[3-[[pentanoyl(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=CC(C=2C=CC(=CC=2)C([O-])=O)=CC=1CN(C(=O)CCCC)CCCC1=CC=CC=C1 LZZGUCRXLKFNMO-UHFFFAOYSA-M 0.000 description 1
- XLIYSIRKJPWFQD-UHFFFAOYSA-M sodium;4-[4-[(n-(4-chlorobenzoyl)anilino)methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C=1C=CC=CC=1)C(=O)C1=CC=C(Cl)C=C1 XLIYSIRKJPWFQD-UHFFFAOYSA-M 0.000 description 1
- HOXPNTAMLMKADN-UHFFFAOYSA-M sodium;4-[4-[[(2-phenylacetyl)-(2-phenylethyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C(=O)CC=1C=CC=CC=1)CCC1=CC=CC=C1 HOXPNTAMLMKADN-UHFFFAOYSA-M 0.000 description 1
- WKVROEGBHRETRD-UHFFFAOYSA-M sodium;4-[4-[[(2-phenylacetyl)-(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C(=O)CC=1C=CC=CC=1)CCCC1=CC=CC=C1 WKVROEGBHRETRD-UHFFFAOYSA-M 0.000 description 1
- DZDNXFOWOWGVJR-UHFFFAOYSA-M sodium;4-[4-[[(4-chlorobenzoyl)-(2-phenylethyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C(=O)C=1C=CC(Cl)=CC=1)CCC1=CC=CC=C1 DZDNXFOWOWGVJR-UHFFFAOYSA-M 0.000 description 1
- YZOQYFVBCPKFHI-UHFFFAOYSA-M sodium;4-[4-[[(4-methoxybenzoyl)-(4-phenylbutyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(OC)=CC=C1C(=O)N(CC=1C=CC(=CC=1)C=1C=CC(=CC=1)C([O-])=O)CCCCC1=CC=CC=C1 YZOQYFVBCPKFHI-UHFFFAOYSA-M 0.000 description 1
- SLKKKKFRNXNZLN-UHFFFAOYSA-M sodium;4-[4-[[2,2-diphenylethyl(pentanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=C(C=2C=CC(=CC=2)C([O-])=O)C=CC=1CN(C(=O)CCCC)CC(C=1C=CC=CC=1)C1=CC=CC=C1 SLKKKKFRNXNZLN-UHFFFAOYSA-M 0.000 description 1
- NQQHOXQHKAPGLU-UHFFFAOYSA-M sodium;4-[4-[[2,2-diphenylethyl-(4-methoxybenzoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(OC)=CC=C1C(=O)N(CC=1C=CC(=CC=1)C=1C=CC(=CC=1)C([O-])=O)CC(C=1C=CC=CC=1)C1=CC=CC=C1 NQQHOXQHKAPGLU-UHFFFAOYSA-M 0.000 description 1
- USRCCZWJICNTLT-UHFFFAOYSA-M sodium;4-[4-[[2-(2-chlorophenyl)ethyl-pentanoylamino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=C(C=2C=CC(=CC=2)C([O-])=O)C=CC=1CN(C(=O)CCCC)CCC1=CC=CC=C1Cl USRCCZWJICNTLT-UHFFFAOYSA-M 0.000 description 1
- BPWKQDZOTBOCEV-UHFFFAOYSA-M sodium;4-[4-[[2-(2-methoxyphenyl)ethyl-pentanoylamino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=C(C=2C=CC(=CC=2)C([O-])=O)C=CC=1CN(C(=O)CCCC)CCC1=CC=CC=C1OC BPWKQDZOTBOCEV-UHFFFAOYSA-M 0.000 description 1
- HYDLJWODWDDUEQ-UHFFFAOYSA-M sodium;4-[4-[[2-(4-chlorophenyl)ethyl-pentanoylamino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=C(C=2C=CC(=CC=2)C([O-])=O)C=CC=1CN(C(=O)CCCC)CCC1=CC=C(Cl)C=C1 HYDLJWODWDDUEQ-UHFFFAOYSA-M 0.000 description 1
- OUOXPJHQMRYSDZ-UHFFFAOYSA-M sodium;4-[4-[[2-(cyclohexen-1-yl)ethyl-(4-methoxybenzoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(OC)=CC=C1C(=O)N(CC=1C=CC(=CC=1)C=1C=CC(=CC=1)C([O-])=O)CCC1=CCCCC1 OUOXPJHQMRYSDZ-UHFFFAOYSA-M 0.000 description 1
- WFSIYFBMESHUMK-UHFFFAOYSA-M sodium;4-[4-[[2-ethylhexyl-(4-methoxybenzoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=C(OC)C=CC=1C(=O)N(CC(CC)CCCC)CC(C=C1)=CC=C1C1=CC=C(C([O-])=O)C=C1 WFSIYFBMESHUMK-UHFFFAOYSA-M 0.000 description 1
- HIKNUELQKHFDCK-UHFFFAOYSA-M sodium;4-[4-[[2-phenylethyl(3-phenylpropanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C(=O)CCC=1C=CC=CC=1)CCC1=CC=CC=C1 HIKNUELQKHFDCK-UHFFFAOYSA-M 0.000 description 1
- ZYBAOGZRYMMLNP-UHFFFAOYSA-M sodium;4-[4-[[3-phenylpropanoyl(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C(=O)CCC=1C=CC=CC=1)CCCC1=CC=CC=C1 ZYBAOGZRYMMLNP-UHFFFAOYSA-M 0.000 description 1
- YTIREDCEDYXYHN-UHFFFAOYSA-M sodium;4-[4-[[benzoyl(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C(=O)C=1C=CC=CC=1)CCCC1=CC=CC=C1 YTIREDCEDYXYHN-UHFFFAOYSA-M 0.000 description 1
- UVBIJMFKLVSNOV-UHFFFAOYSA-M sodium;4-[4-[[benzyl-(2-phenylacetyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C(=O)CC=1C=CC=CC=1)CC1=CC=CC=C1 UVBIJMFKLVSNOV-UHFFFAOYSA-M 0.000 description 1
- SMEQROSZUKRCDO-UHFFFAOYSA-M sodium;4-[4-[[butyl(3-phenylpropanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=CC=CC=1CCC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=C(C([O-])=O)C=C1 SMEQROSZUKRCDO-UHFFFAOYSA-M 0.000 description 1
- OUKKYUNOWLEMJQ-UHFFFAOYSA-M sodium;4-[4-[[butyl-(2-phenylacetyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=CC=CC=1CC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=C(C([O-])=O)C=C1 OUKKYUNOWLEMJQ-UHFFFAOYSA-M 0.000 description 1
- SAEQFTNUPKIMJX-UHFFFAOYSA-M sodium;4-[4-[[butyl-(4-chlorobenzoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=C(Cl)C=CC=1C(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=C(C([O-])=O)C=C1 SAEQFTNUPKIMJX-UHFFFAOYSA-M 0.000 description 1
- UNPZXDCOPNNYPQ-UHFFFAOYSA-M sodium;4-[4-[[cyclopentanecarbonyl(2,2-diphenylethyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C(=O)C1CCCC1)CC(C=1C=CC=CC=1)C1=CC=CC=C1 UNPZXDCOPNNYPQ-UHFFFAOYSA-M 0.000 description 1
- FDBRUENSKHUUFK-UHFFFAOYSA-M sodium;4-[4-[[cyclopentanecarbonyl(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C(=O)C1CCCC1)CCCC1=CC=CC=C1 FDBRUENSKHUUFK-UHFFFAOYSA-M 0.000 description 1
- QLFDSZIZKXPXLU-UHFFFAOYSA-M sodium;4-[4-[[cyclopentanecarbonyl(heptan-4-yl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1CCCC1C(=O)N(C(CCC)CCC)CC(C=C1)=CC=C1C1=CC=C(C([O-])=O)C=C1 QLFDSZIZKXPXLU-UHFFFAOYSA-M 0.000 description 1
- GLCHMNQPQXXABB-UHFFFAOYSA-M sodium;4-[4-[[heptan-4-yl(3-phenylpropanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=CC=CC=1CCC(=O)N(C(CCC)CCC)CC(C=C1)=CC=C1C1=CC=C(C([O-])=O)C=C1 GLCHMNQPQXXABB-UHFFFAOYSA-M 0.000 description 1
- DNWXRLHWMZZTON-UHFFFAOYSA-M sodium;4-[4-[[heptan-4-yl-(2-phenylacetyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=CC=CC=1CC(=O)N(C(CCC)CCC)CC(C=C1)=CC=C1C1=CC=C(C([O-])=O)C=C1 DNWXRLHWMZZTON-UHFFFAOYSA-M 0.000 description 1
- VFUZRHMYIMVYGR-UHFFFAOYSA-M sodium;4-[4-[[pentanoyl(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=C(C=2C=CC(=CC=2)C([O-])=O)C=CC=1CN(C(=O)CCCC)CCCC1=CC=CC=C1 VFUZRHMYIMVYGR-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960004954 sparfloxacin Drugs 0.000 description 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 1
- 235000019385 spermaceti wax Nutrition 0.000 description 1
- PHICBFWUYUCFKS-UHFFFAOYSA-N spiro[4.4]nonane Chemical compound C1CCCC21CCCC2 PHICBFWUYUCFKS-UHFFFAOYSA-N 0.000 description 1
- CTDQAGUNKPRERK-UHFFFAOYSA-N spirodecane Chemical compound C1CCCC21CCCCC2 CTDQAGUNKPRERK-UHFFFAOYSA-N 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- OPYGFNJSCUDTBT-PMLPCWDUSA-N sultamicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(=O)OCOC(=O)[C@H]2C(S(=O)(=O)[C@H]3N2C(C3)=O)(C)C)(C)C)=CC=CC=C1 OPYGFNJSCUDTBT-PMLPCWDUSA-N 0.000 description 1
- 229960001326 sultamicillin Drugs 0.000 description 1
- 229950011082 suplatast tosilate Drugs 0.000 description 1
- 239000003447 supported reagent Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- BJYLYJCXYAMOFT-RSFVBTMBSA-N tacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RSFVBTMBSA-N 0.000 description 1
- 229960004907 tacalcitol Drugs 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- YUSMZDVTEOAHDL-NTMALXAHSA-N tert-butyl (3z)-3-(dimethylaminomethylidene)-4-oxopiperidine-1-carboxylate Chemical compound CN(C)\C=C1\CN(C(=O)OC(C)(C)C)CCC1=O YUSMZDVTEOAHDL-NTMALXAHSA-N 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229940127228 tetracyclic antidepressant Drugs 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- ZXLDQJLIBNPEFJ-UHFFFAOYSA-N tetrahydro-beta-carboline Natural products C1CNC(C)C2=C1C1=CC=C(OC)C=C1N2 ZXLDQJLIBNPEFJ-UHFFFAOYSA-N 0.000 description 1
- KHVCOYGKHDJPBZ-WDCZJNDASA-N tetrahydrooxazine Chemical compound OC[C@H]1ONC[C@@H](O)[C@@H]1O KHVCOYGKHDJPBZ-WDCZJNDASA-N 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- ZYXWYDDFNXBTFO-UHFFFAOYSA-N tetrazolidine Chemical compound C1NNNN1 ZYXWYDDFNXBTFO-UHFFFAOYSA-N 0.000 description 1
- DASUJKKKKGHFBF-UHFFFAOYSA-L thallium(i) carbonate Chemical compound [Tl+].[Tl+].[O-]C([O-])=O DASUJKKKKGHFBF-UHFFFAOYSA-L 0.000 description 1
- RWXZKKKYLRFREK-UHFFFAOYSA-N thiadiazepane Chemical compound C1CCSNNC1 RWXZKKKYLRFREK-UHFFFAOYSA-N 0.000 description 1
- TVQOEGVBMRCMFR-UHFFFAOYSA-N thiadiazinane Chemical compound C1CNNSC1 TVQOEGVBMRCMFR-UHFFFAOYSA-N 0.000 description 1
- GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 description 1
- PGAZQSBUJDVGIX-UHFFFAOYSA-N thiazepane Chemical compound C1CCNSCC1 PGAZQSBUJDVGIX-UHFFFAOYSA-N 0.000 description 1
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 description 1
- AJZGFFKDLABHDD-UHFFFAOYSA-N thiazinane Chemical compound C1CCSNC1 AJZGFFKDLABHDD-UHFFFAOYSA-N 0.000 description 1
- JWCVYQRPINPYQJ-UHFFFAOYSA-N thiepane Chemical compound C1CCCSCC1 JWCVYQRPINPYQJ-UHFFFAOYSA-N 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
- 229940071127 thioglycolate Drugs 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
- 229960001312 tiaprofenic acid Drugs 0.000 description 1
- GUHPRPJDBZHYCJ-UHFFFAOYSA-N tiaprofenic acid Chemical compound S1C(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-UHFFFAOYSA-N 0.000 description 1
- HTJXMOGUGMSZOG-UHFFFAOYSA-N tiaramide Chemical compound C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 HTJXMOGUGMSZOG-UHFFFAOYSA-N 0.000 description 1
- 229950010302 tiaramide Drugs 0.000 description 1
- MIMJSJSRRDZIPW-UHFFFAOYSA-N tilmacoxib Chemical compound C=1C=C(S(N)(=O)=O)C(F)=CC=1C=1OC(C)=NC=1C1CCCCC1 MIMJSJSRRDZIPW-UHFFFAOYSA-N 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- PFENFDGYVLAFBR-UHFFFAOYSA-N tinoridine Chemical compound C1CC=2C(C(=O)OCC)=C(N)SC=2CN1CC1=CC=CC=C1 PFENFDGYVLAFBR-UHFFFAOYSA-N 0.000 description 1
- 229950010298 tinoridine Drugs 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- 229960002044 tolmetin sodium Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229950008187 tosufloxacin Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229960004320 triamcinolone diacetate Drugs 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- PCFIPYFVXDCWBW-UHFFFAOYSA-N tricyclo[3.3.1.03,7]nonane Chemical group C1C(C2)C3CC2CC1C3 PCFIPYFVXDCWBW-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 229960001593 triprolidine hydrochloride Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
Definitions
- the present invention relates to a medical use comprising novel BLT2 mediated disease, a BLT2 binding agent, a novel compound to bind to BLT2 and compound thereof.
- the present invention relates to a medical use which (1) a preventive and/or therapeutic drug for skin disease comprising the compound to bind to BLT2, salt thereof, solvate thereof and prodrug thereof, (2) the BLT2 binding agent comprising a compound represented by formula (I) (in the formula, all symbols have the same meanings as follows), salt thereof, solvate thereof and prodrug thereof as an active ingredients, (3) a compound represented by formula (1-1) (in the formula, all symbols have the same meanings as follows), salt thereof, solvate thereof and prodrug thereof, and (4) a medical use of the compound represented by formula (I-1), salt thereof, solvate thereof and prodrug thereof
- Leukotriene B4 (5[S], 12[R]-dihydroxy-6, 14-cis-8, 10-trans-eicosatetraenoic acid; it is abbreviated to LTB4 hereafter.) is a lipid mediator producted by arachidonate cascade and that promotes the migration of leukocytes, the production of active oxygen and the release of lysosomal enzyme, etc., by binding to receptor in the presence of membrane surface, and that plays a key role for organism such as the inflammatory reaction and the defense to bacterial infection etc.
- BLT1 and BLT2 which are G-protein coupled receptors
- LTB4 receptor J.Exp.Med., Volume 192, Number 3, 2000, 421 -. It has been confirmed that these receptors, which bind to G-protein such as Gi and Gq, etc., cause the induction of intracellular signal such as the rise of intracellular calcium concentration and the suppression of adenylate cyclase activity, etc., by binding of the ligand LTB4.
- BLT1 specifically strongly binds to LTB4 with Kd value 0.15nM
- BLT2 weakly binds to LTB4 with Kd value 22nM. It is reported that BLT1 is strongly expressed on leukocyte and is very strictly and organ-specifically expressed, while BLT2 is most strongly expressed in spleen and lymphocyte and hereby expressed in a lot of organs including liver and ovary.
- both receptors are different the reactiveness to LTB4 and the expression distribution, it is guessed that both receptors would play a mutually different role in vivo. Therefore, it is thought that a compound that acts on BLT1 shows a pharmacological action different from a compound that acts on BLT2. So far, it has been thought that the compound that acts on BLT1 is useful for diseases including bronchial asthma and articular rheumatism to which leukocytic infiltration relates.
- BLT2 BLT2 mediated diseases
- diseases e.g., human immunodeficiency virus (hereafter, it is abbreviated to HIV) infection, rejection to transplant, transplant rejection, graft-versus-host disease, autoimmune disease (e.g., systemic lupus erythematous, articular rheumatism, myasthenia gravis and sclerosis multiple, etc.), allergic disease (e.g., atopic dermatitis and bronchial asthma, etc.), inflammation, infectious disease, ulcus, lymphoma, carcinoma, leukosis, arteriosclerotic, hepatitis, liver cirrhosis or cancer, etc.
- human immunodeficiency virus hereafter, it is abbreviated to HIV
- autoimmune disease e.g., systemic lupus erythematous, articular rheumatism, myasthenia gravis and sclerosis multiple, etc.
- allergic disease e.g., atopic
- BLT2 is highly expressed in small intestine and skin keratinocyte and that the compound that binds to BLT2 is useful for prevention and/or therapy of intestinal disease including ulcerative colitis or skin disease including psoriasis and dermatitis so far.
- the present inventors find compounds that bind to BLT2 and are useful as drugs, and newly provide preventive and/or therapeutic drugs for BLT2-mediated diseases including skin disease.
- BLT2 is highly expressed in skin keratinocyte and small intestine and that the compound represented by the formula (I), salt thereof, solvate thereof and prodrug thereof has BLT2 binding activity, especially, the compound represented by the formula (I-1), salt thereof, solvate thereof and prodrug thereof has BLT2 binding activity and is useful as a preventive and/or therapeutic drug for BLT2 mediated diseases including skin disease and rejection to transplant to accomplish the present invention as a result of their intensive studies for solving said problems.
- the present invention relates to the followings.
- the compound with BLT2 binding activity which specifically binds to BLT2 that is one of LTB4 receptors, only has to be a compound with agonistic or antagonistic action on BLT2, but it is not limited by the structure, the strength of the action or the presence of the specificity.
- BLT2 agonist means a compound that shows an action on BLT2 as same as LTB4, but BLT2 antagonist means a compound that antagonizes an action of LTB4 on BLT2.
- BLT2 antagonist means a compound that antagonizes an action of LTB4 on BLT2.
- BLT2 agonist includes a compound in which the rising activity of the intracellular calcium concentration as described in example is less than 100uM as EC 50 value.
- BLT2 antagonist includes a compound in which the inhibitory activity of the rise of the intracellular calcium concentration is less than 100uM as IC 50 value.
- BLT2-mediated disease includes an already found disease and a disease that may be newly found.
- diseases include, e.g., skin disease, intestinal disease, HIV transmission, acquired immunodeficiency syndrome, rejection to transplant, transplant abolition, graft-versus-host disease, autoimmune disease, allergic disease, inflammation, infectious disease, ulcus, lymphoma, carcinoma, leukosis, arteriosclerotic, hepatitis, liver cirrhosis and cancer, etc.
- skin disease has only to be a disease that meets either requirement in which it is accompanied by the histological laesio in skin tissue or the cytological dysfunction in keratinocyte (especially, skin keratinocyte), it is not limited especially.
- eczema e.g., cheloma, lupus skin injury, acne (e.g., comedo etc.), dermatitis (e.g., seborrhoeic dermatitis, solar dermatitis, contact dermatitis, and atopic dermatitis, etc.), psoriasis (e.g., psoriasis vulgaris, guttate psoriasis, pustular psoriasis, psoriasis arthropica, and psoriatic erythrodermia, etc.), keratosis (e.g., seborrhoic keratosis, senile keratosis, actinic keratosis, photic evocation keratosis, and follicular keratosis, etc.), verruca (e.g., condyloma,
- skin disease in the present invention includes a disease accompanied by dysfunction of hair root keratinocyte (e.g., alopecia (e.g., congenital alopecia (diffuse congenital alopecia and alopecia triangularis congenitalis, etc.) and acquired alopecia (folliculitis decalvans, alopecia areata, and follicular mucinosis, etc.), etc.), etc.) and dyspigmentation (e.g., spot, freckle, chromatosis by sunburn, etc.), etc.
- alopecia e.g., congenital alopecia (diffuse congenital alopecia and alopecia triangularis congenitalis, etc.) and acquired alopecia (folliculitis decalvans, alopecia areata, and follicular mucinosis, etc.), etc.
- dyspigmentation e.g., spot, freckle, chromatosis
- intestinal disease includes, e.g., inflammatory bowel disease (e.g., ulcerative colitis and Crohn's disease, etc.), irritable bowel syndrome and colitis, etc.
- inflammatory bowel disease e.g., ulcerative colitis and Crohn's disease, etc.
- irritable bowel syndrome e.g., irritable bowel syndrome, etc.
- the compound with BLT2 binding activity, salt thereof, solvate thereof and prodrug thereof for treatment of skin disease it is preferable that the compound is bifurcated, depending on whether it is BLT2 agonist or antagonist.
- said skin diseases if it is, e.g., alopecia (e.g., congenital alopecia (diffuse congenital alopecia and alopecia triangularis congenitalis, etc.) and acquired alopecia (folliculitis decalvans, alopecia areata, and follicular mucinosis, etc.), etc.) and dyspigmentation (e.g., spot, freckle, chromatosis by sunburn), etc., it is prefer to use BLT2 agonist.
- alopecia e.g., congenital alopecia (diffuse congenital alopecia and alopecia triangularis congenitalis, etc.) and acquired alopecia (folliculitis decalvans
- eczema e.g., cheloma, lupus skin injury, acne (e.g., comedo etc.), dermatitis (e.g., seborrhoeic dermatitis, solar dermatitis, contact dermatitis, and atopic dermatitis, etc.), psoriasis (e.g., psoriasis vulgaris, guttate psoriasis, pustular psoriasis, psoriasis arthropica, and psoriatic erythrodermia, etc.), keratosis (e.g., seborrhoic keratosis, senile keratosis, actinic keratosis, photic evocation keratosis, and follicular keratosis, etc.), verruca (e.g., condyloma, pointed con
- the compound with BLT binding activity is preferably the compound represented by formula (I) (wherein, ring A and ring B each independently represent a ring that further may contain substituents, X represents an acidic group, Y represents a bond or a spacer in which the number of atom in the principal chain is one to three, and E represents an amino group that may contain substituents.).
- the compound represented by formula (I) in the present invention has BLT2 binding activity, they is used for expressing agonistic or antagonistic action accompanied by binding to BLT2.
- the ring in the ring that further may contain substituents represented by ring A or ring B includes a bivalent group in which two arbitrary hydrogen atoms are excluded from homocycle or heterocycle.
- the homocycle includes, e.g., saturated cyclic hydrocarbon or unsaturated cyclic hydrocarbon, etc.
- the 3 to 15-membered saturated cyclic hydrocarbon includes, e.g., (a) cycloalkane (e.g., cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, cycloundecane, cyclododecane, cyclotridecane, cyclotetradecane and cyclopentadecane ring, etc.), (b) saturated polycyclic compound (e.g., perhydropentalene, perhydroazulene, perhydroindene, perhydronaphthalene, perhydroheptalene, spiro[4.4]nonane, spiro[4.5]decane, s
- the unsaturated cyclic hydrocarbon includes, e.g., 3 to 15-membered unsaturated cyclic hydrocarbon etc.
- the 3 to 15-membered unsaturated cyclic hydrocarbon includes, e.g., (a) cycloalkene (e.g., cyclopentene, cyclohexane, cycloheptene, cyclooctene, cyclopentadiene, cyclohexadiene, cycloheptadiene and cyclooctadiene ring, etc.), (b) aromatic hydrocarbon (e.g., benzene, azulene, naphthalene, phenanthrene and anthracene ring, etc.), (c) unsaturated polycyclic compound (e.g., pentalene, indene, indane, dihydronaphthalene, tetrahydronaphtalene, heptalene, biphenylene, as
- the heterocycle includes monocycle or polycyclic heterocycle that may contain 1 to 7 of hetero atom(s) selected from a nitrogen atom, an oxygen atom and a sulfur atom.
- the monocycle or the polycyclic heterocycle that may contain 1 to 7 of hetero atom(s) selected from a nitrogen atom, an oxygen atom and a sulfur atom includes, e.g., 3 to 15-membered unsaturated monocycle or polycyclic heterocycles and 3 to 15-membered saturated monocycle or polycyclic heterocycles, etc.
- the 3 to 15-membered unsaturated monocycle or polycyclic heterocycles includes, e.g., (a) aromatic monocyclic heterocycle (e.g., pyrrole, imidazole, triazole, tetrazole, pyrazol, pyridine, pyrazine, pyrimidine, pyridazine, triazine, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, furazan, oxadiazole and thiadiazole ring, etc.), (b) aromatic fused heterocycle (e.g., indole, isoindole, benzofuran, isobenzofuran, benzothiophene, isobenzothiophene, indazole, quinoline, isoquinoline, purine, phthalazine, pteridine, naphthyridine, quinoxaline, quinazoline, cinn
- the 3 to 15-membered saturated monocycle or polycyclic heterocycles includes, e.g., aziridine, azetidine, pyrrolidine, imidazolidine, triazolidine, tetrazolidine, pyrazolidine, piperidine, piperazine, perhydropyrimidine, perhydropyridazine, perhydroazepine, perhydrodiazepine, perhydroazocine, oxirane, oxetane, tetrahydrofuran, tetrahydropyran, perhydrooxepin, thiirane, thietane, tetrahydrothiophene, tetrahydrothiopyran, perhydrothiepin, tetrahydrooxazole (oxazolidine), tetrahydroisoxazole (isoxazolidine), tetrahydrothiazole (thiazolidine), tetrahydroisothiazole
- the ring A or the ring B is preferable to be a bivalent group in which two arbitrary hydrogen atoms are excluded from monocyclic aromatic ring.
- the monocyclic aromatic ring includes, e.g., benzene ring and said aromatic monocyclic heterocycle, etc., benzene ring is especially preferable.
- substituents in the ring that further may contain substituents represented by ring A or ring B include, e.g., [1] a hydrocarbon that may contain substituents (e.g., (a) C1-8 aliphatic hydrocarbon, (b) amino, (c) sulfo, (d) halogen atom, (e) carboxyl, (f) cyano, (g) nitro, (h) oxo, (i) thioxo, (j) hydroxyl, (k) methoxy, (l) trifluoromethyl, and (m) trifluoromethoxy, etc.), [2] a heterocycle that may contain substituents (e.g., (a) C1-8 aliphatic hydrocarbon that may contain substituents (e.g., (1) halogen atom, (2) hydroxyl, (3) trifluoromethyl, (4) trifluoromethoxy, and (5) acetyloxy, etc.), (b
- the hydrocarbon includes, e.g., [1] aliphatic hydrocarbon, [2] cyclic hydrocarbon, [3] cyclic hydrocarbon-aliphatic hydrocarbon or [4] cyclic hydrocarbon-cyclic hydrocarbon, etc.
- the aliphatic hydrocarbon includes, e.g., C1-8 aliphatic hydrocarbon etc.
- the C1-8 aliphatic hydrocarbon may be linear or branched and includes, e.g., (a) C1-8 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, and octyl, etc.), (b) C2-8 alkenyl (e.g., vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, butadienyl, pentadienyl, hexadienyl, heptadienyl, octadienyl, hexatrienyl, heptatrienyl, and octt
- the cyclic hydrocarbon means a univalent group in which an arbitrary hydrogen atom is excluded from cyclic hydrocarbon, and includes the same as said homocycle.
- the cyclic hydrocarbon-aliphatic hydrocarbon includes one in which said cyclic hydrocarbon binds to said aliphatic hydrocarbon, e.g., (a) C7-16 aralkyl (e.g., benzyl, phenylethyl, phenylpropyl, and naphthalen-1-yl methyl, etc.), (b) C8-16 aralkenyl (e.g., 3-phenyl-2-propenyl, 2-(2-naphthyl vinyl) and 4-cyelobutyl-1-butenyl, etc.), (c) (C3-8 cycloalkyl)-(C1-4 alkyl) (e.g., cyclopropylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, 1-methyl-1-cyclohexylmethyl, etc.), and (d) (C3-8 cycloalken
- the cyclic hydrocarbon-cyclic hydrocarbon includes one in which two said cyclic hydrocarbon combine, e.g., 3-phenylphenyl and 4-phenylphenyl, etc.
- the C1-8 aliphatic hydrocarbon contained in the substituent of ring A or ring B includes said C1-8 alkyl, said C2-8 alkenyl, and said C2-8 alkynyl, etc.
- cyclic hydrocarbon contained in the substituent of ring A or ring B includes a univalent group etc., in which an arbitrary hydrogen atom is excluded from said homocycle.
- heterocycle contained in the substituent of ring A or ring B includes a univalent group etc., in which an arbitrary hydrogen atom is excluded from said heterocycle.
- the substituent(s) in amino that may contain substituents as the substituent of ring A or ring B include(s), e.g., (a) hydrocarbon that may contain substituents, (b) sulfo, and (c) sulfonyl that binds to hydrocarbon that may contain substituents, etc.
- the hydrocarbon that may contain substituents means the same as the hydrocarbon that may contain substituents as the substituent of said ring A or said ring B.
- the protecting group in the hydroxyl that may be protected or the mercapto group that may be protected as the substituent of ring A or ring B includes, e.g., a hydrocarbon that may contain substituents.
- the hydrocarbon that may contain substituents means the same as the hydrocarbon that may contain substituents as the substituent of said ring A or said ring B.
- the substituent(s) in the carbamoyl that may contain substituents or sulfamoyl that may contain substituents as the substituent of ring A or ring B include(s), e.g., a hydrocarbon that may contain substituents etc.
- the hydrocarbon group that may contain substituents means the same as the hydrocarbon group that may contain substituents as the substituent of said ring A or said ring B.
- the halogen atom includes, e.g., fluorine, chlorine, bromide and iodine, etc.
- the sulfo group means -SO 3 H.
- the sulfino group means -SO 2 H.
- the phosphono group means -PO(OH) 2 .
- the dihydroxyboryl group means -B(OH) 2 .
- the acidic group represented by X includes, e.g., [1] hydroxyl, [2] alkoxy, [3] carboxyl, [4] sulfo, [5] sulfino, [6] sulfonamide(SO 2 NH 2 or -NR 101 SO 3 H (R 101 represents a hydrogen atom or said hydrocarbon.).), [7] phosphono, [8] phenol and [9] various protonic acids that are nitrogen-containing ring residues that contain hydrogen atom(s) that may be deprotonated, etc.
- the alkoxy includes, e.g., C1-8 alkoxy etc.
- the C1-8 alkoxy may be linear or a branched, and includes, e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, tert-butoxy, pentyloxy, hexyloxy, heptyloxy and octyloxy, etc.
- the ring residues containing nitrogen atoms that contain hydrogen atom(s) that may be deprotonated include, e.g.,
- the phenolic group means -C 6 H 4 OH.
- the acidic group represented by X is preferable to be carboxyl and etc. It is more preferable to be carboxyl.
- the bond represented by Y means a direct bond without other atoms.
- the spacer represented by Y in which the number of atom in the principal chain is one to three means the space in which one to three atom(s) in the principal chain is/are aligned.
- the number of atom in the principal chain shall be counted to minimize the number of the atom in the principal chain.
- the number of 1, 2-cyclopentene is two and the number of 1, 3-cyclopentene is three.
- the spacer in which the number of the principal chain is one to three includes, e.g., [1] -O-, [2] -S-, [3] -CO-, [4] -SO-, [5] -SO 2 -, [6] a nitrogen atom that may contain substituents and [7] a bivalent group in which one to three atom(s) in the principal chain is/are aligned comprising one to three group(s) arbitrarily selected from a group consisting of bivalent C1-3 aliphatic hydrocarbon that may contain substituents.
- the nitrogen atom that may contain substituents represents one in which a hydrogen atom in -NH- is arbitrarily substituted for a hydrocarbon that may contain substituents.
- the hydrocarbon in the hydrocarbon that may contain substituents means the same as the above.
- the substituents in the hydrocarbon that may contain substituents includes, e.g., [a] hydroxyl, [b] oxo, [c] thioxo, [d] halogen atom, [e] cyano, [f] nitro, [g] carboxyl, [h] C1-4 alkoxy(e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy tert-butoxy, etc.), [i] amino and [j] the first or second amino substituted by said aliphatic hydrocarbon etc., and these arbitrary substituents may be substituted at one to eight replaceable position(s), preferably at one to five position(s).
- C1-3 alkylene e.g., -CH 2 -, -(CH 2 ) 2 -, -(CH 2 ) 3 -, etc.
- Y is preferable to be a bivalent C1-3 aliphatic hydrocarbon, more preferable to be methylene.
- the substituents in the amino that may contain substituents which is represented by E, includes, e.g., [1] hydrocarbon that may contain substituents, [2] sulfo and [3] sulfonyl that binds to hydrocarbon that may contain substituents, etc.
- the hydrocarbon in the hydrocarbon that may contain substituents means the same as the above.
- the substituents in the hydrocarbon that may contain substituents includes, e.g., [a] the hydrocarbon that may contain substituents (e.g., (1) C1-4 alkyl(e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl and tert-butyl, etc.), (2) amino, (3) sulfo, (4) halogen atom, (5) carboxyl, (6) cyano, (7) nitro, (8) oxo, (9) thioxo, (10) hydroxyl, (11) methoxy, (12) trifluoromethyl, and (13) trifluoromethoxy, etc.), [b] the heterocycle that may contain substituents (e.g., (1) the hydrocarbon, (2) amino, (3) sulfo, (4) halogen atom, (5) carboxyl, (6) cyano, (7) nitro, (8) oxo, (9) thioxo, (10) hydroxyl,
- R 3 and R 4 each independently represent [1] hydrogen atom, [2] hydrocarbon that may contain substituent(s), [3] sulfo, [4] sulfonyl that binds to hydrocarbon that may contain substituent(s).
- the hydrocarbon in the hydrocarbon that may contain substituent(s) means the same as the above.
- the substituent(s) in the hydrocarbon that may contain substituent(s) includes, e.g., [a] said hydrocarbon that may contain substituent(s) (e.g., (1) C1-4 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl and tert-butyl, etc.), (2) amino, (3) sulfo, (4) halogen atom, (5) carboxyl, (6) cyano, (7) nitro, (8) oxo, (9) thioxo, (10) hydroxyl, (11) methoxy, (12) trifluoromethyl, and (13) trifluoromethoxy, etc.), [b] said heterocyclic that may contain substituent(s) (e.g., (1) said hydrocarbon, (2) amino, (3) sulfo, (4) halogen atom, (5) carboxyl, (6) cyano, (7) nitro, (8) oxo, (9) thio
- R 5 represents a hydrogen atom or a hydrocarbon that may contain substituents, which means the same as the hydrocarbon that may contain substituents represented by R 3 .
- Preferable compounds in compounds represented by formula (I) include, e.g., compounds represented by formula (I-1) etc. (wherein, ring A 1 and ring B 1 each independently represent a benzene ring that may further contain substituents, and R 1 and R 2 each independently represent a hydrogen atom or a hydrocarbon that may contain substituents.).
- the substituent(s) in the benzene ring that may further contain substituents include(s), e.g., said group etc., as substituent(s) of ring A or ring B.
- the one to five or one to three arbitrary substituent(s), which may be same or different respectively when the number of substituents is two or more, may be substituted at each replaceable position(s) of each benzene ring.
- the hydrocarbon in the hydrocarbon that may contain substituents which is represented by R 1 or R 2 , means the same as the above.
- the substituent(s) in the hydrocarbon that may contain substituents includes, e.g., [a] said hydrocarbon that may contain substituent(s) (e.g., (1) C1-4 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl and tert-butyl, etc.), (2) amino, (3) sulfo, (4) halogen atom, (5) carboxyl, (6) cyano, (7) nitro, (8) oxo, (9) thioxo, (10) hydroxyl, (11) methoxy, (12) trifluoromethyl, and (13) trifluoromethoxy, etc.), [b] said heterocycle that may contain substituents(e.g., (1) said hydrocarbon, (2) amino, (3) sulfo, (4) halogen
- R 6 , R 7 and R 8 each independently represent a hydrogen atom or a hydrocarbon that may contain substituents.
- the hydrocarbon in the hydrocarbon that may contain substituents means the same as the above, and the substituent(s) in the hydrocarbon that may contain substituents include(s), e.g., [a] said hydrocarbon that may contain substituent(s) (e.g., (1) C1-4 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl and tert-butyl, etc.), (2) amino, (3) sulfo, (4) halogen atom, (5) carboxyl, (6) cyano, (7) nitro, (8) oxo, (9) thioxo, (10) hydroxyl, (11) methoxy, (12) trifluoromethyl, and (13) trifluoromethoxy, etc.), [b] said heterocycle that may contain substituents (e.g., (1)
- Preferable compounds in compounds represented by formula (I-1) include, e.g., the compound described in examples.
- preferable compounds in compounds represented by formula (I) include, e.g., compounds represented by the following (1) to (46), salts thereof, solvates thereof, and prodrugs thereof, etc.
- the compound (5), (7), (9), (10), (11), (12), (13), (16), (17), (19), (20), (21), (22), (30), (34), (39), (40), (43), and (45) have BLT2 agonistic activity and other compounds have BLT2 antagonistic activity.
- the present invention includes all isomers.
- alkyl, alkenyl, alkynyl, alkyloxy, alkoxy, alkenyloxy, alkynyloxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylene, alkenylene, alkynylene, acyl and acyloxy include linear and branched ones.
- the present invention includes all isomers due to double bond, ring and fused ring (E-, Z-, cis- and trans-substances), isomers due to presence of asymmetric carbon etc.
- the present invention also includes all isomers including tautomers.
- Salts of the compound represented by formula (I) include all salts allowed in pharmacology.
- the salts allowed in pharmacology are preferable to be little toxic and water-soluble.
- the suitable salts include, e.g., alkali metal salts (e.g., potassium, sodium and lithium, etc.), alkaline earth metal salts (e.g., calcium and magnesium, etc.), ammonium salts (e.g., tetramethylammonium and tetrabutylammmonium, etc.), organic amine salts (e.g., triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris(hydroxymethyl)methylamine, lysine, arginine and N-methyl-D-glucamine, etc.), acid-addition salts (e.g., inorganic acid salts (e.g., hydrochlor
- the salts include quaternary ammonium salt.
- the quaternary ammonium salt represents one in which nitrogen atoms of the compound represented by formula (I) were quaternarized by R° R° represents Cl-8 alkyl substituted with Cl-8 alkyl or phenyl.
- the solvates of the compound represented by formula (I) include, e.g., solvates such as water and alcohols solvents (e.g., methanol and ethanol, etc.). The solvates are preferable to be little toxic and water-soluble.
- the solvates of the compounds of the present invention include solvates of alkaline (earth) metal salts, ammonium salt, organic amine salts or acid-addition salts of the above compounds of the present invention.
- the present invention compounds may be converted into the above salts and solvates by known methods.
- the prodrug of the compound represented by formula (I) means a compound that is converted into the compound represented by formula (I) by enzymes or gastric acid, etc., in vivo.
- the prodrug of the compound represented by formula (I) includes compounds in which the amino was, e.g., acylated, alkylated or phosphorylated(e.g., the compounds in which the amino of the compound represented by formula (I) was eicosanoylated, alanylated, pentylaminocarbonylated, (5-methyl-2-oxo-1, 3-dioxolen-4-yl)methoxycarbonylated, tetrahydrofuranylated, pyrrolidyimethylated, pivaloyloxymethylated and acetoxymethylated tert-butylated, etc.) when the compound represented by formula (I) has amino(s); the compounds in which the hydroxyl was, e.g., acylated, alkylated
- the prodrug of the compound represented by formula (I) may change into the compound represented by formula (I) in physiological condition described in " The development of drug", Vol.7, “molecular design", p.163-198 (1990), Hirokawa shoten .
- the compound represented by formula (I) may be labeled by an isotope (e.g., 3 H, 14 C, 35 S and 125 I, etc.) etc.
- the compound of the present invention represented by formula (I), salt thereof, solvate thereof or prodrug thereof (hereafter, it may be abbreviated to the compound of the present invention.) is a compound that excels in solubility, absorptivity and metabolic stability and has long-acting pharmacological activity (BLT2 binding activity), and further is weak in inhibition of drug metabolizing enzyme and circulatory toxicity. These properties are most important physical, pharmacological and chemical properties that are demanded when developing as a medicine and the compound of the present invention has the possibility to become a very excellent medicine that meets these requirements (The Merck Manual of Diagnosis and Therapy (17th Ed.), Merck & Co.).
- the compound of the present invention can be evaluated to be useful as a medicine by various experimental systems, methods described in biological examples and appropriate improved methods thereof as follows. Further, the compound of the present invention can be evaluated to be excellent in dynamics, e.g., half-life in blood, stability in gut, oral absorptivity and bioavailability by known methods, e.g., methods described in "drug bioavailability (science of evaluation and improvement)", July 6, 1998, gendai-iryousya.
- the compound of the present invention is named by ACD/NAMETM, which is a computer program to mechanically generate IUPAC name, of Advanced Chemistry Development company. For example, the following compound was named sodium 3'- ⁇ [4-methoxybenzoyl(4-phenylbutyl)amino]methyl ⁇ -1, 1'-biphenyl-3-carboxylate.
- the compound of the present invention is known as itself and can be produced by known methods, e.g., EP0632008 , WO99/58513 , WO00/48982 , WO03/051852 , and WO03/097851 , etc., the method described in Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition (Richard C. Larock, John Wiley & Sons Inc, 1999 ), the appropriate improved methods and the combined methods.
- the compound represented by formula (I-1) can be produced by subjecting the compound represented by formula (II) (wherein, ring A 1P and ring B 1P represent the same meaning as ring A 1 and ring B 2 respectively, and R p represents a protecting group of carboxyl group. However, carboxyl, hydroxyl, amino and thiol group contained in a group represented by ring A and ring B are protected if necessary and other symbols have the same meanings as defmed above.) and the compound represented by formula (III) R 1P -NH-R 2P (III) (wherein, R 1P and R 1P represent the same meaning as R 1 and R 2 respectively.
- the reductive amination reaction is well-known and carried out at 0-40 ⁇ , e.g., in an organic solvent (e.g., dichloroethane, dichloromethane, dimethylformamide, acetate or the mixture, etc.) in the existence of a reducing agent (e.g., sodium triacetoxyborohydride, sodium cyanoborohydride, sodium borohydride or tetrabutylammonium borohydride, etc.).
- an organic solvent e.g., dichloroethane, dichloromethane, dimethylformamide, acetate or the mixture, etc.
- a reducing agent e.g., sodium triacetoxyborohydride, sodium cyanoborohydride, sodium borohydride or tetrabutylammonium borohydride, etc.
- the aimed compound of the present invention may be prepared by continuously subjecting to the deprotection reaction after appropriately protecting the groups in advance and subjecting to reaction.
- the protective group of the amino includes, e.g., benzyloxycarbonyl, tert-butoxycarbonyl, allyloxycarbonyl (Alloc), 1-methyl-1-(4-biphenyl)ethoxycarbonyl (Bpoc), trifluoroacetyl, 9-fluorenylmethoxycarbonyl, benzyl (Bn), p-methoxybenzyl, benzyloxymethyl (BOM) and 2-(trimethylsilyl)ethoxymethyl (SEM), etc.
- the protective group for the hydroxyl includes, e.g., methyl, trityl, methoxymethyl(MOM), 1-ethoxyethyl(EE), methoxyethoxymethyl(MEM), 2-tetrahydropyranyl(THP), trimethylsilyl(TMS), triethylsilyl(TES), tert-butyldimethylsilyl(TBDMS), tert-butyldiphenylsil(TBDPS), acetyl(Ac), pivaloyl, benzoyl, benzyl(Bn), p-methoxybenzyl, allyloxycarbonyl(Alloc) and 2, 2, 2-trichloroethocycarbonyl(Troc).
- methyl, trityl methoxymethyl(MOM), 1-ethoxyethyl(EE), methoxyethoxymethyl(MEM), 2-tetrahydropyranyl(THP), trimethylsilyl(TMS
- the protective group of the mercapto includes, e.g., benzyl, methoxybenzyl, methoxymethyl(MOM), 2-tetrahydropyranyl(THP), diphenylmethyl and acetyl(Ac), etc.
- the protective group of the carboxyl group includes, e.g., methyl, ethyl, tert-butyl, aryl, phenacyl and benzyl, etc.
- the protective group of the carboxyl, hydroxyl, amino or thiol is not limited to the above protective group so far as it is a group which can be easily and selectively detached.
- a deprotection reaction may be carried out by a method described in " T. W. Greene, Protective Groups in Organic Synthesis, Wiley, New York, 1999 ".
- the deprotection reaction for the protective group of the carboxyl, hydroxyl, amino, or mercapto is known and includes, e.g.,
- the aimed compound of the present invention can be easily produced by using these deprotection reactions properly.
- a compound that R 1 is represented by (wherein, R 101 represents a hydrocarbon group containing hydrogen(s)or substituent(s).), that is, a compound represented by formula (I-1a) (wherein, all symbols have the same meanings as defined above.) may be prepared by subjecting a compound represented by formula (IV) (wherein, all symbols have the same meanings as defined above.
- the amidation reaction has been known and includes, e.g.,
- the deprotection reaction of the protecting group can be carried by the same method above.
- the compound represented by formula (II) can be produced by subjecting a compound represented by formula (VII) (wherein, Z represents a halogen atom or triflate and other symbols have the same meanings as those defined above.) and a compound represented by formula (VII) (wherein, all symbols have the same meanings as those defined above.) to the following reaction.
- a compound represented by formula (VII) wherein, Z represents a halogen atom or triflate and other symbols have the same meanings as those defined above.
- a compound represented by formula (VII) wherein, all symbols have the same meanings as those defined above.
- This reaction is known and carried out at room temperature to 120°C, e.g., in a base (e.g., sodium ethylate, sodium hydroxide, potassium hydroxide, triethylamine, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, cesium carbonate, thallium carbonate, potassium phosphate tribasic, cesium fluoride, barium hydroxide or tetrabutylammonium fluoride, etc.), the solution or the mixture and catalyst (e.g., tetrakis(triphenylphosphine)palladium(Pd(PPh 3 ) 4 ), bis dichloride(triphenylphosphine)palladium(PdCl 2 (PPh 3 ) 2 ), palladium acetate(Pd(OAc) 2 ), palladium black, 1, 1'-bis(diphenylphosphinoferrocene)dioljloropalladium(PdCl 2 (dppf)
- reaction with heating in each reaction in the present specification may be carried out by using bathe, oil bath, sand bath or microwave.
- solid-supported reagents supported on high molecule polymer e.g., polystyrene, polyacrylamide, polypropylene or polyethylene glycol etc.
- high molecule polymer e.g., polystyrene, polyacrylamide, polypropylene or polyethylene glycol etc.
- the reaction product can be purified by conventional purification techniques, e.g., distillation under atmospheric or reduced pressure, high performance liquid chromatography, thin-layer chromatography or column chromatography using silica gel or magnesium silicate, washing or recrystallization etc..
- the purification can be carried out for each reaction or after some reactions.
- the toxicities of the compounds of the present invention are very low so that they are sufficiently safe for using as pharmaceuticals.
- the compounds of present invention have BLT2 binding activities.
- BLT2 most strongly is expressed to spleen and lymphocyte and is ubiquitous in a lot of organs including liver and ovary and further is highly expressed in keratinocyte and small intestine, in mammal (e.g., human, non-human animal, e.g., monkey, sheep, bovine, horse, dog, cat, rabbit, rat, and mouse, etc.)
- the compounds are useful for prevention and/or treatment of BLT2 mediated diseases, e.g., dermatosis [e.g., eczema, cheloma, lupus accompanied by skin injury, acne(e.g., acne vulgaris etc.), dermatitis(e.g., seborrheic dermatitis, solar dermatitis, contact dermatitis and atopic dermatitis, etc.), psoriasis(e.g., psoriasis vulgaris, guttate ps
- the compound of the present invention may be administered as a combined preparation by combining with other pharmaceutical(s) for the purpose of;
- a blending pharmaceutical in which both components are compounded in a preparation may be administered or separate preparations may be administered.
- the administration of separate preparations includes a simultaneous administration and administrations with time difference.
- the compound of the present invention may be firstly administered followed by administering the other pharmaceutical or the other pharmaceutical may be firstly administered followed by administering the compound of the present invention.
- Each administration method may be same or different.
- the other pharmaceutical may be a low molecular weight compound, protein, polypeptide, polynucleotide (DNA, RNA or gene), antisense, decoy, antibody or vaccine, etc.
- a dosage of the other pharmaceutical can be properly selected on the basis of the clinical dose. Further, a mix proportion of the other pharmaceutical and the compound of the present invention can be properly selected on the basis of age and weight of a subject, medication method, administration period, disease, symptom or combination, etc. For example, 0.01 to 100 of the other pharmaceutical for a mass of the compound of the present invention may be used. Two or more arbitrary other pharmaceuticals may be combinationally administered at a suitable proportion.
- dermatosis such as eczema, cheloma, lupus accompanied by skin injury, acne (e.g., acne vulgaris etc.), dermatitis (e.g., seborrheic dermatitis, solar dermatitis, contact dermatitis and atopic dermatitis, etc.), psoriasis (e.g., psoriasis vulgaris, guttate psoriasis, pustular psoriasis, arthropathic psoriasis, and psoriatic erythroderma, etc.), keratosis(e.g., seborrheic keratosis, senile keratosis, actinic keratosis, photic keratosis and follicular keratosis, etc.), wart (e.g., acne vulgaris etc.), dermatitis (e.g., seborrheic
- antiinflammatory and analgetic drug e.g., ufenamate etc.
- antiinflammatory drug e.g., azulene etc.
- neural immunoregulating, paregoric, calmative and antiallergic drug e.g., vaccinia virus inoculable rabbit inflammatory dermal extract etc.
- drug for psoriasis vulgaris e.g., calcipotriol etc.
- agent for biological oxidation-reduction balance e.g., glutathione etc.
- dysbolism improving drug e.g., pantethine, panthenol and calcium pantothenate, etc.
- antipruritic astringent and antiinflammatory drug (e.g., zinc oxide and salicylic acid etc.), antipruritic and antiinflammatory drug (e.g., hydrocortisone crotamiton etc.), antipruritic drug (e.g., crotamiton etc.), drug for kera
- alopecic e.g., congenital alopecia(e.g., diffuse congenital alopecia and congenital triangular alopecia, etc.), acquired alopecia(folliculitis decalvans, alopecia areata and follicular mucinosis, etc.), etc.
- dyspigmentation e.g., stain, freckle and suntan, etc.
- vitamin C e.g., ascorbate etc.
- vitamin C preparation e.g., ascorbate and calcium pantothenate, etc.
- chinese medicine e.g., keisi-ka-ryukotu-boreito etc.
- drug for liver disease and allergy e.g., glycyron etc.
- antiseptic disinfectants e.g., resorcine etc.
- agent for biological oxidation-reduction balance e.g., glutathione etc.
- epilatory and effusion and hypoleukocytosis inhibitor e.g., cepharanthin etc.
- parasympathomimetic drug e.g., acetylcholine chloride etc.
- parasympathetic nerve stimulator e.g., carpronium chloride etc.
- adrenocorticosteroid e.g., amcinonide, difluprednate, betamethasone di
- the other preventive and/or therapeutic phannaceutical(s), which is/are combined with the compound of the present invention, for autoimmune disease include(s), e.g., nonsteroidal antiinflammatory drug (e.g., sasapyrine, sodium salicylate, aspirin, aspirin/dialuminate, diflunisal, indometacin, suprofen, ufenamate, dimethyl isopropyl azulene, bufexamac, felbinac, diclofenac, tolmetin sodium, clinoril, fenbufen, napument, puroglumetacine, indomethacin farnesyl, acemetacin, proglumetacin maleate, amfenac sodium, mofebutazone, etodolac, ibuprofen, ibuprofenpiconol, naproxen, flurbiprofen, flurbiprofen axetil, ketoprofen
- PG receptor includes PGE receptor (EP1,EP2,EP3 and EP4), PGD receptor (DP and CRTH2), PGF receptor (FP), PGI receptor (IP) and TX receptor(TP), etc.) and include(s) phosphodiesterase inhibitor (e.g., rolipram(PDE4 inhibitor), cilomilast (trade name Arifro), Bay19-8004, NIK-616, Roflumilast(BY-217), cipamphiline(BRL-61063), atizoram(CP-80633), SCH-351591, YM-976, V-11294A, PD-168787, D-4396, IC-485 and ONO-6126, etc.), metalloproteinase inhibitor, chemokine receptor antagonist (e.g., endogenous ligand of chemokine receptor (e.g., MIP-1 ⁇ , MIP-1 ⁇ , RANTES, SDF-1 ⁇ , SDF-1 ⁇ , MCP-1, MCP-2, MCP-4, Eotax
- the other preventive and/or therapeutic pharmaceutical(s), which is/are combined with the compound of the present invention, for HIV infection and acquired immunological deficiency syndrome include(s), e.g., reverse transcriptase inhibitor, protease inhibitor, chemokine (e.g., CCR2, CCR3, CCR4, CCR5, CXCR1, CXCR2, CXCR3 or CXCR4) antagonist, fusion inhibitor, antibody for surface antigen of HIV-1 and HIV-1 vaccine, etc.
- chemokine e.g., CCR2, CCR3, CCR4, CCR5, CXCR1, CXCR2, CXCR3 or CXCR4
- fusion inhibitor e.g., antibody for surface antigen of HIV-1 and HIV-1 vaccine, etc.
- the other preventive and/or therapeutic pharmaceutical(s), which is/are combined with the compound of the present invention, for atopic dermatitis include(s), e.g., steroid, non-steroidal antiinflammatory drug, immunosuppressive drug, PGs, antiallergic drug, mediator release inhibitor, antihistaminic, forskolin preparation, phosphodiesterase inhibitor and cannabinoid-2 receptor stimulator, etc.
- the other preventive and/or therapeutic pharmaceutical(s), which is/are combined with the compound of the present invention, for arteriosclerosis include(s), e.g., HMG-CoA reductase inhibitor, fibrate preparation, probucol preparation, anion exchange resin, EPA preparation, nicotinic acid preparation, MTP inhibitor, other anti-cholesterol drug and EDG-2 antagonist, etc.
- the other preventive and/or therapeutic pharmaceutical(s), which is/are combined with the compound of the present invention, for Crohn's disease and ulceous colitis include(s), e.g., steroid, elastase inhibitor, cannabinoid-2 receptor stimulator, prostaglandins, prostaglandin synthase inhibitor, phosphodiesterase inhibitor, metalloproteinase inhibitor, adhesive molecule inhibitor, anti-cytokine protein preparation, anti-cytokine drug, immunomodulator, leukotriene receptor antagonist, antiparasympathomimetic drug, 5-lipoxygenase inhibitor, nitric oxide synthase (NOS) inhibitor, interleukin-8 antagonist, poly(ADP-ribose)polymerase(PARP) inhibitor, mitochondriaa benzodiazepine receptor(MBR) agonist, antioxidant, local anesthetic, antiulcer drug, protection factor promoter, mesalazine, salazosulfapyridine and TNF-alpha antagonist, etc
- the other preventive and/or therapeutic pharmaceutical(s), which is/are combined with the compound of the present invention, for irritable bowel syndrome include(s), e.g., antianxiety drug (e.g., benzodiazepine, thienodiazepin and non-benzodiazepine, etc.), antidepressant drug (e.g., monoamine releaser, monoamine oxidase(MAO) inhibitor, monoamine reuptake inhibitor (SNRI and SSRI), dopamine(D2) antagonist, CRF antagonist, Beta 3 agonist, neurotensin antagonist, NK1 antagonist, tricyclic antidepressant and tetracyclic antidepressant, etc.), antiparasympathomimetic drug, affinity polyacrylamide resin, antidiarrheal drug, mucosal paralyzant, bulk catharic, saline cathartic, fiber pharmaceutical, drug for controlling intestinal function, autonomic nerve modulator, calcium channel blocking agent, phosphodiesterase inhibitor, serotonin antagonist (
- the other preventive and/or therapeutic pharmaceutical(s), which is/are combined with the compound of the present invention, for colitis include(s), e.g., steroid, nitric oxide synthase(NOS) inhibitor, prostaglandins, poly(ADP-ribose)polymerase(PARP) inhibitor, phosphodiesterase 4 inhibitor, elastase inhibitor, Interleukin-8 antagonist and cannabinoid-2 receptor stimulatior, etc.
- the dose varies depending upon age, body weight, symptom, therapeutic effect, administering method or treating time, etc. Generally, 100 ⁇ g to 1,000 mg per an adult is orally administered once to several times per a day, or 50 ⁇ g to 500 mg per an adult is parenterally administered one to several times per a day, or is continuously administered from vein for 1 to 24 hour(s) per a day.
- the compound of the present invention or the combined preparation of the compound of the present invention and other pharmaceutical is administered, it is used as internal solid composition for oral administration, internal liquid composition and injection, external preparation, suppository, eye drop or inhalant, etc., for parenteral administration.
- the internal solid composition for oral administration includes, e.g., tablets, pills, capsules, diluted powder and granules etc.
- the capsules include hard capsules and soft capsules.
- one or more active substance(s) is used by itself or by being mixed with vehicle (e.g., lactose, mannitol, glucose, microcrystalline cellulose, and starch, etc.), binding agent (e.g., hydroxypropylcellulose, polyvinyl pyrrolidone, and magnesium aluminometasilicate, etc.), disintegrator (e.g., sodium carboxymethylcellulose etc.), lubricant (e.g., magnesium stearate etc.), stabilizer or solubilizer (e.g., glutamate and aspartic acid, etc.), etc., and being pharmaceutically manufactured by a conventional method.
- vehicle e.g., lactose, mannitol, glucose, microcrystalline cellulose, and starch, etc.
- binding agent e.g., hydroxypropylcellulose, polyvinyl pyrrolidone, and magnesium aluminometasilicate, etc.
- disintegrator e.g., sodium carb
- the solid composition may be coated with coating (e.g., saccharose, gelatin, hydroxypropylcellulose or hydroxypropylmethylcellulose phthalate, etc.), if necessary, or may be coated with two or more layers.
- coating e.g., saccharose, gelatin, hydroxypropylcellulose or hydroxypropylmethylcellulose phthalate, etc.
- Capsule of a substance that can be absorbed such as gelatin is also included.
- the internal liquid composition for oral administration includes pharmaceutically acceptable solution, suspension, emulsum, syrup and elixir, etc.
- one or more active substance(s) is/are dissolved, suspended or emulsified in a commonly used inert diluent (e.g., pure water, ethanol or the mixture, etc.).
- the composition may contain moisturizer, suspending agent, sweetener, flavor, aromatic agent, preservative and buffer, etc.
- the external preparation for parenteral administration includes, e.g., ointment, gel, cream, fomentation, patch, embrocation, nebula, inhalant, spray, aerosol, eye drop and nosedrop, etc. These may contain one or more activator(s) and may be prepared by known methods or conventional methods.
- the ointment may be prepared by known methods or conventional methods. For example, it may be prepared by levigating and melting one or more activator(s) into a base.
- the ointment base is chosen from known or usually used ones. For example, it is used by mixing with one or more chosen from higher fatty acid or higher fatty acid ester (e.g., adipic acid, myristic acid, palmitic acid, stearic acid, oleic acid, adipic acid ester, myristic acid ester, palmitate, stearic acid ester or oleate, etc.), rows (e.g., beeswax, spermaceti wax or ceresin, etc.), surfactant (e.g., polyoxyethylene alkyl ether phosphate ester etc.), higher alcohol (e.g., cetanol, stearyl alcohol or cetostearyl alcohol, etc.), silicone oil (e.g., dimethylpolysiloxane etc
- the gel may be prepared by known methods or conventional methods. For example, it may be prepared by melting one or more activator(s) into a base.
- the gel base is chosen from known or usually used ones. For example, it is used by mixing with one or more base(s) chosen from lower alcohol (e.g., ethanol and isopropyl alcohol, etc.), gelatinizer (e.g., carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose or ethylcellulose, etc.), neutralizer (e.g., triethanolamine or diisopropanolamine, etc.), surfactant (e.g., polyethylene glycol monostearate etc.), gums, water, absorption promoter and poisoned inhibitor. Further, it may include preservative, anti-oxidant or flavor, etc.
- lower alcohol e.g., ethanol and isopropyl alcohol, etc.
- gelatinizer e.g., carboxymethylcellulose, hydroxyethylcellulose, hydroxypropyl
- the cream is prepared by known methods or conventional methods. For example, it may be prepared or emulsified by melting one or more activator(s) into a base.
- the cream base is chosen from known or usually used ones. For example, it is used by mixing with one or more base(s) chosen from higher fatty acid ester, lower alcohol, hydrocarbons or polyhydric alcohol (e.g., three propyleneglycol or 1, 3-butyleneglycol, etc.), higher alcohol (e.g., 2-hexyldecanol or cetanol, etc.) and emulsifier (e.g., polyoxyethylene alkyl ethers or fatty acid esters, etc.). Further, it may include preservative, anti-oxidant or flavor, etc.
- base(s) chosen from higher fatty acid ester, lower alcohol, hydrocarbons or polyhydric alcohol (e.g., three propyleneglycol or 1, 3-butyleneglycol, etc.), higher alcohol (e.g., 2-hexy
- the fomentation is prepared by known methods or conventional methods. For example, it may be prepared by melting one or more activator(s) into a base, followed by kneading, rolling and spreading on carrier.
- the fomentation base is chosen from known or usually used ones.
- the styrene resin is used by mixing with one or more base(s) chosen from thickener (e.g., polyacrylic acid, polyvinyl pyrrolidone, arabic gum, starch, gelatin or methylcellulose, etc.), penetrant (e.g., urea, glycerin or propyleneglycol, etc.), filler (e.g., china clay, zinc oxide, talc, calcium or magnesium, etc.), water, solubilizer, tackifier and poison inhibitor. Further, it may include preservative, anti-oxidant or flavor, etc.
- thickener e.g., polyacrylic acid, polyvinyl pyrrolidone, arabic gum, starch, gelatin or methylcellulose, etc.
- penetrant e.g., urea, glycerin or propyleneglycol, etc.
- filler e.g., china clay, zinc oxide, talc, calcium or magnesium, etc.
- the patch is prepared by known methods or conventional methods. For example, it may be prepared by melting one or more activator(s) into a base followed by rolling and spreading on carrier.
- the patch base is chosen from known or usually used ones. For example, it is used by mixing with one or more base(s) chosen from polymeric matrix, oils and fats, and higher fatty acid, tackifier and poison inhibitor. Further, it may include preservative, anti-oxidant or flavor, etc.
- the liniment is prepared by known methods or conventional methods. For example, it may be prepared by dissolving, suspending or emulsifying one or more activater(s) into one or more base(s) chosen from water, alcohol (e.g., ethanol or polyethylene glycol, etc.), higher fatty acid, glycerin, soap, emulsifier and suspending agent, etc. Further, it may include preservative, anti-oxidant or flavor, etc.
- base(s) chosen from water, alcohol (e.g., ethanol or polyethylene glycol, etc.), higher fatty acid, glycerin, soap, emulsifier and suspending agent, etc.
- it may include preservative, anti-oxidant or flavor, etc.
- the spray, the inhalant and the aerosol may contain a stabilizer such as sodium hydrogen sulfite or a buffer giving isotonicity, e.g., isotonizing agent such as sodium chloride, sodium citrate or citric acid, etc.
- a stabilizer such as sodium hydrogen sulfite or a buffer giving isotonicity, e.g., isotonizing agent such as sodium chloride, sodium citrate or citric acid, etc.
- the injection for parenteral administration includes all injections and the drip, too. It includes, e.g., muscle injection, hypodermic injection, intradermic injection, intra-arterial injection, intravenous injection, endoceliac injection, intrathecal injection and intravenous drip, etc.
- the injection for parenteral administration includes solution, suspension, emulsion, and solid injection that is dissolved or suspended into a solvent before use.
- the injection may be used by dissolving, suspending or emulsifying one or more activator(s) into a solvent.
- distilled water for injection e.g., distilled water for injection, physiologic saline, vegetable oil, propylene glycol, polyethylene glycol or alcohols such as ethanols or combination thereof is used as a solvent.
- the injection may include stabilizer, solubilizer (e.g., glutamic acid, glutamic acid and POLYSORBATE 80(registered trade mark), etc.), glutamic acid, emulsifier, soothing agent, buffer and preservative, etc. These are sterilized in the final process or manufactured by the aseptic manipulation.
- Sterile solid compositions may also be used, e.g., by being freeze-dried and being aseptic or dissolved to aseptic distilled purified water or other solvents before use.
- the eye drop for parenteral administration includes eye drops, eye drops of a suspension type, eye drops of an emulsion type, eye drops which is dissolved upon actual use, and eye ointment.
- the eye drop may be manufactured according to a known method. For example, is/are used by being dissolving, suspending or emulsifying one or more activator(s) into a solvent.
- a solvent for example, sterile purified water, physiologic saline and other water solvents or injectable non-aqueous solvent (e.g., vegetable oil etc.), etc., and combination thereof is used as a solvent of the eye drop.
- the eye drop may appropriately contain isotonizing agent (e.g., sodium chloride or concentrated glycerol, etc.), buffering agent (e.g., sodium phosphate or sodium acetate, etc.), surfactant (e.g., Polysorbate 80 (trade name), polyoxyl stearate 40 or polyoxyethylene hydrogenated castor oil, etc.), stabilizer (e.g., sodium citrate or sodium edetate, etc.), antiseptic agent (e.g., benzalkonium chloride or paraben, etc.), if necessity.
- isotonizing agent e.g., sodium chloride or concentrated glycerol, etc.
- buffering agent e.g., sodium phosphate or sodium acetate, etc.
- surfactant e.g., Polysorbate 80 (trade name), polyoxyl stearate 40 or polyoxyethylene hydrogenated castor oil, etc.
- stabilizer e.g., sodium citrate or sodium edetate, etc.
- the inhalation agent for parenteral administration includes aerosol preparation, powder for inhalation and liquid for inhalation.
- the liquid for inhalation may be such a form that the ingredient is dissolved or suspended in water or in other appropriate medium in actual use.
- Those inhalation agents are prepared according to known methods.
- antiseptic agent benzalkonium chloride or paraben etc.
- coloring agent for example, buffer (sodium phosphate or sodium acetate etc.), isotonizing agent (sodium chloride or concentrated glycerol etc.), thickener (carboxyvinyl polymer etc.) or absorption promoter, etc.
- buffer for example, buffer, isotonizing agent (sodium chloride or concentrated glycerol etc.), thickener (carboxyvinyl polymer etc.) or absorption promoter, etc.
- lubricant stearic acid or salt thereof, etc.
- binder e.g., starch or dextrin, etc.
- excipient e.g., lactose or cellulose, etc.
- coloring agent e.g., antiseptic (e.g., benzalkonium chloride or paraben, etc.) or absorption promoter, etc.
- antiseptic e.g., benzalkonium chloride or paraben, etc.
- absorption promoter etc.
- a spraying device e.g., atomizer or nebulizer etc.
- an administering device for inhalation of powdery pharmaceutical is usually used.
- composition for parenteral administration which contains one or more activator(s)
- the solvent in parentheses shown in chromatographic separation or TLC represents a used dissolution medium or eluent and the ratio of both solvents represents the volume ratio.
- NMR data is the data of 1 H-NMR unless otherwise stated.
- the solvent in parentheses of NMR represents a solvent used for measurement.
- MS is carried out in ESI (electron spray ion) method, in which cation (pos.) was detected.
- the condition of HPLC is as follows.
- Wang resin (Argonaut Technology) was washed with N, N-dimethylformamide.
- the reaction mixture was reacted during 18 hours at room temperature.
- the resin was filtered and sequentially washed with N, N-dimethylformamide, tetrahydrofuran, methanol and 1, 2-dimethoxyethane.
- the obtained resin was washed with 1% acetate/1 , 2-dichloroethane. Further, the corresponding 0.5 mol/L amine compound (5 equivalents) in 1% acetate/1, 2-dichloroethane solution was added and reacted for 5 hours at room temperature. 0.5 mol/L tetrabutylammonium borohydride in 1% acetate/1, 2-dichloroethane solution (5 equivalents) was added to the above mixture and then reacted overnight. The resin was filtered and washed with methanol, tetrahydrofuran and N, N-dimethylformamide.
- the obtained resin was washed with 1, 2-dichloroethane. Further, the corresponding 1 mol/L acylchloride in 1, 2-dichloroethane solution (5 equivalents) and diisopropylethylamine in 1, 2-dichloroethane solution (7.5 equivalents) were sequentially added. The reaction mixture was reacted overnight, and the resin was filtered and washed with 1, 2-dichloroethane, methanol and tetrahydrofuran.
- the resin obtained in Reaction 3 on Example 1 was washed with 1% acetate/N, N-dimethylformamide solution. Further, the corresponding 1% acetate/N, N-dimethylformamide solution in 0.5 mol/L aldehyde derivative (5 equivalents) was added and reacted for 5 hours at room temperature. N, N-dimethylformamide solution in 0.5 mol/L sodium triacetoxyborohydride (5 equivalents) was added to the mixture and then reacted overnight. The resin was filtered and washed with methanol, N, N-dimethylformamide, tetrahydrofuran and 1, 2-dichloroethane. Trifluoroacetic acid/20% 1, 2-dichloroethane was added to the obtained resin and reacted for 30 minutes. The solution obtained by filtering the mixture was concentrated to obtain the following compound of the present invention.
- Benzylamine(128mg) was added to the compound(120mg) prepared in Example 4 in methanol solution (3mL) and stirred for 4 hours at room temperature.
- Cyano sodium borohydride (62mg) was added to the reaction mixture and then acetic acid was dropped until pH.5.5 and stirred for 1 hour at room temperature.
- the reaction mixture was concentrated and alkalinized with 5mo1/L sodium hydroxide solution, and then extracted with ethyl acetate. The organic layer was washed with saturated brine and dried by anhydrous sodium sulfate, and then concentrated.
- Phenylamine (56mg) was added to the compound (120mg) prepared in Example 4 in methanol solution (3mL) and stirred for 4 hours at room temperature.
- the reaction mixture was added to sodium borohydride(37mg) and stirred for 1.5 hours.
- 5 mol/L sodium hydroxide solution was added to the concentrated reaction mixture and then extracted with ethyl acetate.
- the receptor antagonist activity was evaluated by using human BLT2 gene-overexressing Chinese Hamster Ovar (CHO) cells (see J.Exp.Med. Volume 192, Number 3 2000, and 421 -.). BLT2-expressing cells were cultured in Ham's F1 medium (GIBCO BRL and No. 11765-047) containing 10% FBS (fetal bovine serum), penicillin/streptomycin and blasticidin (5 ⁇ g/ml).
- FBS fetal bovine serum
- penicillin/streptomycin fetal bovine serum
- blasticidin 5 ⁇ g/ml
- Fura2-AM (Dojindo and No.348-05831)
- the cells were incubated in 5 ⁇ M Fura2-AM solution (Ham's F1 medium containing 10% FBS, 20mM HEPES buffer(pH7.4) and 2.5mM probenecid (Sigma and No. P-8761)) at 37°C for 60 minutes.
- the cells were washed once with Hanks solution containing 20mM HEPES buffer (pH7.4) and 2.5mM probenecid, and soaked in Hanks solution until assay.
- the plate was sat up on fluorescent drug screening system (Hamamatsu Photonics FDSS-2000) and measured without any stimulation for 30 seconds, to which the compound solution of the present invention was added.
- LTB4 (final concentration: 3 ⁇ M) was added to the plates 3 minutes later, of which the intracellular calcium ion concentration around the addition were measured at 3 seconds intervals (excitation wavelength 340nm, 380nm and fluorescent wave-length 500nm).
- the compound of the present invention was dissolved to dimethylsulfoxide (DMSO) and added in order that the final concentration is 1nM-10 ⁇ M.
- IC 50 value is a concentration of the compound of the present invention in which the inhibition ratio is 50%. Also, BLT1 antagonistic activity was measured by the same way. For example, IC 50 value for BLT2 of the compound prepared in Example 1(32) is 1.8 ⁇ M and the compound did not have BLT1 antagonistic activity.
- the compound of the present invention (final concentration: 1-10 ⁇ M, dimethylsulfoxide(DMSO)) was added 3 minutes later, and the intracellular calcium ion concentrations around addition of LTB4 were measured at 3 seconds intervals (excitation wavelength 340nm, 380nm and fluorescent wave-length 500nm).
- the EC 50 value was calculated by calculating the rate of increase in each concentration of the compound.
- BLT1 antagonistic activity was measured by the same way. For example, IC 50 value for BLT2 of the compound prepared in Example 13 is 0.045 ⁇ M and the compound did not have BLT1 agonistic activity.
- mBLT2 ORF was amplified by PCR using a sense primer having BamHI restriction enzyme site (sense primer; 5'-CGGGATCCCGCATGTCTGTCTGCTACCGTC-3' (SEQ ID N0.1)) and an antisense primer having EcoRI restriction enzyme site(antisense primer; 5'-CGGAATTCTACCATTCTTGACTGTCTT-3 (SEQ ID N0.2)).
- the PCR product was digested with BamHI and EcoRI and inserted in expression plasmid (pcDNA3 Invitrogen). The inserted sequence was confirmed by the DNA sequence.
- Plasmid DNA (3 ⁇ g) was transfected into CHO cells cultured in Ham's F-12 medium containing 10% fetal bovine serum and antibiotic (streptomycin (100 ⁇ g/mL) and penicillin (100 ⁇ g/mL)) in cell culture plates (6cm).
- the resistant strains were obtained by culturing for 2 weeks in the existence of antibiotic (G418 [Wako], 1mg/mL).
- the stable expressing strains were obtained by culturing 19 obtained resistant strains with limiting dilution method.
- mice tissue BLT2 mRNA was northern-blotted to explore the expression pattern.
- total RNA of mouse tissue C57B1/6J Jcl [Japan clea]
- mouse peritoneal macrophages were collected 4 days later by injecting thioglycolate (4.05 w/v %, 2mL) into mouse peritoneal cavity.
- Mouse neutrophils were collected 7 hours later by injecting casein (2.0 w/v %, 2mL) into mouse peritoneal cavity.
- RNA Poly(A) + RNA was separated from total RNA(200 ⁇ g) with mRNA extraction kit ( ⁇ MACS mRNA isolation kit [Miltenyi Biotec]). Mouse tissue mRNA(5 ⁇ g), total RNA(10 ⁇ g) of macrophages and neutrophils was degenerated and transfered nylon membrane filter (Hybond N+ [Amersham Biosciences]) after 0.7% formaldehyde agarose gel electrophoresis. 32 P-dCTP-labeled mBLT2 or glyceraldehydes-3-phosphate dehydrogenase(g.3PDH) ORF was hybridized for 2 hours at 65°C and washed with 2xSSC and 0.1% SDS.
- cDNA was synthesized (Superscript II [Invitrogen]) from mouse tissue mRNA(50ng), total RNA(50ng) of macrophages and neutrophils, and diluted 100 times with distilled water. Then, the cDNA was amplified in 20 ⁇ L microcapillary as PCR solution containing diluted cDNA(5 ⁇ L), 1xFastStart DNA Master SYBR Green I(Roche; Molecular Biochemicals), MgCl 2 (final concentration 4mM) and primers(0.5 ⁇ M) by PCR (LightCyclerSystem[Roche Molecular Biochemicals]).
- pCXN2-mBLT2 and pcDNA3.1 were used as controls and the following were used as a primer; mBLT2 820+, 5'-ACAGCCTTGGCTTTCTTCAG-3' (SEQ ID N0.3); mBLT2 1013-, 5'-TGCCCCATTACTTTCAGCTT-3' (SEQ ID NO.4); GAPDH-1013+, GTGGACCTCATGGCCTACAT-5'(SEQ ID NO.5); GAPDH-1226-, 5'-GGGTGCAGCGAACTTTATTG-3' (SEQ ID NO.6).
- each mRNA amount of BLT2 and G3PDH was calculated based on the signal and frequency of SYBR Green I as indicators.
- Paraffin sections of mouse (C57B1/6J Jc1 [Japan clea]) skin sample were fixed by 10% formalin containing PBS, of which BLT2 mRNA expressions were observed by non-radioactive in situ hybridization.
- the paraffin-embedded mouse tissues were cut into 4 ⁇ m thickness and mounted on silane coated glass, and deparaffinized.
- the samples were prepared by being processed by proteinase K (5 ⁇ g/mL in PBS) (for 10 minutes at room temperature) and being processed by glycine (2mg/mL in PBS) (for 15 minutes at room temperature.).
- mBLT2 ORF fragment (741-941) was amplified by PCR using a downstream primer containing HindIII restriction enzyme site and an upstream primer containing EcoRI restriction enzyme site and inserted into vector (pSPT18) by directional cloning system.
- An antisense probe was prepared by digesting them with HindIII and a sense probe was prepared by digesting them with EcoRI.
- probes were digoxigenin-11-UTP-labeled with DIG RNA labeling kit (Roche Molecular Biochemicals). They were hybridized under humidification for 16 hours at 42°C. The samples were washed 3 times using 50% formamide containing 2 ⁇ SSC for 20 minutes at 42°C. Non-hybridized probes were digested by enzyme (RNaseA(20 ⁇ g/mL) in NaCl(500mM), EDTA(1mM) and Tris-HCl(10mM, pH8.0)) for 30 minutes at 37°C. Further, the samples were visualized by digoxigenin-labeled probes prepared according to the attached manual using DIG nucleic acid detection kit (Roche Mollecular Biochemical). And, they were counterstained by methyl green.
- DIG RNA labeling kit Roche Molecular Biochemicals
- Figure 3 shows the result of In Situ hybridization.
- mBLT2-expressing CHO cells prepared by Biological Example 3 were cultured in modified Hepes-Tyrode's BSA buffer (Hepes-NaOH(25mM, pH7.4), NaCl(140mM), KCl(2.7mM), CaCl 2 (1.0mM), NaHCO 3 (12mM), D-Glucose(5.6mM), NaH 2 PO 4 (0.37mM), MgCl 2 (0.49mM), cremophour(0.01%), fatty acid-free BSA(fraction V, 0.1w/v%)) containing fluorochrome (Fura-2 AM [Dojin], 3 ⁇ m) at 37°C for 2 hours to make to take fluorochrome.
- fluorochrome Fluorine
- Figure 4 shows a graph of the rise of the intracellular calcium concentration using the compound prepared in Example 9 as a ligand (hereafter, it is abbreviated to compound A).
- Compound A (filed triangle) indicated EC 50 value (compound A: 21nM; LTB4: 121nM) lower than that of LTB4(filed Diamond).
- the intracellular calcium concentration was not rised though compound A was added to mBLT1-expressing CHO cells (opened triangle) and mock(opened square).
- mBLT2-expressing CHO cells prepared in Biological Example 3 were cultured in 12 well-culture plate at cell density of 2.0 ⁇ 10 5 cell/well. The cells were transfered to F-12 medium containing 0.1% BSA 2 days later and cultured without serum for 12 hours. The cells were preincubated in F..12 medium containing 0.1% BSA for 10 minutes and exposed to various concentrations of ligand for 5 minutes. After removing the medium, the cells were digested by lysis buffer (Tris-HCl(20mM), ⁇ -glycerophosphate(50mM), EGTA(5mM), Na 3 VO 3 (1mM), DTT(2mM), PMSF(1 ⁇ M), NP-40(1%), 250 ⁇ L) and frozen at -80°C.
- lysis buffer Tris-HCl(20mM), ⁇ -glycerophosphate(50mM), EGTA(5mM), Na 3 VO 3 (1mM), DTT(2mM), PMSF(1 ⁇ M), NP-40
- the membrane was incubated in blocking buffer containing 1000 times diluted primary antibody(anti-phospho-ERK antidbody(phospho-p44/p42 MAPK(Thr202/tyr204) antibody[Cell Signaling TECHNOLOGY]) and anti-ERK antibody(p44/p42 MAP Kinase Antibody[Cell Signaling TECHNOLOGY])) for 2 hours and reacted with 2000 times diluted second HRP-labeled antibody and then detected using ECL system(Amersham).
- Figure 5 shows ERK phosphorylation when mBLT2-expressing CHO cells and mBLT1-expressing CHO cells were stimulated with LTB4 or compound A (upper row: mBLT2-expressing CHO cells; lower row: mBLT1-expressing CHO cells).
- ERK phosphorylations in mBLT2-expressing CHO cells and mBLT1-expressing CHO cells were induced by LTB4 and compound A.
- ERK phosphorylation in BLT1-expressing CHO cells was induced by compound A.
- the primary culture keratinocytes prepared in Biological Example 8 were cultured in 12-well culture plate at cell density of 4.0 ⁇ 10 5 cell/well. They were transfered to Defined keratinocyte SFM medium (GibcoBRL) 1 day later from culture and cultured without serum for 12 hours. The cells were preincubated for 10 minutes in Defined keratinocyte SFM medium containing 0.1%BSA and stimulated as well as Biological Example 9, of which ERK phosphorylation was observed.
- Figure 7 shows ERK phosphorylation when mouse primary culture keratinocytes were stimulated with LTB4 or compound A.
- LTB4 and compound A induced ERK phosphorylation of mouse primary culture keratinocytes.
- BLT2 is highly expressed in keratinocyte
- a compound with BLT2 binding activity, salt thereof, solvate thereof or prodrug thereof is useful for prevention and/or therapy for skin disease.
- the compound represented in formula (I), salt thereof, solvate thereof or prodrug thereof is useful for prevention and/or therapy of BLT2 mediated diseases, e.g., dermatosis, intestinal disease, HIV infection, acquired immunodeficiency syndrome, rejection to transplant, transplant rejection, graft-versus-host disease, autoimmune disease, allergic disease, inflammation, infection, ulcers, lymphoma, malignant tumor, leucaemia, arterial sclerosis, hepatitis, hepatic cirrhosis or cancer, etc.
- diseases e.g., dermatosis, intestinal disease, HIV infection, acquired immunodeficiency syndrome, rejection to transplant, transplant rejection, graft-versus-host disease, autoimmune disease, allergic disease, inflammation, infection, ulcers, lymphoma, malignant tumor, leucaemia, arterial
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
[PROBLEM] The compound that selectively binds to BLT2 and the preventive and/or therapeutic drug for BLT2-mediated disease such as skin disease are needed.
[MEANS FOR SOLVING THE PROBLEMS] The present invention provides the compound with BLT2 binding activity, salt thereof, solvate thereof or prodrug thereof. Since the compound with BLT2 binding activity, particularly the compound represented by the formula (I)
, salt thereof, solvate thereof or prodrug thereof (symbols in formula have the same meanings as specification.) have BLT2 binding activity, it is useful for prevention and/or therapy of BLT2 mediated diseases, e.g., dermatosis, intestinal disease, HIV infection, acquired immunodeficiency syndrome, rejection to transplant, transplant rejection, graft-versus-host disease, autoimmune disease, allergic disease, inflammation, infection, ulcers, lymphoma, malignant tumor, leucaemia, arterial sclerosis, hepatitis, hepatic cirrhosis or cancer, etc.
Description
- The present invention relates to a medical use comprising novel BLT2 mediated disease, a BLT2 binding agent, a novel compound to bind to BLT2 and compound thereof. For details, the present invention relates to a medical use which (1) a preventive and/or therapeutic drug for skin disease comprising the compound to bind to BLT2, salt thereof, solvate thereof and prodrug thereof, (2) the BLT2 binding agent comprising a compound represented by formula (I)
- It is thought that Leukotriene B4 (5[S], 12[R]-dihydroxy-6, 14-cis-8, 10-trans-eicosatetraenoic acid; it is abbreviated to LTB4 hereafter.) is a lipid mediator producted by arachidonate cascade and that promotes the migration of leukocytes, the production of active oxygen and the release of lysosomal enzyme, etc., by binding to receptor in the presence of membrane surface, and that plays a key role for organism such as the inflammatory reaction and the defense to bacterial infection etc.
- Two kinds of BLT1 and BLT2, which are G-protein coupled receptors, have been already reported as LTB4 receptor (J.Exp.Med., Volume 192, Number 3, 2000, 421-). It has been confirmed that these receptors, which bind to G-protein such as Gi and Gq, etc., cause the induction of intracellular signal such as the rise of intracellular calcium concentration and the suppression of adenylate cyclase activity, etc., by binding of the ligand LTB4. Affinity of LTB4 to both receptors is different though the homology in amino acid sequence between BLT1 and BLT2 is high (45%) and BLT1 specifically strongly binds to LTB4 with Kd value 0.15nM, BLT2 weakly binds to LTB4 with Kd value 22nM. It is reported that BLT1 is strongly expressed on leukocyte and is very strictly and organ-specifically expressed, while BLT2 is most strongly expressed in spleen and lymphocyte and sincerely expressed in a lot of organs including liver and ovary.
- Thus, because both receptors are different the reactiveness to LTB4 and the expression distribution, it is guessed that both receptors would play a mutually different role in vivo. Therefore, it is thought that a compound that acts on BLT1 shows a pharmacological action different from a compound that acts on BLT2. So far, it has been thought that the compound that acts on BLT1 is useful for diseases including bronchial asthma and articular rheumatism to which leukocytic infiltration relates. On the other hand, it has been thought that the compound that acts on BLT2 is useful for prevention and/or therapy of BLT2 mediated diseases, e.g., human immunodeficiency virus (hereafter, it is abbreviated to HIV) infection, rejection to transplant, transplant rejection, graft-versus-host disease, autoimmune disease (e.g., systemic lupus erythematous, articular rheumatism, myasthenia gravis and sclerosis multiple, etc.), allergic disease (e.g., atopic dermatitis and bronchial asthma, etc.), inflammation, infectious disease, ulcus, lymphoma, carcinoma, leukosis, arteriosclerotic, hepatitis, liver cirrhosis or cancer, etc. However, there is no report that BLT2 is highly expressed in small intestine and skin keratinocyte and that the compound that binds to BLT2 is useful for prevention and/or therapy of intestinal disease including ulcerative colitis or skin disease including psoriasis and dermatitis so far.
- And, there is no report about an agonist or antagonist specific to BLT2 and usage thereof at all so for.
- On the other hand, it is known that a compound containing biphenyl structure has an antagonism against angiotensin II and a regulatory action on peroxisome proliferator-activated receptor (e.g., see
patent literature 1, 2, 3 and 4). - Patent document 1:1P-A-06-72985
- Patent document 2:
JP-A-06-184086 - Patent document 3:
JP-A-06-211814 - Patent document 4:
WO99/12534 - The present inventors find compounds that bind to BLT2 and are useful as drugs, and newly provide preventive and/or therapeutic drugs for BLT2-mediated diseases including skin disease.
- The present inventors found that BLT2 is highly expressed in skin keratinocyte and small intestine and that the compound represented by the formula (I), salt thereof, solvate thereof and prodrug thereof has BLT2 binding activity, especially, the compound represented by the formula (I-1), salt thereof, solvate thereof and prodrug thereof has BLT2 binding activity and is useful as a preventive and/or therapeutic drug for BLT2 mediated diseases including skin disease and rejection to transplant to accomplish the present invention as a result of their intensive studies for solving said problems.
- That is, the present invention relates to the followings.
- (1) An agent for the prevention and/or treatment of skin diseases, which comprises a compound with BLT2 binding activity, a salt thereof, a solvate thereof or a prodrug thereof.
- (2) The agent according to (1), wherein the compound with BLT2 binding activity is a compound with agonistic action on BLT2.
- (3) The agent according to (1), wherein the compound with BLT2 binding activity is a compound with antagonistic action on BLT2.
- (4) The agent according to (1), wherein the skin disease is psoriasis, eczema, skin cancer, keratosis, dyspigmentation or psilosis.
- (5) The agent according to (1), wherein the compound with BLT2 binding activity is a compound represented by the formula (I)
X represents an acidic group,
Y represents a bond or a spacer in which the number of atom in the principal chain is one to three, and
E represents an amino group which may be substituted. - (6) The agent according to (5), wherein the compound with BLT2 binding activity is a compound represented by the formula (I-1)
R1 and R2 each independently represent a hydrogen atom or a hydrocarbon group which may be substituted. - (7) A pharmaceutical composition comprising a compound with BLT2 binding activity, a salt thereof, a solvate thereof or a prodrug thereof; in combination with one or more kinds of drugs selected from immunosuppressant, antibiotic, antihistaminic and drenocortical steroid.
- (8) A BLT2 binding agent comprising a compound represented by the formula (I)
- (9) The agent according to (8), wherein the BLT2 binding agent is an agonist for BLT2.
- (10) The agent according to (8), wherein the BLT2 binding agent is an antagonist for BLT2.
- (11) The agent according to (8), which is an agent for the prevention and/or treatment of BLT2-mediated diseases.
- (12) The agent according to (11), wherein the BLT2-mediated disease is rejection to transplant, transplant rejection, graft-versus-host disease, autoimmune disease, allergic disease, inflammation, infectious disease, ulcus, lymphoma, carcinoma, leukosis, arteriosclerotic, hepatitis, liver cirrhosis or cancer.
- (13) The agent according to (11), wherein the BLT2-mediated disease is intestinal disease or human immunodeficiency virus infection.
- (14) A pharmaceutical composition comprising the compound represented by the formula (I) according to (8), a salt thereof, a solvate thereof or a prodrug thereof; in combination with one or more kinds of drugs selected from nonsteroidal antiinflammatory drug, disease-modifying antirheumatic drug, drenocortical steroid, immunosuppressant, antiinflammatory enzyme drug, cartilage protective drug, T lymphocyte inhibitor, TNF-α inhibitor, prostaglandin synthase inhibitor, IL-6 inhibitor, interferon γ agonist, IL-1 inhibitor, EDG-1 agonist, EDG-6 agonist, prostaglandins, phosphodiesterase inhibitor, metalloproteinase inhibitor and chemokine receptor antagonist.
- (15) A compound represented by the formula (I-1)
- (16) A method for the prevention and/or treatment of skin diseases in mammal, which comprises administrating to a mammal an effective amount of a compound with BLT2 binding activity, a salt thereof, a solvate thereof or a prodrug thereof.
- (17) Use of a compound with BLT2 binding activity, a salt thereof, a solvate thereof or a prodrug thereof for the manufacture of an agent for the prevention and/or treatment of skin diseases.
- (18) A method for the prevention and/or treatment of BLT2-mediated diseases in mammal, which comprises administrating to a mammal an effective amount of a compound represented by the formula (I)
- (19) Use of a compound represented by the formula (I)
- In the present specification, the compound with BLT2 binding activity, which specifically binds to BLT2 that is one of LTB4 receptors, only has to be a compound with agonistic or antagonistic action on BLT2, but it is not limited by the structure, the strength of the action or the presence of the specificity.
- In the present specification, BLT2 agonist means a compound that shows an action on BLT2 as same as LTB4, but BLT2 antagonist means a compound that antagonizes an action of LTB4 on BLT2. These classifications can be judged by monitoring an event induced by LTB4, e.g., monitoring the rise of the intracellular calcium concentration as described in example using BLT2-expressing cells etc. (e.g., BLT2 overexpressing cells etc.). In particular, for example, if the compound can raise the intracellular calcium concentration in BLT2-expressing cells, it can be judged as BLT2 agonist and if the compound can inhibit the rise of the intracellular calcium concentration by LTB4 in BLT2-expressing cells, it can be judged as BLT2 antagonist.
- In the present specification, BLT2 agonist includes a compound in which the rising activity of the intracellular calcium concentration as described in example is less than 100uM as EC50 value. And, BLT2 antagonist includes a compound in which the inhibitory activity of the rise of the intracellular calcium concentration is less than 100uM as IC50 value.
- In the present specification, BLT2-mediated disease includes an already found disease and a disease that may be newly found. These diseases include, e.g., skin disease, intestinal disease, HIV transmission, acquired immunodeficiency syndrome, rejection to transplant, transplant abolition, graft-versus-host disease, autoimmune disease, allergic disease, inflammation, infectious disease, ulcus, lymphoma, carcinoma, leukosis, arteriosclerotic, hepatitis, liver cirrhosis and cancer, etc.
- In the present specification, skin disease has only to be a disease that meets either requirement in which it is accompanied by the histological laesio in skin tissue or the cytological dysfunction in keratinocyte (especially, skin keratinocyte), it is not limited especially. Concretely, it includes, e.g., eczema, cheloma, lupus skin injury, acne (e.g., comedo etc.), dermatitis (e.g., seborrhoeic dermatitis, solar dermatitis, contact dermatitis, and atopic dermatitis, etc.), psoriasis (e.g., psoriasis vulgaris, guttate psoriasis, pustular psoriasis, psoriasis arthropica, and psoriatic erythrodermia, etc.), keratosis (e.g., seborrhoic keratosis, senile keratosis, actinic keratosis, photic evocation keratosis, and follicular keratosis, etc.), verruca (e.g., condyloma, pointed condyloma, venereal verruga, virus verruga, molluscum contagious, leukoplakia, verruga including human papilloma virus infection (HPV) such as vesicobullous lichen ruber, etc.), and skin cancer (e.g., rodent cancer, cutaneous T lymphoma, and localized benign epidermal tumor (e.g., keratoderma and hard nevus, etc.), etc.), etc. Further, skin disease in the present invention includes a disease accompanied by dysfunction of hair root keratinocyte (e.g., alopecia (e.g., congenital alopecia (diffuse congenital alopecia and alopecia triangularis congenitalis, etc.) and acquired alopecia (folliculitis decalvans, alopecia areata, and follicular mucinosis, etc.), etc.), etc.) and dyspigmentation (e.g., spot, freckle, chromatosis by sunburn, etc.), etc.
- In the present specification, intestinal disease includes, e.g., inflammatory bowel disease (e.g., ulcerative colitis and Crohn's disease, etc.), irritable bowel syndrome and colitis, etc.
- In the present specification, using the compound with BLT2 binding activity, salt thereof, solvate thereof and prodrug thereof for treatment of skin disease, it is preferable that the compound is bifurcated, depending on whether it is BLT2 agonist or antagonist. Concretely, among said skin diseases, if it is, e.g., alopecia (e.g., congenital alopecia (diffuse congenital alopecia and alopecia triangularis congenitalis, etc.) and acquired alopecia (folliculitis decalvans, alopecia areata, and follicular mucinosis, etc.), etc.) and dyspigmentation (e.g., spot, freckle, chromatosis by sunburn), etc., it is prefer to use BLT2 agonist. If it is, e.g., eczema, cheloma, lupus skin injury, acne (e.g., comedo etc.), dermatitis (e.g., seborrhoeic dermatitis, solar dermatitis, contact dermatitis, and atopic dermatitis, etc.), psoriasis (e.g., psoriasis vulgaris, guttate psoriasis, pustular psoriasis, psoriasis arthropica, and psoriatic erythrodermia, etc.), keratosis (e.g., seborrhoic keratosis, senile keratosis, actinic keratosis, photic evocation keratosis, and follicular keratosis, etc.), verruca (e.g., condyloma, pointed condyloma, venereal verruga, virus verruga, molluscum contagious, leukoplakia, verruga including human papilloma virus infection (HPV) such as vesicobullous lichen ruber, etc.), and skin cancer (e.g., rodent cancer, cutaneous T lymphoma, and localized benign epidermal tumor (e.g., keratoderma and hard nevus, etc.), etc.), etc., it is prefer to use BLT2 antagonist.
- In the present invention, the compound with BLT binding activity is preferably the compound represented by formula (I)
- Because the compound represented by formula (I) in the present invention has BLT2 binding activity, they is used for expressing agonistic or antagonistic action accompanied by binding to BLT2.
- In the present invention, the ring in the ring that further may contain substituents represented by ring A or ring B includes a bivalent group in which two arbitrary hydrogen atoms are excluded from homocycle or heterocycle.
- In the present invention, the homocycle includes, e.g., saturated cyclic hydrocarbon or unsaturated cyclic hydrocarbon, etc. The 3 to 15-membered saturated cyclic hydrocarbon includes, e.g., (a) cycloalkane (e.g., cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, cycloundecane, cyclododecane, cyclotridecane, cyclotetradecane and cyclopentadecane ring, etc.), (b) saturated polycyclic compound (e.g., perhydropentalene, perhydroazulene, perhydroindene, perhydronaphthalene, perhydroheptalene, spiro[4.4]nonane, spiro[4.5]decane, spira[5.5]undecana, bicyclo[2.2.1]heptane, bicyclo[3.1.1]heptane, bicyclo[22.2]octane, adamantane and noradamantane ring, etc.), etc. Further, the unsaturated cyclic hydrocarbon includes, e.g., 3 to 15-membered unsaturated cyclic hydrocarbon etc. The 3 to 15-membered unsaturated cyclic hydrocarbon includes, e.g., (a) cycloalkene (e.g., cyclopentene, cyclohexane, cycloheptene, cyclooctene, cyclopentadiene, cyclohexadiene, cycloheptadiene and cyclooctadiene ring, etc.), (b) aromatic hydrocarbon (e.g., benzene, azulene, naphthalene, phenanthrene and anthracene ring, etc.), (c) unsaturated polycyclic compound (e.g., pentalene, indene, indane, dihydronaphthalene, tetrahydronaphtalene, heptalene, biphenylene, as-indacene, s-indacene, acenaphthene, acenaphthylene, fluorene, phenalene, bicyclo[2.2.1]hepta-2-en, bicyclo[3.1.1]hepta-2-en and bicyclo[2.2.2]octa-2-en ring, etc.), etc.
- In the present specification, the heterocycle includes monocycle or polycyclic heterocycle that may contain 1 to 7 of hetero atom(s) selected from a nitrogen atom, an oxygen atom and a sulfur atom. The monocycle or the polycyclic heterocycle that may contain 1 to 7 of hetero atom(s) selected from a nitrogen atom, an oxygen atom and a sulfur atom includes, e.g., 3 to 15-membered unsaturated monocycle or polycyclic heterocycles and 3 to 15-membered saturated monocycle or polycyclic heterocycles, etc. The 3 to 15-membered unsaturated monocycle or polycyclic heterocycles includes, e.g., (a) aromatic monocyclic heterocycle (e.g., pyrrole, imidazole, triazole, tetrazole, pyrazol, pyridine, pyrazine, pyrimidine, pyridazine, triazine, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, furazan, oxadiazole and thiadiazole ring, etc.), (b) aromatic fused heterocycle (e.g., indole, isoindole, benzofuran, isobenzofuran, benzothiophene, isobenzothiophene, indazole, quinoline, isoquinoline, purine, phthalazine, pteridine, naphthyridine, quinoxaline, quinazoline, cinnoline, benzoxazole, benzothiazole, benzimidazole, benzofurazan, benzothiadiazole, benzotriazole, carbazole, β-carboline, acridine, phenazine, dibenzofuran, dibenzothiophene, phenanthridine, phenanthroline and perimidine ring, etc.), (c) Nonaromatic unsaturated heterocycle (e.g., azepine, diazepine, pyran, oxepin, thiopyran, thiepin, oxazine, oxadiazine, oxazepine, oxadiazepine, thiazine, thiadiazine, thiazepine, thiadiazepin, indolizine, dithia naphthalene, quinolizine, chromene, benzoxepin, benzoxazepine, benzoxadiazepine, benzothiepine, benzothiazepine, benzo thiadiazepine, benzazepine, benzodiazepine, xanthene, phenothiazine, phenoxazine, phenoxathiine, thianthrene, pyrroline, imidazoline, triazoline, tetrazoline, pyrazoline, dihydropyridine, tetrahydropyridine, dihydropyrazine, tetrahydropyrazine, dihydropyrimidine, tetrahydropyrimidine, dihydropyridazin, tetrahydropyridazine, tetrahydrotriazine, dihydroazepine, tetrahydroazepine, dihydrodiazepine, tetrahydrodiazepine, dihydrofuran, dihydropyran, dihydrooxepin, tetrahydrooxepin, dihydrothiophene, dihydrothiopyran, dihydro thiepin, tetrahydrothiepin, dihydrooxazole, dihydroisoxazole, dihydrothiazol, dihydroisathiazole, dihydrofurazan, dihydrooxadiazole, dihydrooxazine, dihydro oxadiazine, dihydrooxazepine, tetrahydrooxazepine, dihydrooxadiazepine, tetrahydrooxadiazepine, dihydrothiadiazole, dihydrothiazine, dihydrothiadiazine, dihydrothiazepine, tetrahydrothiazepine, dihydrothiadiazepin, tetrahydrothiadiazepin, indoline, isoindolin, dihydrobenzofuran, dihydroisobenzofuran, dihydrobenzothiophene, dihydroisobenzothiophene, dihydroindazole, dihydroquinoline, tetrahydroquinoline, dihydroisoquinoline, tetrahydroisoquinoline, dihydrophthalazine, tetrahydrophthalazine, dihydronaphthyridine, tetrahydronaphthyridine, dihydroquinoxaline, tetrahydroquinoxaline, dihydroquinazoline, tetrahydroquinazoline, dihydrocinnoline, tetrahydrocinnoline, benzoxathian, dihydrobenzooxazine, dihydrobenzothiazine, pyrazinomorpholine, dihydrobenzooxazole, dihydrobenzothiazole, dihydrobenzimidazol, dihydrobenzoazepine, tetrahydrobenzoazepine, dihydrobenzodiazepine, tetrahydrobenzodiazepine, benzodioxepane, dihydrobenzooxazepine, tetrahydrobenzooxazepine, dihydrocarbazole, tetrahydrocarbozole, dihydro-β-carboline, tetrahydro-β-carboline, dihydroacridine, tetrahydroacridine, dihydrodibenzofuran, dihydrodibenzo thiophene, tetrahydrodibenzofuran, tetrahydrodibenzothiophene, dioxanindane, benzodioxan, chroman, benzodithiolane, benzodithiane, 6, 7, 8, 9-tetrahydro-5H-pyrid[4', 3': 4, 5]pyrrolo[2, 3-b]pyridine, 2, 3, 4, 5-tetrahydro-1H-pyrid[4, 3-b]indole, and 6, 7,8,9-tetrahydro-5H-pyrid[3', 4': 4, 5]pyrrolo[2, 3-b]pyridine ring, etc.). And the 3 to 15-membered saturated monocycle or polycyclic heterocycles includes, e.g., aziridine, azetidine, pyrrolidine, imidazolidine, triazolidine, tetrazolidine, pyrazolidine, piperidine, piperazine, perhydropyrimidine, perhydropyridazine, perhydroazepine, perhydrodiazepine, perhydroazocine, oxirane, oxetane, tetrahydrofuran, tetrahydropyran, perhydrooxepin, thiirane, thietane, tetrahydrothiophene, tetrahydrothiopyran, perhydrothiepin, tetrahydrooxazole (oxazolidine), tetrahydroisoxazole (isoxazolidine), tetrahydrothiazole (thiazolidine), tetrahydroisothiazole (isothiazolidine), tetrahydrofurazan, tetrahydrooxadiazole (oxadiazolidine), tetrahydrooxazine, tetrahydrooxadiazine, perhydrooxazepine, perhydrooxadiazepine, tetrahydrothiadiazole (thiadiazolidine), tetrahydrothiazine, tetrahydrothiadiazine, perhydrothiazepine, perhydrothiadiazepin, morpholine, thiomorphaline, oxathiane, perhydrobenzofuran, perhydroisobenzofuran, perhydrobenzothiophene, perhydroisobenzothiophene, perhydroindazole, perhydroquinoline, perhydroisoquinoline, perhydrophthalazine, perhydronaphthyridine, perhydroquinoxaline, perhydroquinazoline, perhydrocinnoline, perhydrobenzoxazole, perhydrobenzothiazole, perhydrobenzimidazole, perhydrocarbazole, perhydro-β-carboline, perhydroacridine, perhydrodibenzofuran, perhydrodibenzothiophene, dioxolane, dioxane, dithiolane, and dithiane ring, etc.
- The ring A or the ring B is preferable to be a bivalent group in which two arbitrary hydrogen atoms are excluded from monocyclic aromatic ring. The monocyclic aromatic ring includes, e.g., benzene ring and said aromatic monocyclic heterocycle, etc., benzene ring is especially preferable.
- In the present specificaion, some substituents in the ring that further may contain substituents represented by ring A or ring B include, e.g., [1] a hydrocarbon that may contain substituents (e.g., (a) C1-8 aliphatic hydrocarbon, (b) amino, (c) sulfo, (d) halogen atom, (e) carboxyl, (f) cyano, (g) nitro, (h) oxo, (i) thioxo, (j) hydroxyl, (k) methoxy, (l) trifluoromethyl, and (m) trifluoromethoxy, etc.), [2] a heterocycle that may contain substituents (e.g., (a) C1-8 aliphatic hydrocarbon that may contain substituents (e.g., (1) halogen atom, (2) hydroxyl, (3) trifluoromethyl, (4) trifluoromethoxy, and (5) acetyloxy, etc.), (b) cyclic hydrocarbon that may contain substituents (e.g., (1) halogen atom, (2) hydroxyl, (3) trifluoromethyl, (4) trifluoromethoxy, and (5) acetyloxy, etc.), (c) amino, (d) sulfo, (e) halogen atom, (f) carboxyl, (g) cyano, (h) nitro, (i) oxo, (j) thioxo, (k) hydroxyl, (1) methoxy, (m) methoxycarbonyl, (n) trifluoromethyl, (o) trifluoromethoxy, and (p) acetyl, etc.), [3] an amino that may contain substituents, [4] C1-4 alkylsulfonyl (e.g., methylsulfonyl and ethylsulfonyl, etc.), [5] phenylsulfonyl, [6] halogen atom, [7] carboxyl, [8] cyano, [9] nitro, [10] oxo, [11] thioxo, [12] hydroxyl that may be protected, [13] mercapto that may be protected, [14] carbamoyl that may contain substituents, [15] sulfamoyl that may contain substituents, [16] C1-6 alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, and tert-butoxycarbonyl, etc.), [17] sulfo, [18] sulfino, [19] phosphono, [20] amidino, [21] imino, [22]dihydroxyboryl, [23] C1-6 acyl (e.g., formyl, acetyl, propionyl, and butyryl, etc.), etc. The 1 to 5 or 1 to 3 arbitrary substituent(s), which may be same or different when the number of substituents is two or more, may be substituted at the position in which ring A or ring B can be substituted respectively.
- In the present specification, the hydrocarbon includes, e.g., [1] aliphatic hydrocarbon, [2] cyclic hydrocarbon, [3] cyclic hydrocarbon-aliphatic hydrocarbon or [4] cyclic hydrocarbon-cyclic hydrocarbon, etc.
- In the present specification, the aliphatic hydrocarbon includes, e.g., C1-8 aliphatic hydrocarbon etc. The C1-8 aliphatic hydrocarbon may be linear or branched and includes, e.g., (a) C1-8 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, and octyl, etc.), (b) C2-8 alkenyl (e.g., vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, butadienyl, pentadienyl, hexadienyl, heptadienyl, octadienyl, hexatrienyl, heptatrienyl, and octatrienyl, etc.), and (c) C2-8 alkynyl (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, butadiynyl, pentadiynyl, hexadiynyl, heptadiynyl, octadiynyl, hexatriynyl, heptatriynyl, and octatriynyl, etc.), etc.
- In the present specification, the cyclic hydrocarbon means a univalent group in which an arbitrary hydrogen atom is excluded from cyclic hydrocarbon, and includes the same as said homocycle.
- In the present specification, the cyclic hydrocarbon-aliphatic hydrocarbon includes one in which said cyclic hydrocarbon binds to said aliphatic hydrocarbon, e.g., (a) C7-16 aralkyl (e.g., benzyl, phenylethyl, phenylpropyl, and naphthalen-1-yl methyl, etc.), (b) C8-16 aralkenyl (e.g., 3-phenyl-2-propenyl, 2-(2-naphthyl vinyl) and 4-cyelobutyl-1-butenyl, etc.), (c) (C3-8 cycloalkyl)-(C1-4 alkyl) (e.g., cyclopropylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, 1-methyl-1-cyclohexylmethyl, etc.), and (d) (C3-8 cycloalkenyl)-(C1-4 alkyl) (e.g., 3-cyclohexylmethyl etc.), etc.
- In the present specification, the cyclic hydrocarbon-cyclic hydrocarbon includes one in which two said cyclic hydrocarbon combine, e.g., 3-phenylphenyl and 4-phenylphenyl, etc.
- In the present specification, the C1-8 aliphatic hydrocarbon contained in the substituent of ring A or ring B includes said C1-8 alkyl, said C2-8 alkenyl, and said C2-8 alkynyl, etc.
- In the present specification, cyclic hydrocarbon contained in the substituent of ring A or ring B includes a univalent group etc., in which an arbitrary hydrogen atom is excluded from said homocycle.
- In the present specification, heterocycle contained in the substituent of ring A or ring B includes a univalent group etc., in which an arbitrary hydrogen atom is excluded from said heterocycle.
- In the present specification, the substituent(s) in amino that may contain substituents as the substituent of ring A or ring B include(s), e.g., (a) hydrocarbon that may contain substituents, (b) sulfo, and (c) sulfonyl that binds to hydrocarbon that may contain substituents, etc. Herein, the hydrocarbon that may contain substituents means the same as the hydrocarbon that may contain substituents as the substituent of said ring A or said ring B.
- In the present specification, the protecting group in the hydroxyl that may be protected or the mercapto group that may be protected as the substituent of ring A or ring B includes, e.g., a hydrocarbon that may contain substituents. Herein, the hydrocarbon that may contain substituents means the same as the hydrocarbon that may contain substituents as the substituent of said ring A or said ring B.
- In the present specification, the substituent(s) in the carbamoyl that may contain substituents or sulfamoyl that may contain substituents as the substituent of ring A or ring B include(s), e.g., a hydrocarbon that may contain substituents etc. Herein, the hydrocarbon group that may contain substituents means the same as the hydrocarbon group that may contain substituents as the substituent of said ring A or said ring B.
- In the present specification, the halogen atom includes, e.g., fluorine, chlorine, bromide and iodine, etc.
- In the present specification, the sulfo group means -SO3H.
- In the present specification, the sulfino group means -SO2H.
- In the present specification, the phosphono group means -PO(OH)2.
- In the present specification, the dihydroxyboryl group means -B(OH)2.
- In the present specification, the acidic group represented by X includes, e.g., [1] hydroxyl, [2] alkoxy, [3] carboxyl, [4] sulfo, [5] sulfino, [6] sulfonamide(SO2NH2 or -NR101SO3H (R101 represents a hydrogen atom or said hydrocarbon.).), [7] phosphono, [8] phenol and [9] various protonic acids that are nitrogen-containing ring residues that contain hydrogen atom(s) that may be deprotonated, etc.
- In the present specification, the alkoxy includes, e.g., C1-8 alkoxy etc. The C1-8 alkoxy may be linear or a branched, and includes, e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, tert-butoxy, pentyloxy, hexyloxy, heptyloxy and octyloxy, etc.
-
- In the present specification, the phenolic group means -C6H4OH.
-
- In the present specification, the bond represented by Y means a direct bond without other atoms.
- In the present specification, the spacer represented by Y in which the number of atom in the principal chain is one to three means the space in which one to three atom(s) in the principal chain is/are aligned. Herein, the number of atom in the principal chain shall be counted to minimize the number of the atom in the principal chain. For example, the number of 1, 2-cyclopentene is two and the number of 1, 3-cyclopentene is three. The spacer in which the number of the principal chain is one to three includes, e.g., [1] -O-, [2] -S-, [3] -CO-, [4] -SO-, [5] -SO2-, [6] a nitrogen atom that may contain substituents and [7] a bivalent group in which one to three atom(s) in the principal chain is/are aligned comprising one to three group(s) arbitrarily selected from a group consisting of bivalent C1-3 aliphatic hydrocarbon that may contain substituents. Herein, besides -NH-, the nitrogen atom that may contain substituents represents one in which a hydrogen atom in -NH- is arbitrarily substituted for a hydrocarbon that may contain substituents. Herein, the hydrocarbon in the hydrocarbon that may contain substituents means the same as the above. The substituents in the hydrocarbon that may contain substituents includes, e.g., [a] hydroxyl, [b] oxo, [c] thioxo, [d] halogen atom, [e] cyano, [f] nitro, [g] carboxyl, [h] C1-4 alkoxy(e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy tert-butoxy, etc.), [i] amino and [j] the first or second amino substituted by said aliphatic hydrocarbon etc., and these arbitrary substituents may be substituted at one to eight replaceable position(s), preferably at one to five position(s). The bivalent C1-3 aliphatic hydrocarbon in the bivalent C1-3 aliphatic hydrocarbon that may contain substituents includes, e.g., [a] C1-3 alkylene (e.g., -CH2-, -(CH2)2-, -(CH2)3-, etc.), [b] C2-3 alkenylene(e.g., -CH=CH-, -CH2-CH=CH- and -CH=CH-CH2-, etc.) and [c] C2-3 alkinylene(e.g., -C≡ C-, -CH2-C≡ C- and -C≡ C-CH2-, etc.), etc. The substituents in the bivalent C1-3 aliphatic hydrocarbon that may contain substituents includes, e.g., [a] C1-8 alkyl, [b] C1-8 alkoxy, [c] halogen atom, [d] hydroxyl, [e] oxo, [f] thioxo, [g] amino, [h] =N-ORn (wherein, Rn means the same as the substituents in the nitrogen atom that may contain substituents.), etc., and these arbitrary substituents may be substituted at one to five replaceable position(s), preferably at one to two position(s).
- Y is preferable to be a bivalent C1-3 aliphatic hydrocarbon, more preferable to be methylene.
- In the present specification, the substituents in the amino that may contain substituents, which is represented by E, includes, e.g., [1] hydrocarbon that may contain substituents, [2] sulfo and [3] sulfonyl that binds to hydrocarbon that may contain substituents, etc. Herein, the hydrocarbon in the hydrocarbon that may contain substituents means the same as the above. The substituents in the hydrocarbon that may contain substituents includes, e.g., [a] the hydrocarbon that may contain substituents (e.g., (1) C1-4 alkyl(e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl and tert-butyl, etc.), (2) amino, (3) sulfo, (4) halogen atom, (5) carboxyl, (6) cyano, (7) nitro, (8) oxo, (9) thioxo, (10) hydroxyl, (11) methoxy, (12) trifluoromethyl, and (13) trifluoromethoxy, etc.), [b] the heterocycle that may contain substituents (e.g., (1) the hydrocarbon, (2) amino, (3) sulfo, (4) halogen atom, (5) carboxyl, (6) cyano, (7) nitro, (8) oxo, (9) thioxo, (10) hydroxyl, (11) methoxy, (12) trifluoromethyl, (13) trifluoromethoxy, and (14) acetyl, etc.), [c] -NR3R4, [d] C1-4 alkylsulfonyl(e.g., methylsulfonyl and ethylsulfonyl, etc.), [d] C1-4 alkylsulfonyl(e.g., methylsulfonyl and ethylsulfonyl, etc.), [e] phenylsulfonyl, [f] halogen atom, [g] carboxyl, [h] cyano, [i] nitro, [j] oxo, [k] thioxo, and [1] -OR5, [m] mercapto, [n] C1-4 alkylthio(e.g., methylthio, ethylthio, propylthio, isopropylthio, butylthio and tert-butylthio, etc.), [o] phenylthio, [p] carbamoyl, [q] aminocarbonyl substituted by the hydrocarban(e.g., N-butylaminocarbonyl, N-cyclohexylmethylaminocarbonyl, N-butyl-N-cyclohexylmethylaminocarbonyl, N-cyclohexylaminocarbonyl and phenylaminocarbonyl, etc.), [r] sulfamoyl, [s] aminosulfonyl substituted by the hydrocarbon(e.g., methylamino sulfonyl etc.), [t] aminosulfonyl substituted by the hydrocarbon substituted by amino(e.g., dimethylaminoethylaminosulfonyl and dimethylaminopropyl aminosulfonyl, etc.), [u] C1-6 alkoxycarbonyl(e.g., methoxycarbonyl, ethoxycarbonyl and tert-butoxycarbonyl, etc.), [v] sulfo, [w] sulfino, [x] phosphono, [y] amidino, and [z] imino, [aa] dihydroxyboryl, [bb] C1-4 alkylsulfinyl (e.g., methylsulfinyl and ethylsulfinyl, etc.), [cc] C1-6 acyl(e.g., formyl, acetyl, propionyl and butyryl, etc.), [dd] benzoyl, [ee] hydroxyimino, and [ff] alkyloxyimino (e.g., methyloxyimino and ethyloxyimino, etc.), etc. These arbitrary substituents, which may be same or different respectively when the number of substituents is two or more, may be substituted at one to five replaceable position(s), and each substituent.
- In the present specification, R3 and R4 each independently represent [1] hydrogen atom, [2] hydrocarbon that may contain substituent(s), [3] sulfo, [4] sulfonyl that binds to hydrocarbon that may contain substituent(s). Herein, the hydrocarbon in the hydrocarbon that may contain substituent(s) means the same as the above. The substituent(s) in the hydrocarbon that may contain substituent(s) includes, e.g., [a] said hydrocarbon that may contain substituent(s) (e.g., (1) C1-4 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl and tert-butyl, etc.), (2) amino, (3) sulfo, (4) halogen atom, (5) carboxyl, (6) cyano, (7) nitro, (8) oxo, (9) thioxo, (10) hydroxyl, (11) methoxy, (12) trifluoromethyl, and (13) trifluoromethoxy, etc.), [b] said heterocyclic that may contain substituent(s) (e.g., (1) said hydrocarbon, (2) amino, (3) sulfo, (4) halogen atom, (5) carboxyl, (6) cyano, (7) nitro, (8) oxo, (9) thioxo, (10) hydroxyl, (11) methoxy, (12) trifluoromethyl, (13) trifluoromethoxy, (14) acetyl, and (15) methoxycarbonyl, etc.), [c] amino, [d] C1-6 acylamino(e.g., acetylamino and propionylamino, etc.), [e] the first or second amino substituted by said hydrocarbon that may be substituted by halogen atom, oxo, amino, and carbamoyl, etc. (e.g., methylamino, ethylamimo, propylamino, isopropylamino, butylamino, heptylamino, octylamino, dimethylamino, diethylamino, cyclohexylamino, 1-carbamoylcyclohexyl-2-ethylamino, N-butyl-N-cyclohexylmethylamino, phenylamino, 6, 6-dimethylbicyclo[3.1.1]heptylmethylamino, etc.), [f] C1-4 alkylsulfonylamino(e.g., methylsulfonylamino and ethylsulfonylamino, etc.), [g] phenylsulfonylamino, [h] C1-4 alkylsulfonyl(e.g., methylsulfonyl and ethylsulfonyl, etc.), [I] phenylsulfonyl, [j] halogen atom, [k] carboxyl, [l] cyano, [m] nitro, [n] oxo, [o] thioxo, and [p] hydroxyl, [q] C1-10 alkoxy(e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, decyloxy, cyclohexylmethyloxy, benzyloxy and trifluoromethoxy, etc.) that may be substituted by halogen atom(s), [r] C3-8 cycloalkoxy(e.g., cyclohexyloxy etc.), [s] phenoxy that may be substituted by substituent(s) (e.g., (1) C1-4 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, and tert-butyl, etc.), (2) halogen atom, (3) trifluoromethyl, and (4) trifluoromethoxy, etc.), [t] 5, 6, 7, 8-tetrahydro-1-naphthyloxy, [u] mercapto, [v] C1-4 alkylthio(e.g., methylthio, ethylthio, propylthio, isopropylthio, butylthio, and tert-butylthio, etc.), [w] phenylthio, [x] carbamoyl, [y] aminocarbonyl substituted by said hydrocarbon(e.g., N-butylaminocarbonyl, N-cyclolxexylmethyl aminocarbonyl, N-butyl-N-cyclohexylmethylaminocarbonyl, N-cyclohexylaminocarbonyl, and phenylaminocarbonyl, etc.), [z] sulfamoyl, [aa] aminosulfonyl substituted by said hydrocarbon(e.g., methylaminasulfonyl etc.), [bb] aminosulfonyl substituted by said hydrocarbon substituted by amino(e.g., dimethylaminoethylaminosulfonyl and dimethylaminopropylaminosulfonyl, etc.), [cc] alkoxycarbonyl(e.g., methoxycarbonyl, ethoxycarbonyl, and tert-butoxycarbonyl, etc.), [dd] sulfo, [ee] sulfino, [ff] phosphono, [gg] amidino, [hh] imino, [ii] dihydroxyboryl, [jj] C1-4 alkylsulfinyl (e.g., methylsulfinyl and ethylsulfinyl, etc.), [kk] C1-6 acyl(e.g., formyl, acetyl, propionyl, and butyryl, etc.), [ll] benzoyl, [mm] hydroxyimino, and [nn] C1-4 alkyloxyimino(e.g., methyloxyimino and ethyloxyimino, etc.), etc. The one to five arbitrary substituent(s), which may be same or different respectively when the number of substituents is two or more, may be substituted at replaceable position(s).
- In the present specification, R5 represents a hydrogen atom or a hydrocarbon that may contain substituents, which means the same as the hydrocarbon that may contain substituents represented by R3.
- Preferable compounds in compounds represented by formula (I) include, e.g., compounds represented by formula (I-1) etc.
- In the present specification, the substituent(s) in the benzene ring that may further contain substituents, which is represented by ring A1 or B1, include(s), e.g., said group etc., as substituent(s) of ring A or ring B. The one to five or one to three arbitrary substituent(s), which may be same or different respectively when the number of substituents is two or more, may be substituted at each replaceable position(s) of each benzene ring.
- In the present specification, the hydrocarbon in the hydrocarbon that may contain substituents, which is represented by R1 or R2, means the same as the above. The substituent(s) in the hydrocarbon that may contain substituents includes, e.g., [a] said hydrocarbon that may contain substituent(s) (e.g., (1) C1-4 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl and tert-butyl, etc.), (2) amino, (3) sulfo, (4) halogen atom, (5) carboxyl, (6) cyano, (7) nitro, (8) oxo, (9) thioxo, (10) hydroxyl, (11) methoxy, (12) trifluoromethyl, and (13) trifluoromethoxy, etc.), [b] said heterocycle that may contain substituents(e.g., (1) said hydrocarbon, (2) amino, (3) sulfo, (4) halogen atom, (5) carboxyl, (6) cyano, (7) nitro, (8) oxo, (9) thioxo, (10) hydroxyl, (11) methoxy, (12) trifluoromethyl, (13) trifluoromethoxy, and (14) acetyl, etc.), [c] -NR6R7, [d] halogen atom, [e] cyano, [f] oxo, [g] thioxo and [h] -OR8, etc. The one to five arbitrary substituent(s), which may be same or different respectively when the number of substituents is two or more, may be substituted at replaceable position(s) of the hydrocarbon.
- In the present specification, R6, R7 and R8 each independently represent a hydrogen atom or a hydrocarbon that may contain substituents. The hydrocarbon in the hydrocarbon that may contain substituents means the same as the above, and the substituent(s) in the hydrocarbon that may contain substituents include(s), e.g., [a] said hydrocarbon that may contain substituent(s) (e.g., (1) C1-4 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl and tert-butyl, etc.), (2) amino, (3) sulfo, (4) halogen atom, (5) carboxyl, (6) cyano, (7) nitro, (8) oxo, (9) thioxo, (10) hydroxyl, (11) methoxy, (12) trifluoromethyl, and (13) trifluoromethoxy, etc.), [b] said heterocycle that may contain substituents (e.g., (1) said hydrocarbon, (2) amino, (3) sulfo, (4) halogen atom, (5) carboxyl, (6) cyano, (7) nitro, (8) oxo, (9) thioxo, (10) hydroxyl, (11) methoxy, (12) trifluoromethyl, (13) trifluoromethoxy, and (14) acetyl, (15) methoxycarbonyl, etc.), [c] halogen atom, [d] carboxyl, [e] cyano, [f] nitro, [g] oxo, [h] hydroxyl, [i] C1-10 alkoxy that may be substituted by halogen atoms (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, decyloxy, cyclohexylmethyloxy, benzyloxy and trifluoromethoxy, etc.), [j] C1-4 alkylthio (e.g., methylthio, ethylthio, propylthio, isopropylthio, butylthio and tert-butylthio, etc.), and [k] C1-6 alkoxycarbonyl(e.g., methoxycarbonyl, ethoxycarbonyl and tert-butoxycarbonyl, etc), etc.
- Preferable compounds in compounds represented by formula (I-1) include, e.g., the compound described in examples.
- Further, preferable compounds in compounds represented by formula (I) include, e.g., compounds represented by the following (1) to (46), salts thereof, solvates thereof, and prodrugs thereof, etc.
- (1) O-(tert-butyl)-N-[(pentyl{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}amino)carbonyl]serine,
- (2) N-[(pentyl {[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}amino)carbonyl]serine,
- (3) N-butyl-N'-[2-(4-methoxyphenyl)ethyl]-N-{[2'-(1H-tetrazol-5-y1)biphenyl-4-yl]methyl}urea,
- (4) diethyl {[(butyl{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}amino)carbonyl]amino}(2-cyanoethyl)malonate,
- (5) N-butyl-N'-(2-phenylethyl)-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (6) N-butyl-N'-(2,2-diphenylethyl)-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (7) N-butyl-N'-isopropyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (8) methyl 2-{[(butyl{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}amino)carbonyl]oxy}-3-phenylpropanoate,
- (9) N-butyl-N'-[2-(4-hydroxyphenyl)ethyl]-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (10) methyl N-[(butyl{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}amino)carbonothioyl]glycinate,
- (11) N, N'-dibutyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (12) N-butyl-N'-cyclohexyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (13) N-butyl-N'-phenyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (14) decyl N-[(butyl{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}amino)carbonyl]tyrosinate,
- (15) N'-biphenyl-2-yl-N-butyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (16) N-butyl-N'-(3 -methoxyphenyl)-N- {[2'-(1H-tetrazol-5 -yl)biphenyl-4-yl]methyl}urea,
- (17) N-butyl-N'-(4-methoxyphenyl)-N- {[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (18) ethyl 2-{[(butyl{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}amino)carbonyl]amino}benzoate,
- (19) ethyl 3-{[(butyl{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}amino)carbonyl]amino}benzoate,
- (20) N-buyl-N'-(4-methylphenyl)-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (21) N-butyl-N'-[(1S)-1-phenylethyl]-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (22) N'-benzyl-N-butyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (23) N-butyl-N'-(3-ethylphenyl)-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (24) ethyl N-benzyl-N-[(butyl{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}amino)carbonyl]glycinate,
- (25) N-butyl-N'-(4-ethylphenyl)-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (26) N'-(2-bromophenyl)-N-butyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (27) N'-biphenyl-4-yl-N-buty-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (28) N-butyl-N'-(2-ethoxyphenyl)-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (29) N-butyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-N'-[4-(trifluoromethoxy)phenyl]urea,
- (30) N-butyl-N'-(3,4-difluorophenyl)-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (31) N-butyl-N'-(2,6-diisopropylphenyl)-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (32) ethyl N-[(butyl{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}amino)carbonyl]-O-ethyl-α-methyltyrosinate,
- (33) N-butyl-N'-(2-nitrophenyl)-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (34) ethyl[(butyl{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}amino)carbonyl]carbamate,
- (35) methyl 3-{[(butyl{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}amino)carbonyl]amino}thiophen-2-carboxylate,
- (36) N-butyl-N'-[(1R)-1-phenylethyl]-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (37) N-butyl-N'-(4-methyl-2-nitrophenyl)-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (38) N-butyl-N'-[1-(3-isopropenylphenyl)-1-methylethyl]-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (39) N-butyl-N'-(2-hydroxyphenyl)-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (40) 2-{[(butyl{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}amino)carbonyl]amino}-4,5, 6, 7-tetrahydro-1-benzothiophen-3-carboxylic acid,
- (41) ethyl 2-{[(butyl{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}amino)carbonyl]amino}-4-nitrobenzoate,
- (42) methyl N-[(butyl{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}amino)carbonyl]-N-(cyclohexylmethyl)glycinate,
- (43) N-butyl-N'-(tetrahydrofuran-2-ylmethyl)-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea,
- (44) N-butyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-3, 4-dihydroquinolin-1(2H)-carboamide,
- (45) N-butyl-N'-(2-morpholin-4-ylethyl)-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea, or
- (46) N-butyl-N'-[2-(methylthio)phenyl]-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}urea.
- In the above compounds, the compound (5), (7), (9), (10), (11), (12), (13), (16), (17), (19), (20), (21), (22), (30), (34), (39), (40), (43), and (45) have BLT2 agonistic activity and other compounds have BLT2 antagonistic activity.
- Unless otherwise specifically mentioned, the present invention includes all isomers. For example, alkyl, alkenyl, alkynyl, alkyloxy, alkoxy, alkenyloxy, alkynyloxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylene, alkenylene, alkynylene, acyl and acyloxy include linear and branched ones. Further, the present invention includes all isomers due to double bond, ring and fused ring (E-, Z-, cis- and trans-substances), isomers due to presence of asymmetric carbon etc. (R-, S-, α- and β-substances, enantiomer, and diastereomer), optically active substances having optical rotation (D-, L-, d-, and 1-substances), polar substances by chromatographic separation (high-polar substance and low- polar substance), equilibrium compounds, rotational isomers, a mixture thereof in any proportion and a racemic mixture. Further, the present invention also includes all isomers including tautomers.
- Salts of the compound represented by formula (I) include all salts allowed in pharmacology. The salts allowed in pharmacology are preferable to be little toxic and water-soluble. The suitable salts include, e.g., alkali metal salts (e.g., potassium, sodium and lithium, etc.), alkaline earth metal salts (e.g., calcium and magnesium, etc.), ammonium salts (e.g., tetramethylammonium and tetrabutylammmonium, etc.), organic amine salts (e.g., triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris(hydroxymethyl)methylamine, lysine, arginine and N-methyl-D-glucamine, etc.), acid-addition salts (e.g., inorganic acid salts (e.g., hydrochloride, hydrobromate, hydroiodate, sulfate, phosphate and nitrate, etc.), organic acid salts (e.g., acetate, trifluoroacetate, lactate, tartrate, oxalate, fumarate, maleate, benzoate, citrate, methane sulfonate, ethane sulfonate, benzene sulfonate, toluene sulfonate, isethionate, glucuronate and gluconate, etc.), etc.
- Further, the salts include quaternary ammonium salt. The quaternary ammonium salt represents one in which nitrogen atoms of the compound represented by formula (I) were quaternarized by R° R° represents Cl-8 alkyl substituted with Cl-8 alkyl or phenyl. The solvates of the compound represented by formula (I) include, e.g., solvates such as water and alcohols solvents (e.g., methanol and ethanol, etc.). The solvates are preferable to be little toxic and water-soluble. Further, the solvates of the compounds of the present invention include solvates of alkaline (earth) metal salts, ammonium salt, organic amine salts or acid-addition salts of the above compounds of the present invention. The present invention compounds may be converted into the above salts and solvates by known methods.
- The prodrug of the compound represented by formula (I) means a compound that is converted into the compound represented by formula (I) by enzymes or gastric acid, etc., in vivo. The prodrug of the compound represented by formula (I) includes compounds in which the amino was, e.g., acylated, alkylated or phosphorylated(e.g., the compounds in which the amino of the compound represented by formula (I) was eicosanoylated, alanylated, pentylaminocarbonylated, (5-methyl-2-oxo-1, 3-dioxolen-4-yl)methoxycarbonylated, tetrahydrofuranylated, pyrrolidyimethylated, pivaloyloxymethylated and acetoxymethylated tert-butylated, etc.) when the compound represented by formula (I) has amino(s); the compounds in which the hydroxyl was, e.g., acylated, alkylated, phosphorylated or borated (e.g., the compounds in which the hydroxyl of the compound represented by formula (I) was acetylated, palmitoylated, propanoylated, pivaloylated, succinylated, fumarylated, alanylated or dimethylaminomethylcarbonylated) when the compound represented by formula (I) has a hydroxyl; the carboxyl of the compound represented by formula (I) was, e.g., esterified or amidated (e.g., compounds in which the carboxyl of the compound represented by formula (I) was ethylesterified, phenylesterified, phenylethylesterified, carboxymethylesterified, dimethylaminomethylesterified, pivaloyloxymethylesterified, ethoxycarbonyloxyethylesterified, phthalidylesterified, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methylesterified, cyclohexyloxycarbonylethylesterified, methyl amidated, alkylsulfonylamidated (e.g., -CONHSO2CH3 etc.) or arylsulfonylamidated (e.g., -CONHSO2Ph etc.)) when the compound represented by formula (I) has carboxy(s). These compounds may be produced by known method. The prodrug of the compound represented by formula (I) may be either a hydrate or a non-hydrate.
- Further, the prodrug of the compound represented by formula (I) may change into the compound represented by formula (I) in physiological condition described in "The development of drug", Vol.7, "molecular design", p.163-198 (1990), Hirokawa shoten. Further, the compound represented by formula (I) may be labeled by an isotope (e.g., 3H, 14C, 35S and 125I, etc.) etc.
- The compound of the present invention represented by formula (I), salt thereof, solvate thereof or prodrug thereof (hereafter, it may be abbreviated to the compound of the present invention.) is a compound that excels in solubility, absorptivity and metabolic stability and has long-acting pharmacological activity (BLT2 binding activity), and further is weak in inhibition of drug metabolizing enzyme and circulatory toxicity. These properties are most important physical, pharmacological and chemical properties that are demanded when developing as a medicine and the compound of the present invention has the possibility to become a very excellent medicine that meets these requirements (The Merck Manual of Diagnosis and Therapy (17th Ed.), Merck & Co.).
- The compound of the present invention can be evaluated to be useful as a medicine by various experimental systems, methods described in biological examples and appropriate improved methods thereof as follows. Further, the compound of the present invention can be evaluated to be excellent in dynamics, e.g., half-life in blood, stability in gut, oral absorptivity and bioavailability by known methods, e.g., methods described in "drug bioavailability (science of evaluation and improvement)", July 6, 1998, gendai-iryousya. The compound of the present invention is named by ACD/NAMETM, which is a computer program to mechanically generate IUPAC name, of Advanced Chemistry Development company. For example, the following compound was named sodium 3'-{[4-methoxybenzoyl(4-phenylbutyl)amino]methyl}-1, 1'-biphenyl-3-carboxylate.
- The compound of the present invention is known as itself and can be produced by known methods, e.g.,
EP0632008 ,WO99/58513 WO00/48982 WO03/051852 WO03/097851 - As a example of concrete production methods, the production method of the compound represented by formula (I-1) is described as follows.
- The compound represented by formula (I-1) can be produced by subjecting the compound represented by formula (II)
R1P-NH-R2P (III)
(wherein, R1P and R1P represent the same meaning as R1 and R2 respectively. However, carboxyl, hydroxyl, amino and thiol group contained in a group represented by R1P and R2P are protected if necessary and other symbols have the same meanings as defined above.) to the reductive amidation reaction, followed by subjecting to deprotection, if necessary. - The reductive amination reaction is well-known and carried out at 0-40□, e.g., in an organic solvent (e.g., dichloroethane, dichloromethane, dimethylformamide, acetate or the mixture, etc.) in the existence of a reducing agent (e.g., sodium triacetoxyborohydride, sodium cyanoborohydride, sodium borohydride or tetrabutylammonium borohydride, etc.).
- As be easily predictable for a person skilled in the art, the aimed compound of the present invention may be prepared by continuously subjecting to the deprotection reaction after appropriately protecting the groups in advance and subjecting to reaction.
- The protective group of the amino includes, e.g., benzyloxycarbonyl, tert-butoxycarbonyl, allyloxycarbonyl (Alloc), 1-methyl-1-(4-biphenyl)ethoxycarbonyl (Bpoc), trifluoroacetyl, 9-fluorenylmethoxycarbonyl, benzyl (Bn), p-methoxybenzyl, benzyloxymethyl (BOM) and 2-(trimethylsilyl)ethoxymethyl (SEM), etc.
- The protective group for the hydroxyl includes, e.g., methyl, trityl, methoxymethyl(MOM), 1-ethoxyethyl(EE), methoxyethoxymethyl(MEM), 2-tetrahydropyranyl(THP), trimethylsilyl(TMS), triethylsilyl(TES), tert-butyldimethylsilyl(TBDMS), tert-butyldiphenylsil(TBDPS), acetyl(Ac), pivaloyl, benzoyl, benzyl(Bn), p-methoxybenzyl, allyloxycarbonyl(Alloc) and 2, 2, 2-trichloroethocycarbonyl(Troc).
- The protective group of the mercapto includes, e.g., benzyl, methoxybenzyl, methoxymethyl(MOM), 2-tetrahydropyranyl(THP), diphenylmethyl and acetyl(Ac), etc.
- The protective group of the carboxyl group includes, e.g., methyl, ethyl, tert-butyl, aryl, phenacyl and benzyl, etc.
- The protective group of the carboxyl, hydroxyl, amino or thiol is not limited to the above protective group so far as it is a group which can be easily and selectively detached. For example, a deprotection reaction may be carried out by a method described in "T. W. Greene, Protective Groups in Organic Synthesis, Wiley, New York, 1999".
- The deprotection reaction for the protective group of the carboxyl, hydroxyl, amino, or mercapto is known and includes, e.g.,
- (1) alkaline hydrolysis;
- (2) a deprotection reaction under acidic conditions;
- (3) a deprotection reaction by hydrogenolysis;
- (4) a deprotection reaction using metal complex;
- (5) a deprotection reaction using metal; and
- (6) a deprotection reaction of silyl group
- These methods are specifically illustrated;
- (1) The deprotection reaction by alkaline hydrolysis is carried out, e.g., using hydroxide of alkaline metal (e.g., sodium hydroxide, potassium hydroxide or lithium hydroxide, etc.), hydroxide of alkaline earth metal (e.g., barium hydroxide or calcium hydroxide, etc.), carbonate (e.g., sodium carbonate or potassium carbonate, etc.), the aqueous solution or the mixture in an organic solvent (e.g., methanol, tetrahydrofuran or dioxane, etc.) at 0 to 40°C.
- (2) The deprotection reaction under acidic condition (e.g., deprotection reaction of tert-butoxycarbonyl or trityl, etc.) is carried out, e.g., in water or an organic solvent (e.g., dichloromethane, chloroform, 1, 4-dioxane, ethyl acetate or anisole, etc.), inorganic acid (e.g., hydrochloric acid or sulfuric acid, etc.), or the mixture(e.g., hydrogen bromide/acetic acid) at 0 to 100°C.
- (3) The deprotection reaction by hydrogenolysis (e.g., deprotection reaction of benzyl, benzhydryl, benzyloxycarbonyl or allyloxycarbonyl group, etc.) is carried out, e.g., in a solvent (e.g., ethers (e.g., tetrahydrofuran, dioxane, dimethoxyethane or diethyl ether, etc.), alcohol (e.g., methanol or ethanol etc.), benzene (e.g., benzene or toluene etc.), ketone (e.g., acetone or methylethylketone, etc.), nitrile (e.g., acetonitrile etc.), amide (e.g., dimethylformamide etc.), water, ethyl acetate or acetic acid, or the mixed solvent composed of two or more kinds.), in hydrogen atmosphere of ordinary pressure or high pressure or in the presence of ammonium formate, in the presence of a catalyst (e.g., palladium-carbon, palladium black, palladium hydroxide, platinum hydroxide, platinum oxide or raney nickel, etc.), at 0 to 200°C.
- (4) The deprotection reaction using a metal complex (e.g., a deprotection reaction of allyloxycarbonyl group etc.) is carried out, e.g., using a metal complex (e.g, tetrakistriphenylphosphine palladium (0), bis(triphenylphosphine)palladium (II) dichloride, palladium (II) acetate or tris(triphenylphosphine) rhodium (I) chloride), in the presence or absence of a phosphine agent (e.g., triphenyl phosphine etc.), in the presence of a trap reagent (e.g., tributyltin hydride, triethylsilane, dimedone, morpholine, diethylamine or pyrrolidine, etc.), an organic acid (e.g., acetic acid, formic acid or 2-ethylhexanoic acid, etc.) and/or an organic acid salt (e.g., sodium 2-ethylhexanoate or potassium 2-ethylhexanoate, etc.), in an organic solvent (e.g., dichloromethane, dimethylformamide, tetrahydrofuran, ethyl acetate, acetonitrile, dioxane or ethanol, etc.), water or the mixed solvent at 0 to 40°C.
- (5) The deprotection reaction using metal is carried out, e.g., in an acidic solvent (e.g., acetic acid, a buffer of pH 4.2 to 7.2 or a mixed solution of a solution thereof with an organic solvent such as tetrahydrofuran etc.), with ultrasonic wave if necessary, in the presence of powdery zinc, at 0 to 40°C.
- (6) The deprotection reaction of silyl is carried out, e.g., using tetrabutylammonium fluoride, in an organic solvent miscible with water (e.g., tetrahydrofuran or acetonitrile, etc.) at 0 to 40°C.
- As a person skilled in the art can easily understand it, the aimed compound of the present invention can be easily produced by using these deprotection reactions properly.
- Among the compounds represented by formula (I-1), a compound that R1 is represented by
HOOC-R101P (V)
(wherein, R101P has the same meaning as R101, other symbols have the same meanings as defined above. However, carboxyl, hydroxyl, amino and thiol contained in a group represented by R101P are optionally protected.) to the amidation reaction and optionally subjecting to the deprotection reaction. - The amidation reaction has been known and includes, e.g.,
- (1) a process using an acid halide,
- (2) a process using a mixed acid anhydride and
- (3) a process using a condensing agent.
- These methods are specifically illustrated;
- (1) The process using an acid halide is carried out, e.g., by reacting carboxylic acid with an acid halide (e.g., oxalyl chloride or thionyl chloride, etc.) in an organic solvent (e.g., chloroform, dichloromethane, diethyl ether, tetrahydrofuran, dimethoxyethane or toluene, etc.) or without solvent at -20 °C to refluxing temperature and reacting the resulting acid halide with an amine in the presence of a base (e.g., pyridine, triethylamine, dimethylaniline, dimethylaminopyridine or diisopropylethylamine, etc.) in an organic solvent (e.g., chloroform, dichloromethane, diethyl ether or tetrahydrofuran, etc.) at 0 to 40°C. The reaction can be also carried by reacting the resulting acid halide with an amine in an organic solvent (e.g., dioxane or tetrahydrofuran, etc.) using an alkali solution (e.g., sodium bicarbonate solution or sodium hydroxide solution, etc.) at 0 to 40°C.
- (2) The process using a mixed acid anhydride is carried out, e.g., by reacting carboxylic acid with an acid halide (e.g., pivaloyl chloride, tosyl chloride or mesyl chloride, etc.) or an acid derivative (e.g., ethyl chloroformate or isobutyl chloroformate, etc.) in the presence of an organic solvent (e.g., chloroform, dichloromethane, diethyl ether or tetrahydrofuran, etc.) or without a solvent in the presence of a base (e.g., pyridine, triethylamine, dimethylaniline, dimethylaminopyridine or diisopropylethylamine, etc.) at 0 to 40°C and reacting the resulting mixed acid anhydride with an amine in an organic solvent (e.g., chloroform, dichloromethane, diethyl ether or tetrahydrofuran, etc.) at 0 to 40°C.
- (3) The process using a condensing agent is carried out, e.g., by reacting carboxylic acid with an amine using a condensing agent (e.g., 1, 3-dicyclohexylcarbodiimide(DCC), I-ethyl-3-[3-(dimethylamino)propyl] carbodiimide(EDC), 1, 1'-carbonyldiimidazole (CDI), 2-chioro-1-methylpyridinium iodide and 1-propylphosphonic acid cyclic anhydride; PPA, etc.), with or without 1-hydroxybenztriazole(HOBt), in the presence or absence of a base (e.g., pyridine, triethylamine, dimethylanilin or dimethylaminopyridine, etc.), in an organic solvent (e.g., chloroform, dichloromethane, dimethylformamide, diethyl ether or tetrahydrofuran, etc.) or without a solvent at 0 to 40°C.
- The deprotection reaction of the protecting group can be carried by the same method above.
- It is preferable that all of (1), (2) and (3) reactions are carried out in the water free condition under the inert gas atmosphere (e.g., argon or nitrogen, etc.).
- The compounds represented by formula (II), (III), (IV) or (V) used as starting materials have been known as itself or can be easily produced by known methods, e.g., the method described in "Comprehensive Organic Transformations: A Guide to Functional Group Preparations 2nd Edition(Richard C. Larock, John Wiley & Sons Inc, 1999)", the appropriate improved methods and the combined methods.
- For example, the compound represented by formula (II) can be produced by subjecting a compound represented by formula (VII)
- This reaction is known and carried out at room temperature to 120°C, e.g., in a base (e.g., sodium ethylate, sodium hydroxide, potassium hydroxide, triethylamine, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, cesium carbonate, thallium carbonate, potassium phosphate tribasic, cesium fluoride, barium hydroxide or tetrabutylammonium fluoride, etc.), the solution or the mixture and catalyst (e.g., tetrakis(triphenylphosphine)palladium(Pd(PPh3)4), bis dichloride(triphenylphosphine)palladium(PdCl2(PPh3)2), palladium acetate(Pd(OAc)2), palladium black, 1, 1'-bis(diphenylphosphinoferrocene)dioljloropalladium(PdCl2(dppf)2) diallyl palladium dichloride(PdCl2(allyl)2), or bis(triphenylphosphine)palladium iodide(PhPdI(PPh3)2), etc.) in an organic solvent (e.g., benzene, toluene, dimethylformamide, dioxane, tetrahydrofuran, methanol, acetonitrile, dimethoxyethane or acetone, etc.).
- As be known by the persons skilled in the art, a reaction with heating in each reaction in the present specification may be carried out by using bathe, oil bath, sand bath or microwave.
- In each reaction in the present specification, solid-supported reagents supported on high molecule polymer (e.g., polystyrene, polyacrylamide, polypropylene or polyethylene glycol etc.) may be properly used.
- In each reaction described in the present specification, the reaction product can be purified by conventional purification techniques, e.g., distillation under atmospheric or reduced pressure, high performance liquid chromatography, thin-layer chromatography or column chromatography using silica gel or magnesium silicate, washing or recrystallization etc.. The purification can be carried out for each reaction or after some reactions.
- The toxicities of the compounds of the present invention are very low so that they are sufficiently safe for using as pharmaceuticals.
- The compounds of present invention have BLT2 binding activities. On the other hand, since BLT2 most strongly is expressed to spleen and lymphocyte and is ubiquitous in a lot of organs including liver and ovary and further is highly expressed in keratinocyte and small intestine, in mammal (e.g., human, non-human animal, e.g., monkey, sheep, bovine, horse, dog, cat, rabbit, rat, and mouse, etc.), the compounds are useful for prevention and/or treatment of BLT2 mediated diseases, e.g., dermatosis [e.g., eczema, cheloma, lupus accompanied by skin injury, acne(e.g., acne vulgaris etc.), dermatitis(e.g., seborrheic dermatitis, solar dermatitis, contact dermatitis and atopic dermatitis, etc.), psoriasis(e.g., psoriasis vulgaris, guttate psoriasis, pustular psoriasis, arthropathic psoriasis, psoriatic erythroderma, etc.), keratosis(e.g., seborrheic keratosis, senile keratosis, actinic keratosis, photic keratosis and follicular keratosis, etc.), wart (e.g., condyloma, pointed condyloma, venereal wart, wart virus, molluscum contagiosum, leukoplakia and wart with human papillomavirus(HPV) infection such as vesicobullous lichen planus, etc.), skin cancer(e.g., rodent cancer, skin T lymphoma and local benign epidermosis(e.g., keratoderma and hard nevus, etc.), etc.), alopecic (e.g., congenital alopecia(e.g., diffuse congenital alopecia and congenital triangular alopecia, etc.), acquired alopecia(folliculitis decalvans, alopecia areata and follicular mucinosis, etc.), etc.), dyspigmentation(e.g., stain, freckle and suntan, etc.), etc.], intestinal disease(e.g., inflammatory intestinal disease (e.g., inflammatory bowel disease and Crohn's disease, etc.), irritable bowel syndrome and colitis, etc.), HIV infection, acquired immunodeficiency syndrome, rejection to transplant, transplant rejection, graft-versus-host disease, autoimmune disease(e.g., systemic erythematodes, rheumathritis, myasthenia gravis and multiple sclerosis, etc.), allergic disease (e.g., atopic dermatitis and bronchial asthma, etc.), inflammation, infection, ulcers, lymphoma, malignant tumor, leucaemia, arterial sclerosis, hepatitis, hepatic cirrhosis or cancer, etc.
- The compound of the present invention may be administered as a combined preparation by combining with other pharmaceutical(s) for the purpose of;
- 1) the supplementing and/or enhancing of the prevention and/or treatment effect of the compound of the present invention,
- 2) the improvement in pharmacokinetics and absorption and the dose reduction of the compound of the present invention and/or
- 3) the side effect reduction of the compound of the present invention.
- As a concomitant use of the compound of the present invention and other pharmaceutical, a blending pharmaceutical in which both components are compounded in a preparation may be administered or separate preparations may be administered. The administration of separate preparations includes a simultaneous administration and administrations with time difference. In the administration with time difference, the compound of the present invention may be firstly administered followed by administering the other pharmaceutical or the other pharmaceutical may be firstly administered followed by administering the compound of the present invention. Each administration method may be same or different.
- The other pharmaceutical may be a low molecular weight compound, protein, polypeptide, polynucleotide (DNA, RNA or gene), antisense, decoy, antibody or vaccine, etc. A dosage of the other pharmaceutical can be properly selected on the basis of the clinical dose. Further, a mix proportion of the other pharmaceutical and the compound of the present invention can be properly selected on the basis of age and weight of a subject, medication method, administration period, disease, symptom or combination, etc. For example, 0.01 to 100 of the other pharmaceutical for a mass of the compound of the present invention may be used. Two or more arbitrary other pharmaceuticals may be combinationally administered at a suitable proportion.
- The other preventive and/or therapeutic pharmaceutical(s), which is/are combined with the compound of the present invention, for dermatosis such as eczema, cheloma, lupus accompanied by skin injury, acne (e.g., acne vulgaris etc.), dermatitis (e.g., seborrheic dermatitis, solar dermatitis, contact dermatitis and atopic dermatitis, etc.), psoriasis (e.g., psoriasis vulgaris, guttate psoriasis, pustular psoriasis, arthropathic psoriasis, and psoriatic erythroderma, etc.), keratosis(e.g., seborrheic keratosis, senile keratosis, actinic keratosis, photic keratosis and follicular keratosis, etc.), wart (e.g., condyloma, pointed condyloma, venereal wart, wart virus, molluscum contagiosum, leukoplakia and wart with human papillomavirus(HPV) infection such as vesicobullous lichen planus, etc.) and skin cancer (e.g., rodent cancer, skin T lymphoma and local benign epidermosis (e.g., keratoderma and hard nevus, etc.), etc.) include(s), e.g., SH-enzyme activator (e.g., L-cysteine etc.), aminoglycoside antibiotic (e.g., gentamicin sulfate etc.), allergic disease agent (olopatadine hydrochloride, cyproheptadine hydrochloride, fexofenadine hydrochloride, bepotastine besilate, tranilast, epinastine hydrochloride, olopatadine hydrochloride, olopatadine hydrochloride, cyproheptadine hydrochloride, fexofenadine hydrochloride, oxatomide, emedastine fumarate, ketotifen fumarate, bepotastine besilate, azelastine hydrochloride, Isothipendyl hydrochloride, epinastine hydrochloride, olopatadine hydrochloride, cyproheptadine hydrochloride, fexofenadine hydrochloride, oxatomide, sodium cromoglycate, suplatast tosilate, tranilast, emedastine fumarate, ketotifen fumarate and bepotastine besilate, etc.), ampicillin-sulbactam mutual prodrug (e.g., sultamicillin tosilate etc.), imidazole fungicide (e.g., ketoconazole etc.), imidazole antiulcer anti-inflammatory drug (e.g., bendazac etc.), calcium preparation (e.g., calcium hydroxide etc.), cephalosporin antibiotics (e.g., cefalexin and cefuroxime axetil, etc.), cephem antibiotics (e.g., cefotiam hexetil hydrochloride, cefadroxil and cefpodoxime proxetil, etc.), tetracycline antibiotics (e.g., doxycycline hydrochloride and minocycline hydrochloride, etc.), acne drug (e.g., pregnanediol etc.), new quinolone antimicrobial drug (e.g., enoxacin, lomefloxacin hydrochloride, ofloxacin, ciprofloxacin, sparfloxacin, tosufloxacin tosilate, nadifloxacin, norfloxacin, fleroxacin, levofloxacin and enoxacin, etc.), pantothenate drug (e.g., pancal granules etc.), vitamin A (e.g., retinol palmitate and vitamin A, etc.), riboflavins (e.g., riboflavin, riboflavin sodium phosphate, and butyric acid riboflavin, etc.), vitamin B2/B6 (e.g., riboflavin pyridoxine hydrochloride etc.), vitamin B6 (e.g., pyridoxine hydrochloride etc.), vitamin C (e.g., ascorbic acid etc.), vitamin E/A (e.g., tocopherol vitamin A oil etc.), vitamin H (e.g., biotin etc.), phenylpropionic acid antiphlogistic sedative drug (e.g., suprofen and lbuprofenpiconol, etc.), phenothiazine antihistaminic (e.g., alimemazine tartrate and mequitazine, etc.), proprionic acid antiphlogistic-sedative-drug (e.g., ketoprofen etc.), penem antibiotics (e.g., faropenem sodium etc.), benzhydryl ether antihistaminic (e.g., clemastine fumarate etc.), macrolide antibiotics (e.g., erythromycin, clarithromycin, josamycin and rokitamycin, etc.), lincomycin antibiotics (e.g., clindamycin etc.), pharmaceutical gas (e.g., carbon dioxide etc.), vesicant (e.g., cantharidis tincture etc.), antipyretic analgesics (e.g., aluminium flufenamate etc.), dermatologic (e.g., sulfur and camphor etc.), keratosis drug (e.g., urea etc.), aromatic tetraene derivative for keratosis (e.g., etretinate etc.), keratin softening and anti-trichophytia medicine (e.g., salicylic acid etc.), active vitamin D3 keratosis and psoriasis vulgaris drug (e.g., tacalcitol etc.), chinese medicine (e.g., syohusan, zyumi-haidokuto, toki-syakuyaku-san, makyo-kansekito, unkeitou, eppika-zyututo, kakkonto, kami-shoyo-san, keisibukuryogan, saiko-seikanto, syohusan, sinbuto, zyumi-haidokuto, daio-botanpito, jizusoippo, tokakuzyokito, tokiinshi, hatimi-ziogan, bohutusyo-san, ryutan-syakanto and syouma-kakkontou, etc.), drug for liver disease and allergy (e.g., glycyron etc.), drug for hepatopathy and antiallergic drug (e.g., stronger neo-minophagen C etc.), drug for parasitic dermatosis (e.g., sulfur etc.), bronchodilator and antitussive drug (e.g., dl-methylephedrine hydrochloride etc.), topical astringent (e.g., calamine etc.), anticoagulant drug (e.g., heparin sodium etc.), blood component preparation (e.g., hydroxyzine pamoate and hydroxyzine hydrochloride, etc.), antihistamine drug (e.g., diphenhydramine, diphenhydramine tannate, diphenylpyraline chlorotheophyllinate, chlorpheniramine maleate, diphenhydramine laurylsulfate, diphenhydramine hydrochloride and triprolidine hydrochloride, etc.), antibradykinin antihistaminic drug (e.g., homochlorcyclizine hydrochloride etc.), antiplasmin agent (e.g., epsilon-aminocaproic acid and tranexamic acid, etc.), antipellagra factor (e.g., nicotine acid and nicotinamide, etc.), anti-inflammatory hematogenous promoter and moisturizing agent (e.g., heparinoid etc.), antifungal and anti-inflammatory hemorrhoidal preparation (e.g., proctosedyl etc.), antitumor antibiotics (e.g., bleomycin hydrochloride and peplomycin sulfate, etc.), antibiotics (e.g., fusidate sodium etc.), antibiotic agent (e.g., chlomy-P etc.), semisynthetic penicillin (e.g., amoxicillin and lenampicillin hydrochloride, etc.), antiseptic disinfectants (e.g., resorcine etc.), acid-stable macrolide antibiotics (e.g., roxithromycin etc.), persistent selective H1-receptor antagonist and antiallergic drug (e.g., lolatadine etc.), persistent selective H1-receptor antagonist (e.g., ebastine and cetirizine hydrochloride, etc.), hemorrhoidal preparation (e.g., E. coli killed bacteria and hydrocortisone etc.), antiinflammatory and analgetic drug (e.g., ufenamate etc.), antiinflammatory drug (e.g., azulene etc.), neural immunoregulating, paregoric, calmative and antiallergic drug (e.g., vaccinia virus inoculable rabbit inflammatory dermal extract etc.), drug for psoriasis vulgaris (e.g., calcipotriol etc.), agent for biological oxidation-reduction balance (e.g., glutathione etc.), dysbolism improving drug (e.g., pantethine, panthenol and calcium pantothenate, etc.), antipruritic, astringent and antiinflammatory drug (e.g., zinc oxide and salicylic acid etc.), antipruritic and antiinflammatory drug (e.g., hydrocortisone crotamiton etc.), antipruritic drug (e.g., crotamiton etc.), drug for keratosis such as secondary hyperparathyreosis and psoriasis vulgaris (e.g., maxacalcitol etc.), skin fester drug (e.g., acrinol and zinc oxide oil etc.), drug for dermatosis and Hansen's disease (e.g:, diaphenylsulfone etc.), external drug for dermatosis (e.g., pine tar, aluminum chlorohydroxyallantoinate, eksalb, dexamethasone and defatted soybean retorted tar, defatted soybean retorted tar and diphenhydramine and combined DM, etc.), emollient (e.g., glycerin and potash solution etc.), nonsteroidal antiinflammatory drug (e.g., bufexamac and glycyrrhetic acid, etc.), adrenocorticosteroid (e.g., amcinonide, eurich, kenacort-AG, hydrocortisone sodium succinate, dexamethasone, triamcinolone, triamcinolone acetonide, halcinonide, hydrocortisone, flumetasone pivalate, mometasone Furoate, fluocinonide, fluocinolone acetonide, fludroxycortide, prednisolone, aoclometasone dipropionate, clobetasol propionate, dexamethasone propionate, deprodone propionate, beclometasone dipropionate, betamethasone, dexamethasone sodium metasulfobenzoate, methylprednisolone, dexamethasone sodium phosphate, betamethasone sodium phosphate, diflucortolone valerate, dexamethaxone valerate, betamethasone valerate, prednisolone valerate acetate, cortisone acetate, diflorazone diacetate, dexamethasone acetate, paramethasone acetate, hydrocortisone acetate, betamethasone acetate and phosphate betamethasone sodium, methylprednisolone acetate, prednisolone sodium succinate for injection, clobetasone butyrate, hydrocortisone butyrate, hydrocortisone butyrate propionate and betamethasone butyrate propionate, etc.), adrenocorticosteroid and antibiotics combination drug (e.g., oxytetracycline hydrochloride and hydrocortisone, tetracycline hydrochloride and hydrocortisone acetate, batamethasone valerate and gentamicin sulfate, fradiomycine sulfate and fluocinolone acetonide, fradiomycine sulfate and prednisolone, fradiomycine sulfate and methylprednisolone, fradiomycine sulfate and betamethasone sodium phosphate, fradiomycine sulfate and betamethasone valerate, etc.), adrenocorticosteroid combination drug (e.g., betamethasone and dexchlorpheniramine maleate etc.), vitamin complex (e.g., Wasser-V etc.), complex antibiotic agent (e.g., colistine sulfate and fradiomycine sulfate, etc.), coenzyme vitamin B2 (e.g., flavine adenine dinucleotide etc.), vitamin B2/B6 preparation (e.g., flavin adenin dinucleotide sodium and pyridoxal phosphate, etc.), coenzyme vitamin B6 (e.g., pyridoxal phosphate etc.), immunosuppressive and atopic dermatitis drug (e.g., tacrolimus hydrate etc.) and immunosuppressive drug (e.g., cyclosporine etc.).
- The other preventive and/or therapeutic pharmaceutical(s), which is/are combined with the compound of the present invention, for alopecic (e.g., congenital alopecia(e.g., diffuse congenital alopecia and congenital triangular alopecia, etc.), acquired alopecia(folliculitis decalvans, alopecia areata and follicular mucinosis, etc.), etc.) and dyspigmentation(e.g., stain, freckle and suntan, etc.), etc. include(s), e.g., vitamin C (e.g., ascorbate etc.), vitamin C preparation (e.g., ascorbate and calcium pantothenate, etc.), chinese medicine (e.g., keisi-ka-ryukotu-boreito etc.), drug for liver disease and allergy (e.g., glycyron etc.), antiseptic disinfectants (e.g., resorcine etc.), agent for biological oxidation-reduction balance (e.g., glutathione etc.), epilatory and effusion and hypoleukocytosis inhibitor (e.g., cepharanthin etc.), parasympathomimetic drug (e.g., acetylcholine chloride etc.), parasympathetic nerve stimulator (e.g., carpronium chloride etc.) and adrenocorticosteroid (e.g., amcinonide, difluprednate, betamethasone dipropionate, dexamethasone, triamcinolone, triamcinolone acetonide, hydrocortisone, mometasone furoate, fluocinonide, prednisolone, clobetasol propionate, dexamethasone propionate, deprodone propionate, methylprednisolone, phosphate dexamethasone sodium, phosphate betamethasone sodium, betamethasone valerate, diflorazone diacetate and phosphate betamethasone sodium, methylprednisolone acetate, prednisolone sodium succinate for injection and hydrocortisone butyrate propionate, etc.), etc.).
- The other preventive and/or therapeutic phannaceutical(s), which is/are combined with the compound of the present invention, for autoimmune disease include(s), e.g., nonsteroidal antiinflammatory drug (e.g., sasapyrine, sodium salicylate, aspirin, aspirin/dialuminate, diflunisal, indometacin, suprofen, ufenamate, dimethyl isopropyl azulene, bufexamac, felbinac, diclofenac, tolmetin sodium, clinoril, fenbufen, napument, puroglumetacine, indomethacin farnesyl, acemetacin, proglumetacin maleate, amfenac sodium, mofebutazone, etodolac, ibuprofen, ibuprofenpiconol, naproxen, flurbiprofen, flurbiprofen axetil, ketoprofen, calcium fenprofen, tiaprofen, oxaprozin, pranoprofen, loxoprofen sodium, aluminoprophen, zaltoprofen, mefenamic acid, alminum mefenamete, glycyrrhetic acid, tolfenamic acid, floctafenine, ketophenylbutazone, oxyphenbutazone, piroxicam, tenoxicam, ampiroxicam, napageln ointment, epirizole, tiaramide hydrochloride, tinoridine hydrochloride, emorfazone, sulpyrine, migrenin, saridon, sedes-G, amipylo-N, sorbon, pyrine medicine, acetaminophen, phenacetin, dimetotiazine mesilate, simetride combination drug and non-pyrine medicine, etc.), disease modifying anti-rheumatic drug (DMARDs and delayed anti-rheumatic drug) (e.g., aurothioglucose, sodium aurothiomalate, auranofin, actarit, D-penicillamine preparation, lobenzarit disodium, bucillamine, hydroxychloroquine, salazosulfapyridine, methotrexate and leflunomide, etc.), adrenocorticosteroid (e.g., as a drug for external use, clobetasol propionate, diflorazone diacetate, fluocinonide, mometasone furoate, betamethasone dipropionate, hydrocortisone butyrate propionate, batamethasone valerate, difluprednate, pudesonide, diflucortolone valerate, amcinonide, halcinonide, dexamethasone, dexamethasone propionate, dexamedtason valerate, dexamethasone acetate, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone butyrate propionate, deprodone propionate, prednisolone valerate acetate, fluocinolone acetonide, beclometasone dipropionate, triamcinolone acetonide, flumetasone pivalate, alclometasone dipropionate, clobetasone butyrate, prednisolone, beclometasone dipropionate and fludroxycortide, etc., as an internal medicine and an injection, cortisone acetate, hydrocortisone, phosphate hydrocortisone sodium, hydrocortisone sodium succinate, fludrocortisone acetate, prednisolone, prednisolone acetate, prednisolone sodium succinate, prednisolone butylacetate, prednisolone sodium phosphate, halopredone acetate, methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, triamcinolone, triamcinolone diacetate, dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate, dexamethasone palmitate, paramethasone acetate and betamethasone, etc., as an inhalant, beclometasone dipropionate, fluticasone propionate, budesonide, flunisolide, triamcinolone, ST-126P, ciclesonide, dexamethasone palomithionate, mometasone furoate, prasterone sulfonate, deflazacort, methylprednisolone threbutanate, and methylprednisolone sodium succinate, etc.), immunosuppressive drug (e.g., tacrolimus(FK506), cyclosporine, sirolimus(rapamycin), corticosteroid, azathiopurine, mycophenolate mofetil, cyclophosphamide, etc.), antiphlogistic enzyme (e.g., lysozyme chloride, bromelain, pronase, serrapeptase, streptokinase and streptodornase combination drug, etc.), cartilage protective (e.g., sodium hyaluronate, glucosamine, chondroitin sulfuric acid, glycasaminaglycan polysulfate inhibitor, etc.), T lymphocyte inhibitor, TNF-alpha inhibitor (e.g., infliximab, adalimumab and etanercept, etc.), prostaglandin synthase inhibitor (e.g., salazosulfapyridine, mesalazine, olsalazine, 4-aminosalicylic acid, JTE-522, auranofin, carprofen, diphenpiramide, flunoxaprofen, flurbiprofen, indomethacin, ketoprofen, lornoxicam, loxoprofen, meloxicam, oxaprozin, parsalmid, piproxen, piroxicam, piroxicam betadex, piroxicam cinnamate, tropineindomethacinate, zaltoprofen, pranoprofen, etc.), IL-6 inhibitor (e.g., MRA etc.), Interferon-gamma agonist, IL-1 inhibitor (e.g., anakinra etc.), EDG-1 agonist, EDG-6 agonist, prostaglandins (hereafter, it is abbreviated as PG.)(e.g., PG receptor agonist and PG receptor antagonist, etc. PG receptor includes PGE receptor (EP1,EP2,EP3 and EP4), PGD receptor (DP and CRTH2), PGF receptor (FP), PGI receptor (IP) and TX receptor(TP), etc.) and include(s) phosphodiesterase inhibitor (e.g., rolipram(PDE4 inhibitor), cilomilast (trade name Arifro), Bay19-8004, NIK-616, Roflumilast(BY-217), cipamphiline(BRL-61063), atizoram(CP-80633), SCH-351591, YM-976, V-11294A, PD-168787, D-4396, IC-485 and ONO-6126, etc.), metalloproteinase inhibitor, chemokine receptor antagonist (e.g., endogenous ligand of chemokine receptor (e.g., MIP-1α, MIP-1β, RANTES, SDF-1α, SDF-1β, MCP-1, MCP-2, MCP-4, Eotaxin and MDC, etc., or derivative thereof (e.g., AOP-RANTES, Met-SDF-1alpha, and Met-SDF-1beta, etc.), and non-peptide low molecular weight compound (e.g., CCR2, CCR3, CCR4, CCR5, CXCR1, CXCR2, CXCR3 or CXCR4 receptor antagonist and agonist, etc.) or Chemokine receptor (e.g., Pro-140 etc.) and adhesive molecule inhibitor (e.g, antiIntegrin α 4 antibody, etc.), etc.
- The other preventive and/or therapeutic pharmaceutical(s), which is/are combined with the compound of the present invention, for HIV infection and acquired immunological deficiency syndrome include(s), e.g., reverse transcriptase inhibitor, protease inhibitor, chemokine (e.g., CCR2, CCR3, CCR4, CCR5, CXCR1, CXCR2, CXCR3 or CXCR4) antagonist, fusion inhibitor, antibody for surface antigen of HIV-1 and HIV-1 vaccine, etc.
- The other preventive and/or therapeutic pharmaceutical(s), which is/are combined with the compound of the present invention, for atopic dermatitis include(s), e.g., steroid, non-steroidal antiinflammatory drug, immunosuppressive drug, PGs, antiallergic drug, mediator release inhibitor, antihistaminic, forskolin preparation, phosphodiesterase inhibitor and cannabinoid-2 receptor stimulator, etc.
- The other preventive and/or therapeutic pharmaceutical(s), which is/are combined with the compound of the present invention, for arteriosclerosis include(s), e.g., HMG-CoA reductase inhibitor, fibrate preparation, probucol preparation, anion exchange resin, EPA preparation, nicotinic acid preparation, MTP inhibitor, other anti-cholesterol drug and EDG-2 antagonist, etc.
- The other preventive and/or therapeutic pharmaceutical(s), which is/are combined with the compound of the present invention, for Crohn's disease and ulceous colitis include(s), e.g., steroid, elastase inhibitor, cannabinoid-2 receptor stimulator, prostaglandins, prostaglandin synthase inhibitor, phosphodiesterase inhibitor, metalloproteinase inhibitor, adhesive molecule inhibitor, anti-cytokine protein preparation, anti-cytokine drug, immunomodulator, leukotriene receptor antagonist, antiparasympathomimetic drug, 5-lipoxygenase inhibitor, nitric oxide synthase (NOS) inhibitor, interleukin-8 antagonist, poly(ADP-ribose)polymerase(PARP) inhibitor, mitochondriaa benzodiazepine receptor(MBR) agonist, antioxidant, local anesthetic, antiulcer drug, protection factor promoter, mesalazine, salazosulfapyridine and TNF-alpha antagonist, etc.
- The other preventive and/or therapeutic pharmaceutical(s), which is/are combined with the compound of the present invention, for irritable bowel syndrome include(s), e.g., antianxiety drug (e.g., benzodiazepine, thienodiazepin and non-benzodiazepine, etc.), antidepressant drug (e.g., monoamine releaser, monoamine oxidase(MAO) inhibitor, monoamine reuptake inhibitor (SNRI and SSRI), dopamine(D2) antagonist, CRF antagonist, Beta 3 agonist, neurotensin antagonist, NK1 antagonist, tricyclic antidepressant and tetracyclic antidepressant, etc.), antiparasympathomimetic drug, affinity polyacrylamide resin, antidiarrheal drug, mucosal paralyzant, bulk catharic, saline cathartic, fiber pharmaceutical, drug for controlling intestinal function, autonomic nerve modulator, calcium channel blocking agent, phosphodiesterase inhibitor, serotonin antagonist (e.g., 5-HT3 antagonist and 5-HT4 antagonist, etc.), serotonin agonist (e.g., 5-HT4 agonist and 5-HT1A agonist, etc.), digestive function modulator (e.g., CCK-A antagonist, NK1 antagonist, NK2 antagonist, 5-HT1A agonist, muscarinic agonist, 5-lipoxygenase inhibitor, CRF antagonist, etc.) and mitochondriaa benzodiazepine receptor(MBR) agonist, etc.
- The other preventive and/or therapeutic pharmaceutical(s), which is/are combined with the compound of the present invention, for colitis include(s), e.g., steroid, nitric oxide synthase(NOS) inhibitor, prostaglandins, poly(ADP-ribose)polymerase(PARP) inhibitor, phosphodiesterase 4 inhibitor, elastase inhibitor, Interleukin-8 antagonist and cannabinoid-2 receptor stimulatior, etc.
- Other pharmaceuticals supplementing and/or enhancing of the prevention and/or treatment effect of the compound of the present invention include not only one that was found so far but also one that will be found in the future.
- There is no particular limitation for the diseases showing the prevention and/or treatment effect by the foregoing combined preparation, so far as it is a disease in which the prevention and/or treatment effect of the compound of present invention are supplemented and/or enhanced.
- When the compound of the present invention or the combined preparation of the compound of the present invention and other pharmaceutical(s) is used for the foregoing purpose, it is systemically or topically administered in oral or parenteral form usually.
- The dose varies depending upon age, body weight, symptom, therapeutic effect, administering method or treating time, etc. Generally, 100 µg to 1,000 mg per an adult is orally administered once to several times per a day, or 50 µg to 500 mg per an adult is parenterally administered one to several times per a day, or is continuously administered from vein for 1 to 24 hour(s) per a day.
- Since the dose changes depending on various conditions as described above, there are cases in which doses lower than or greater than the above ranges may be used.
- When the compound of the present invention or the combined preparation of the compound of the present invention and other pharmaceutical is administered, it is used as internal solid composition for oral administration, internal liquid composition and injection, external preparation, suppository, eye drop or inhalant, etc., for parenteral administration.
- The internal solid composition for oral administration includes, e.g., tablets, pills, capsules, diluted powder and granules etc. The capsules include hard capsules and soft capsules.
- In such a solid composition, one or more active substance(s) is used by itself or by being mixed with vehicle (e.g., lactose, mannitol, glucose, microcrystalline cellulose, and starch, etc.), binding agent (e.g., hydroxypropylcellulose, polyvinyl pyrrolidone, and magnesium aluminometasilicate, etc.), disintegrator (e.g., sodium carboxymethylcellulose etc.), lubricant (e.g., magnesium stearate etc.), stabilizer or solubilizer (e.g., glutamate and aspartic acid, etc.), etc., and being pharmaceutically manufactured by a conventional method. The solid composition may be coated with coating (e.g., saccharose, gelatin, hydroxypropylcellulose or hydroxypropylmethylcellulose phthalate, etc.), if necessary, or may be coated with two or more layers. Capsule of a substance that can be absorbed such as gelatin is also included.
- The internal liquid composition for oral administration includes pharmaceutically acceptable solution, suspension, emulsum, syrup and elixir, etc. In the liquid composition, one or more active substance(s) is/are dissolved, suspended or emulsified in a commonly used inert diluent (e.g., pure water, ethanol or the mixture, etc.). The composition may contain moisturizer, suspending agent, sweetener, flavor, aromatic agent, preservative and buffer, etc.
- The external preparation for parenteral administration includes, e.g., ointment, gel, cream, fomentation, patch, embrocation, nebula, inhalant, spray, aerosol, eye drop and nosedrop, etc. These may contain one or more activator(s) and may be prepared by known methods or conventional methods.
- The ointment may be prepared by known methods or conventional methods. For example, it may be prepared by levigating and melting one or more activator(s) into a base. The ointment base is chosen from known or usually used ones. For example, it is used by mixing with one or more chosen from higher fatty acid or higher fatty acid ester (e.g., adipic acid, myristic acid, palmitic acid, stearic acid, oleic acid, adipic acid ester, myristic acid ester, palmitate, stearic acid ester or oleate, etc.), rows (e.g., beeswax, spermaceti wax or ceresin, etc.), surfactant (e.g., polyoxyethylene alkyl ether phosphate ester etc.), higher alcohol (e.g., cetanol, stearyl alcohol or cetostearyl alcohol, etc.), silicone oil (e.g., dimethylpolysiloxane etc.), hydrocarbons (e.g., hydrophilic petrolatum, white petrolatum, purified lanolin or liquid paraffin, etc.), glycols (e.g., ethylene glycol, diethylene glycol, propylene glycol, polyethylene glycol or macrogol, etc.), vegetable oil (e.g., castor oil, olive oil, sesame oil or turpentine oil, etc.), animal oil (e.g., mink oil, yolk oil, squalane or squalene, etc.), water, absorption promoter and poison inhibitor. Further, it may include moisturizing agent, preservative, stabilizing agent, anti-oxidant or flavor, etc.
- The gel may be prepared by known methods or conventional methods. For example, it may be prepared by melting one or more activator(s) into a base. The gel base is chosen from known or usually used ones. For example, it is used by mixing with one or more base(s) chosen from lower alcohol (e.g., ethanol and isopropyl alcohol, etc.), gelatinizer (e.g., carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose or ethylcellulose, etc.), neutralizer (e.g., triethanolamine or diisopropanolamine, etc.), surfactant (e.g., polyethylene glycol monostearate etc.), gums, water, absorption promoter and poisoned inhibitor. Further, it may include preservative, anti-oxidant or flavor, etc.
- The cream is prepared by known methods or conventional methods. For example, it may be prepared or emulsified by melting one or more activator(s) into a base. The cream base is chosen from known or usually used ones. For example, it is used by mixing with one or more base(s) chosen from higher fatty acid ester, lower alcohol, hydrocarbons or polyhydric alcohol (e.g., three propyleneglycol or 1, 3-butyleneglycol, etc.), higher alcohol (e.g., 2-hexyldecanol or cetanol, etc.) and emulsifier (e.g., polyoxyethylene alkyl ethers or fatty acid esters, etc.). Further, it may include preservative, anti-oxidant or flavor, etc.
- The fomentation is prepared by known methods or conventional methods. For example, it may be prepared by melting one or more activator(s) into a base, followed by kneading, rolling and spreading on carrier. The fomentation base is chosen from known or usually used ones. For example, it is used by mixing with one or more base(s) chosen from thickener (e.g., polyacrylic acid, polyvinyl pyrrolidone, arabic gum, starch, gelatin or methylcellulose, etc.), penetrant (e.g., urea, glycerin or propyleneglycol, etc.), filler (e.g., china clay, zinc oxide, talc, calcium or magnesium, etc.), water, solubilizer, tackifier and poison inhibitor. Further, it may include preservative, anti-oxidant or flavor, etc.
- The patch is prepared by known methods or conventional methods. For example, it may be prepared by melting one or more activator(s) into a base followed by rolling and spreading on carrier. The patch base is chosen from known or usually used ones. For example, it is used by mixing with one or more base(s) chosen from polymeric matrix, oils and fats, and higher fatty acid, tackifier and poison inhibitor. Further, it may include preservative, anti-oxidant or flavor, etc.
- The liniment is prepared by known methods or conventional methods. For example, it may be prepared by dissolving, suspending or emulsifying one or more activater(s) into one or more base(s) chosen from water, alcohol (e.g., ethanol or polyethylene glycol, etc.), higher fatty acid, glycerin, soap, emulsifier and suspending agent, etc. Further, it may include preservative, anti-oxidant or flavor, etc.
- The spray, the inhalant and the aerosol may contain a stabilizer such as sodium hydrogen sulfite or a buffer giving isotonicity, e.g., isotonizing agent such as sodium chloride, sodium citrate or citric acid, etc. A manufacturing method of spray is described, e.g., in
U.S. Pat. No. 2,868,691 andNo. 3,095,355 in detail. - The injection for parenteral administration includes all injections and the drip, too. It includes, e.g., muscle injection, hypodermic injection, intradermic injection, intra-arterial injection, intravenous injection, endoceliac injection, intrathecal injection and intravenous drip, etc.
- The injection for parenteral administration includes solution, suspension, emulsion, and solid injection that is dissolved or suspended into a solvent before use. The injection may be used by dissolving, suspending or emulsifying one or more activator(s) into a solvent. For example, distilled water for injection, physiologic saline, vegetable oil, propylene glycol, polyethylene glycol or alcohols such as ethanols or combination thereof is used as a solvent. Further, the injection may include stabilizer, solubilizer (e.g., glutamic acid, glutamic acid and POLYSORBATE 80(registered trade mark), etc.), glutamic acid, emulsifier, soothing agent, buffer and preservative, etc. These are sterilized in the final process or manufactured by the aseptic manipulation. Sterile solid compositions may also be used, e.g., by being freeze-dried and being aseptic or dissolved to aseptic distilled purified water or other solvents before use.
- The eye drop for parenteral administration includes eye drops, eye drops of a suspension type, eye drops of an emulsion type, eye drops which is dissolved upon actual use, and eye ointment.
- The eye drop may be manufactured according to a known method. For example, is/are used by being dissolving, suspending or emulsifying one or more activator(s) into a solvent. For example, sterile purified water, physiologic saline and other water solvents or injectable non-aqueous solvent (e.g., vegetable oil etc.), etc., and combination thereof is used as a solvent of the eye drop. The eye drop may appropriately contain isotonizing agent (e.g., sodium chloride or concentrated glycerol, etc.), buffering agent (e.g., sodium phosphate or sodium acetate, etc.), surfactant (e.g., Polysorbate 80 (trade name), polyoxyl stearate 40 or polyoxyethylene hydrogenated castor oil, etc.), stabilizer (e.g., sodium citrate or sodium edetate, etc.), antiseptic agent (e.g., benzalkonium chloride or paraben, etc.), if necessity. These are sterilized in the final process or manufactured by the aseptic manipulation. Sterile solid compositions may also be used, e.g., by being freeze-dried and being aseptic or dissolved to aseptic distilled purified water or other solvents before use.
- The inhalation agent for parenteral administration includes aerosol preparation, powder for inhalation and liquid for inhalation. The liquid for inhalation may be such a form that the ingredient is dissolved or suspended in water or in other appropriate medium in actual use.
- Those inhalation agents are prepared according to known methods.
- For example, in the case of liquid for inhalation, antiseptic agent (benzalkonium chloride or paraben etc.), coloring agent, buffer (sodium phosphate or sodium acetate etc.), isotonizing agent (sodium chloride or concentrated glycerol etc.), thickener (carboxyvinyl polymer etc.) or absorption promoter, etc., are appropriately selected and prepared if necessary.
- In the case of powder for inhalation, lubricant (stearic acid or salt thereof, etc.), binder (e.g., starch or dextrin, etc.), excipient (e.g., lactose or cellulose, etc.), coloring agent, antiseptic (e.g., benzalkonium chloride or paraben, etc.) or absorption promoter, etc., are appropriately selected and prepared if necessary.
- In the administration of the liquid for inhalation, a spraying device (e.g., atomizer or nebulizer etc.) are usually used and in the administration of the powder for inhalation, an administering device for inhalation of powdery pharmaceutical is usually used.
- Other composition for parenteral administration, which contains one or more activator(s), includes suppository for intrarectal administration and pessary for intravaginal administration, etc., which can be prepared by known methods.
-
- (1) The compound having BLT2 binding activity, salt thereof, solvate thereof or prodrug thereof is useful for the prevention and/or therapy for skin disease.
- (2) The compound of the present invention has BLT2 binding activity. Therefore, it is useful for the prevention and/or therapy for skin disease, intestinal disease, HIV infection, acquired immunological deficiency syndrome, rejection to transplant, transplant rejection, graft-versus-host disease, autoimmune disease, allergic disease, inflammation, infectious disease, ulcus, lymphoma, carcinoma, leukosis, arteriosclerotic, hepatitis or liver cirrhosis or cancer, etc.
-
- FIG. 1 shows BLT2 mRNA expression pattern in each mouse tissue (northern blotting).
- FIG. 2 shows the amount of BLT2 mRNA expression in each mouse tissue (quantitative real time RT-PCR).
- FIG. 3 shows BLT2 mRNA expression in mouse skin keratinocytes.
- FIG. 4 shows the rise of intracellular calcium concentration when BLT2-expressing cells are processed by BLT2 agonist.
- FIG. 5 shows ERK phosphorylation activity when BLT1 or BLT2-expressing cells are processed by BLT2 agonist.
- FIG. 6 shows that alpha-
keratin 5 expresses in primary culture keratinocytes prepared from mouse skin. - FIG. 7 shows ERK phosphorylation activity when primary culture keratinocytes prepared from mouse skin are processed by BLT2 agonist.
- Hereafter, examples illustrate the present invention but do not limit the present invention.
The solvent in parentheses shown in chromatographic separation or TLC represents a used dissolution medium or eluent and the ratio of both solvents represents the volume ratio.
NMR data is the data of 1H-NMR unless otherwise stated.
The solvent in parentheses of NMR represents a solvent used for measurement.
unless otherwise stated, MS is carried out in ESI (electron spray ion) method, in which cation (pos.) was detected.
The condition of HPLC is as follows.
(1) Condition A (analysis)
Instrument: Waters LC/MS
Column: Xterra (registered trademark) MS C185µm, 4.6x50mm I.D
Flow rate: 3mL/min
Solvent: A liquid: 0.1% trifluoroacetic acid solution
B liquid: trifluoroacetic acid-0.1% acetonitrile solutionTABLE 1 Time (min) A liquid B liquid 0 95 5 0.5 95 5 3 0 100 3.5 0 100 3.51 95 5 5 95 5 - Wang resin (Argonaut Technology) was washed with N, N-dimethylformamide. Three equivalents of iodobenzoic acid, 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide and 1-hydroxybenzotriazole, which correspond to N, N-dimethylformamide suspension for Wang resin, were added to Wang resin respectively and diisopropylethylamine (5 equivalents) was added. The reaction mixture was reacted during 18 hours at room temperature. The resin was filtered and sequentially washed with N, N-dimethylformamide, tetrahydrofuran, methanol and 1, 2-dimethoxyethane.
- The corresponding formylphenyl borane acid (2 equivalents) and 2mol/L potassium carbonate solution (2 equivalents) were added to the obtained resin suspension in degassed 1, 2-dimethoxyethane. The catalyst quantity of bis(triphenylphosphine)palladium dichloride was added there. The reaction mixture was reacted for 16 hours at 60°C and then cooled up to room temperature and filtered. The resin was washed with 1, 2-dimethoxyethane/water (2:1), 1, 2-dimethoxyethane, N, N-dimethylformamide, tetrahydrofuran and methanol.
- The obtained resin was washed with 1% acetate/1 , 2-dichloroethane. Further, the corresponding 0.5 mol/L amine compound (5 equivalents) in 1% acetate/1, 2-dichloroethane solution was added and reacted for 5 hours at room temperature. 0.5 mol/L tetrabutylammonium borohydride in 1% acetate/1, 2-dichloroethane solution (5 equivalents) was added to the above mixture and then reacted overnight. The resin was filtered and washed with methanol, tetrahydrofuran and N, N-dimethylformamide.
- The obtained resin was washed with 1, 2-dichloroethane. Further, the corresponding 1 mol/L acylchloride in 1, 2-dichloroethane solution (5 equivalents) and diisopropylethylamine in 1, 2-dichloroethane solution (7.5 equivalents) were sequentially added. The reaction mixture was reacted overnight, and the resin was filtered and washed with 1, 2-dichloroethane, methanol and tetrahydrofuran.
- Methanol/30 % tetrahydrofuran in 0.1 mol/L sodium methylate (1 equivalent) solution was added to the obtained resin. 0.5 mol/L sodium hydroxide solution (1 equivalent) was added to the mixture to be concentrated. The following compound of the present invention was obtained.
-
- sodium 2'-{[(phenylacetyl)(3-phenylpropyl)amino]methyl}-1,1'-biphenyl-2-carboxylate
HPLC retention time: 4.14 minutes; MS: 328, 464 (M+H)+. - sodium 2'-{[phenyl(3-phenylpropanoyl)amino]methyl}-1,1'-biphenyl-2-carboxylate
HPLC retention time: 4.12 minutes; MS: 286, 436 (M+H)+. - sodium 2'-{([(2-phenylethyl)(3-phenylpropanoyl)-amino]methyl}-1,1'-biphenyl-2-carboxylate
HPLC retention time: 4.16 minutes; MS: 464 (M+H)+. - sodium 2'-{[(3-phenylpropanoyl)(3-phenylpropyl)amino]methyl}-1, 1'-biphenyl-2-carboxylate
HPLC retention time: 4.23 minutes; MS: 478 (M+H)+. - sodium 2'-{[(3-phenylpropanoyl)(1-propylbutyl)amino]methyl}-1,1'-biphenyl-2-carboxylate
HPLC retention time: 4.37 minutes; MS: 458 (M+H)+. - sodium 2'-{[(4-chlorobenzoyl)(phenyl)amino]methyl}-1,1'-biphenyl-2-carboxylate
HPLC retention time: 4.1 minutes; MS: 23 2, 442 (M+H)+. - sodium 2'-{[(4-chlorobenzoyl)(3-phenylpropyl)amino]methyl}-1, 1'-biphenyl-2-carboxylate
HPLC retention time: 4.23 minutes; MS: 328, 484 (M+H)+. - sodium 2'-{[(4-chlorobenzoyl)(1-propylbutyl)amino]methyl}-1,1'-biphenyl-2-carboxylate
HPLC retention time: 4.41 minutes; MS: 464 (M+H)+. - sodium 2'-{[(4-methoxybenzoyl)(3-phenylpropyl)amino]methyl}-1,1'-biphenyl-2-carboxylate
HPLC retention time: 4.09 minutes; MS: 480 (M+H)+. - sodium 3'-{[phenyl(phenylacetyl)amino]methyl}-1, 1'-biphenyl-2-carboxylate
HPLC retention time: 4.02 minutes; MS: 422 (M+H)+. - sodium 3'-{[(phenylacetyl)(1-propylbutyl)amino]methyl}-1, 1'-biphenyl-3-carboxylate
HPLC retention time: 4.31 minutes; MS: 444 (M+H)+. - sodium 3'-{[phenyl(3-phenylpropanoyl)amino]methyl}-1, 1'-biphenyl-3-carboxylate
HPLC retention time: 4.12 minutes; MS: 436 (M+H)+. - sodium 3'-{[benzyl(3-phenylpropanoyl)amino]methyl}-1, 1'-biphenyl-3-carboxylate
HPLC retention time: 4.15 minutes; MS: 450 (M+H)+. - sodium 3'-{[(2-phenylethyl)(3-phenylpropanoyl)amino]methyl}-1, 1'-biphenyl-3-carboxylate
HPLC retention time: 4.19 minutes; MS: 464 (M+H)+. - sodium 3'-{[(3-phenylpropanoyl)(3-phenylpropyl)amino]methyl}-1,1'-biphenyl-3-carboxylate
HPLC retention time: 4.24 minutes; MS: 478 (M+H)+. - sodium 3'-{[butyl(3-phenylpropanoyl)amino]methyl}-1,1'-biphenyl-3-carboxylate
HPLC retention time: 4.14 minutes;MS : 416 (M+H)+. - sodium 3'-{[(3-phenylpropanoyl)(1-propylbutyl)amino]methyl}-1,1'-biphenyl-3-carboxylate
HPLC retention time: 4.4 minutes; MS: 458 (M+H)+. - sodium 3'-{[(4-chlorobenzoyl)(phenyl)amino]methyl}-1,1'-biphenyl-3-carboxylate
HPLC retention time: 4.11 minutes; MS: 442 (M+H)+. - sodium 3'-{[benzyl(4-chlorobenzoyl)amino]methyl}-1, 1'-biphenyl-3-carboxylate
HPLC retention time: 4.19 minutes; MS: 456 (M+H)+. - sodium 3'-{[(4-chlorobenzoyl)(2-phenylethyl)amino]methyl}-1, 1'-biphenyl-3-carboxylate
HPLC retention time: 4.23 minutes; MS: 470 (M+H)+. - sodium 3'-{[(4-chlorobenzoyl)(1-propylbutyl)ammo]methyl}-1,1'-biphenyl-3-carboxylate
HPLC retention time: 4.43 minutes; MS: 464 (M+H)+. - sodium 3'-{[(4-methoxybenzoyl)(phenyl)amino]methyl}-1,1'-biphenyl-3-carboxylate
HPLC retention time: 3.96 minutes; MS: 438 (M+H)+. - sodium 3'-{[pentanoyl(3-phenylpropyl)amino]methyl}-1, 1'-biphenyl-3-carboxylate
HPLC retention time: 4.21 minutes; MS: 430 (M+H)+. - sodium 3'-{[benzyl(phenylacetyl)amino]methyl}-1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.06 minutes; MS: 436 (M+H)+. - sodium 3'-{[(phenylacetyl)(2-phenylethyl)amino]methyl}-1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.1 minutes; MS: 450 (M+H)+. - sodium 3'-{[(phenylacetyl)(3-phenylpropyl)amino]methyl}-1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.15 minutes; MS: 464 (M+H)+. - sodium 3'- {[(phenylacetyl)(1-propylbutyl)amino]methyl} -1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.31 minutes; MS: 444 (M+H)+. - sodium 3'-{[phenyl(3-phenylpropanoyl)amino]methyl}-1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.1 minutes; MS: 436 (M+H)+. - sodium 3'-{[benzyl(3-phenylpropanoyl)amino]methyl}-1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.14 minutes; MS: 450 (M+H)+. - sodium 3'-{[(2-phenylethyl)(3-phenylpropanoyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.18 minutes; MS: 464 (M+H)+. - sodium 3'-{[(3-phenylpropanoyl)(3-phenylpropyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.23 minutes; MS: 478 (M+H)+. - sodium 3'-{[benzyl(4-chlorobenzoyl)amino]methyl}-1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.17 minutes; MS: 456 (M+H)+. - sodium 3'-{[(4-chlorobenzoyl)(2-phenylethyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.2 minutes; MS: 470 (M+H)+. - sodium 3'-{[(4-chlorobenzoyl)(3-phenylpropyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.25 minutes; MS: 484 (M+H)+. - sodium 3'-{[benzyl(4-methoxybenzoyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.04 minutes; MS: 452 (M+H)+. - sodium 3'-{[(4-methoxybenzoyl)(3-phenylpropyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.11 minutes; MS: 480 (M+H)+. - sodium 3'-{[benzyl(cyclopentylcarbonyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.13 minutes; MS: 414 (M+H)+. - sodium 3'-{[(cyclopentylcarbonyl)(3-phenylpropyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.24 minutes; MS: 442 (M+H)+. - sodium 3'-{[pentanoyl(3-phenylpropyl)amino]methyl}-1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.19 minutes; MS: 430 (M+H)+. - sodium 4'-{[benzoyl(3-phenylpropyl)amino]methyl}-1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.11 minutes; MS: 450 (M+H)+. - sodium 4'-{[benzyl(phenylacetyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.06 minutes; MS: 436 (M+H)+. - sodium 4'-{[(phenylacetyl)(2-phenylethyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.09 minutes; MS: 450 (M+H)+. - sodium 4'-{[(phenylacetyl)(3-phenylpropyl)amino]methyl}-1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.16 minutes; MS: 464 (M+H)+. - sodium 4'-{[butyl(phenylacetyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.04 minutes; MS: 402 (M+H)+. - sodium 4'-{[(phenylacetyl)(1-propylbutyl)amino]methyl}-1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.34 minutes; MS: 444 (M+H)+. - sodium 4'- {[(2-phenylethyl)(3-phenylpropanoyl)amino]methyl}-1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.17 minutes; MS: 464 (M+H)+, - sodium 4'{[(3-phenylpropanoyl)(3-phenylpropyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.23 minutes; MS: 478 (M+H)+. - sodium 4'-{[butyl(3-phenylpropanoyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.14 minutes; MS: 416 (M+H)+. - sodium 4'-{[(3-phenylpropanoyl)(1-propylbutyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.42 minutes; MS: 458 (M+H)+. - sodium 4'-{[(4-chlorobenzoyl)(phenyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.09 minutes; MS: 442 (M+H)+. - sodium 4'-{[(4-chlorobenzoyl)(2-phenylethyl)amino]methyl}-1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.18 minutes; MS: 470 (M+H)+. - sodium 4'-{[(4-cholorobenzoyl)(3-phenylpropyl)amino]methyl}-1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.24 minutes; MS: 485 (M+H)+. - sodium 4'-{[butyl(4-chlorobenzoyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.17 minutes; MS: 422 (M+H)+. - sodium 4'-{[(4-methoxybenzoyl)(3-phenylpropyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.09 minutes; MS: 480 (M+H)+. - sodium 4'-{[(cyclopentylcarbonyl)(2-phenylethyl)amino]methyl}-1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.17 minutes; MS: 428 (M+H)+. - sodium 4'-{[(cyclopentylcarbonyl)(3-phenylpropyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.25 minutes; MS: 442 (M+H)+. - sodium 4'- {[(cyclopentylcarbonyl)(1-propylbutyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.43 minutes; MS: 422 (M+H)+. - sodium 4'- {[pentanoyl(3 -phenylpropyl)amino]methyl}-1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.19 minutes; MS: 430 (M+H)+. - sodium 3'- {[(4-methoxybenzoyl)(4-phenylbutyl)amino]methyl}-1,1'-biphenyl-3-carboxylate
HPLC retention time: 4.15 minutes; MS: 494 (M+H)+. - sodium 4'-{[(4-methoxybenzoyl)(3-phenylpropyl)amino]methyl}-1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.02 minutes; MS: 480 (M+H)+. - sodium 4'- {[(4-methoxybenzoyl)(4-phenylbutyl)amino]methyl} -1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.11 minutes; MS: 494 (M+H)+. - sodium 4'-{[(2,2-diphenylethyl)(4-methoxybenzoyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.15 minutes; MS: 542 (M+H)+. - sodium 4'- {[(2-cyclohexa-1-en-1-ylethyl)(4-methoxybenzoyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.19 minutes; MS: 470 (M+H)+. - sodium 4'-{[{[(1S,2R,5S)-6, 6-dimethylbicyclo[3.1.1]hepta-2-yl]methyl}(4-methoxybenzoyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.35 minutes; MS: 498 (M+H)+. - sodium 4'-{[(2-ethylhexyl)(4-methoxybenzoyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.33 minutes; MS: 474 (M+H)+. - sodium 4'-{[[2-(4-chlorophenyl)ethyl](pentanoyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.19 minutes; MS: 450 (M+H)+. - sodium 4'-{[[2-(2-chlorophenyl)ethyl](pentanoyl)amino]methyl}-1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.21 minutes; MS: 450 (M+H)+. - sodium 4'-{[[2-(2-methoxyphenyl)ethyl](pentanoyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.10 minutes; MS: 446 (M+H)+. - sodium 4'-{[(2, 2-diphenylethyl)(pentanoyl)amino]methyl}-1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.26 minutes; MS: 492 (M+H)+. - sodium 4'-{[{[(1S, 2R, 5S)-6, 6-dimethylbicyclo[3.1.1]hepta-2-yl]methyl}(pentanoyl)amino]methyl}-1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.52 minutes; MS: 448 (M+H)+. - sodium 4'- {[(cyclopentylcarbonyl)(2-phenylethyl)amino]methyl} -1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.11 minutes; MS: 428 (M+H)+, - sodium 4'-{{[(cyclopentylcarbonyl)(3-phenylpropyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
HPLC retention time: 4.17 minutes; MS: 442 (M+H)+. - sodium 4'-{[(cyclopentylcarbonyl)(2, 2-diphenylethyl)amino]methyl}-1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.28 minutes; MS: 504 (M+H)+. - sodium 4'-[((cyclopentylcarbonyl){[(1S, 2R 5S)-6, 6-dimethylbicyclo[3.1.1]hepta-2-yl]methyl}amino)methyl]-1, 1'-biphenyl-4-carboxylate
HPLC retention time: 4.59 minutes; MS: 460 (M+H)+. - The resin obtained in Reaction 3 on Example 1 was washed with 1% acetate/N, N-dimethylformamide solution. Further, the corresponding 1% acetate/N, N-dimethylformamide solution in 0.5 mol/L aldehyde derivative (5 equivalents) was added and reacted for 5 hours at room temperature. N, N-dimethylformamide solution in 0.5 mol/L sodium triacetoxyborohydride (5 equivalents) was added to the mixture and then reacted overnight. The resin was filtered and washed with methanol, N, N-dimethylformamide, tetrahydrofuran and 1, 2-dichloroethane. Trifluoroacetic acid/20% 1, 2-dichloroethane was added to the obtained resin and reacted for 30 minutes. The solution obtained by filtering the mixture was concentrated to obtain the following compound of the present invention.
-
- 4'-{[(4-cyanobenzyl)(1-propylbutyl)amino]methyl}-1, 1'-biphenyl-2-carboxylic acid trifluoroacetate
HPLC retention time: 3.59 minutes; MS: 441 (M+H)+. - 2'-[(dibenzylamino)methyl]-1, 1'-biphenyl-3-carboxylic acid trifluoroacetate
HPLC retention time: 3.47 minutes; MS: 408 (M+H)+. - 2'-{[(4-chlorobenzyl)(3-phenylpropyl)amino]methyl}-1, 1'-biphenyl-3-carboxylic acid trifluoroacetate
HPLC retention time: 3.64 minutes; MS: 470 (M+H)+. - 2'-{[benzyl(3-phenylpropyl)amino]methyl}-1, 1'-biphenyl-3-carboxylic acid trifluoroacetate
HPLC retention time: 3.56 minutes; MS: 436 (M+H)+. - 2'-{[(2-phenylethyl)(3-phenylpropyl)amino]methyl}-1, 1'-biphenyl-3-carboxylic acid trifluoroacetate
HPLC retention time: 3.62 minutes; MS: 450 (M+H)+. - 3'-{[(4-cyanobenzyl)(3-phenylpropyl)amino]methyl}-1, 1'-biphenyl-3-carboxylic acid trifluoroacetate
HPLC retention time: 3.55 minutes; MS: 461 (M+H)+. - 3'-{[benzyl(3-phenylpropyl)amino]methyl}-1, 1'-biphenyl-3-carboxylic acid trifluoroacetate
HPLC retention time: 3.63 minutes; MS: 436 (M+H)+. - 3'-{[bis(3-phenylpropyl)amino]methyl}-1, 1'-biphenyl-3-carboxylic acid trifluoroacetate
HPLC retention time: 3.72 minutes; MS: 464 (M+H)+. - 4'-{[(4-methoxybenzyl)(2-phenylethyl)amino]methyl}-1,1'-biphenyl-3-carboxylic acid trifluoroacetate
HPLC retention time: 3.58 minutes; MS: 452 (M+H)+. - 2'-{[benzyl(3-phenylpropyl)amino]methyl}-1, 1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.51 minutes; MS: 436 (M+H)+. - 2'-{[(4-chlorobenzyl)(3-phenylpropyl)amino]methyl}-1, 1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.59 minutes; MS: 470 (M+H)+, - 2'-{[butyl(4-chlorobenzyl)amino]methyl}-1, 1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.46 minutes; MS: 408 (M+H)+. - 2'-{[benzyl(4-cyanobenzyl)amino]methyl}-I, 1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.55 minutes; MS: 433 (M+H)+. - 2'-{[(4-cyanobenzyl)(3-phenylpropyl)amino]methyl}-1,1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.48 minutes; MS: 461 (M+H)+. - 2'-{[bis(3-phenylpropyl)amino]methyl}-1,1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.61 minutes; MS: 464 (M+H)+. - 2'-{[benzyl(cyclohexylmethyl)amino]methyl}-1,1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.51 minutes; MS: 414 (M+H)+. - 3'-{[benzyl(3-phenylpropyl)amino]methyl}-1,1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.57 minutes; MS: 436 (M+H)+. - 3'-{[(4-cyanobenzyl)(2-phenylethyl)amino]methyl}-1,1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time; 3.47 minutes; MS: 447 (M+H)+. - 3'-{[(cyclohexylmethyl)(2-phenylethyl)amino]methyl}-1, 1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.64 minutes; MS: 428 (M+H)+. - 4'-[(dibenzylamino)methyl]-1,1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.46 minutes; MS: 408 (M+H)+. - 4'-{[benzyl(2-phenylethyl)amino]methyl}-1, l'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.51 minutes; MS: 422 (M+H)+. - 4'-{[benzyl(3-phenylpropyl)amino]methyl}-1, 1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.56 minutes; MS: 436 (M+H)+. - 4'-{[benzyl(butyl)amino]methyl}-1,1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.4 minutes; MS: 374 (M+H)+. - 4'-{[(4-chlorobenzyl)(2-phenylethyl)amino]methyl}-1,1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.61 minutes; MS: 456 (M+H)+. - 4'-{[(4-chlorobenzyl)(3-phenylpropyl)amino]methyl}-1, 1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.66 minutes; MS: 470 (M+H)+. - 4'-{[(4-chlorobenzyl)(2-methoxyethyl)amino]methyl}-1,1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.39 minutes; MS: 410 (M+H)+. - 4'-{[butyl(4-chlorobenzyl)amino]methyl}-1,1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.51 minutes; MS: 408 (M+H)+. - 4'-{[(4-methoxybenzyl)(2-phenylethyl)amino]methyl}-1, 1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.52 minutes; MS: 452 (M+H)+. - 4'-{[(4-methoxybenzyl)(3-phenylpropyl)amino]methyl}-1, 1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time; 3.58 minutes; MS: 466 (M+H)+. - 4'- {[(4-cyanobenzyl)(2-phenylethyl)amino]methyl}-1, 1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.46 minutes; MS: 447 (M+H)+. - 4'-{[(4-cyanobenzyl)(3-phenylpropyl)amino]methyl}-1,1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.53 minutes; MS: 461 (M+H)+. - 4'-{[butyl(4-cyanobenzyl)amino]methyl}-1,1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.35 minutes; MS: 399 (M+H)+. - 4'-{[benzyl(3-phenylpropyl)amino]methyl}-1,1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.55 minutes; MS: 435 (M+H)+. - 4'-{[(2-phenylethyl)(3-phenylpropyl)amino]methyl}-1,1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.64 minutes; MS: 450 (M+H)+. - 4'-{[bis(3-phenylpropyl)amino]methyl}-1,1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.69 minutes; MS: 464 (M+H)+. - 4'-{[(3-phenylpropyl)(1-propylbutyl)amino]methyl}-1,1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.75 minutes; MS: 444 (M+H)+. - 4'- {[benzyl(cyclohexylmethyl)amino]methyl}-1,1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.57 minutes; MS: 414 (M+H)+. - 4'-{[(cyclohexylmethyl)(2-phenylethyl)amino]methyl}-1, 1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.63 minutes; MS: 428 (M+H)+. - 4'-{[butyl(cyclohexylmethyl)amino]methyl}-1,1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.52 minutes; MS: 380 (M+H)+. - 4'- {[benzyl(pentyl)amino]methyl}-1,1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.49 minutes; MS: 388 (M+H)+. - 4'-{[pentyl(2-phenylethyl)amino]methyl}-1,1'-biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.59 minutes; MS: 402 (M+H)+. - 4'-{[(3-phenylpropyl)(pyridin-2-ylmethyl)amino]methyl}-1,1'- biphenyl-4-carboxylic acid trifluoroacetate
HPLC retention time: 3.46 minutes; MS: 437 (M+H)+. - 2, 2-azobisisobutyronitrile(6.91g) and N-bromosuccinimide (302mg) were added to methyl 4'-methlbiphenyl-2-carboxylate(8.78g) in carbon tetrachloride(500mL) solution. The mixture was refluxed for 6 hours under argon gas and filtered after being cooled to room temperature, and then concentrated. The titled compound(9.30g) having the following physical data was obtained by purifying the obtained residue by silica gel column chromatography(ethyl acetate:hexane=1:5).
TLC: Rf 0.59 (ethyl acetate:hexane=1:4);
NMR (CDCl3): δ 7.89-7.82 (m, 1H), 7.63-7.26 (m, 7H), 4.55 (s, 2H), 3.65 (s, 2H). - 2-nitropropane (3.56g) was added to a solution that sodium (85mg) was added to ethanol (50mL) little by little. Further, the compound (8.40g) prepared in Example 3 in ethanol solution (10mL) was added and stirred for 4 hours at 70°C. The reaction mixture was concentrated and extracted with ethyl acetate after adding water. The extract was sequentially washed with 1 mol/L sodium hydroxide solution and saturated brine and dried by anhydrous sodium sulfate, and then concentrated. The titled compound (5.02g) having the following physical data was obtained by purifying the obtained residue by silica gel column chromatography (ethyl acetate:hexane= 1:5).
TLC: Rf 0.50 (ethyl acetate:hexane=1:2);
NMR (CDCl3) : δ 10.07 (s, 1H), 7.96-7.89 (m, 3H), 7.63-7.34 (m, 5H), 3.66 (s, 3H). - Benzylamine(128mg) was added to the compound(120mg) prepared in Example 4 in methanol solution (3mL) and stirred for 4 hours at room temperature. Cyano sodium borohydride (62mg) was added to the reaction mixture and then acetic acid was dropped until pH.5.5 and stirred for 1 hour at room temperature. The reaction mixture was concentrated and alkalinized with 5mo1/L sodium hydroxide solution, and then extracted with ethyl acetate. The organic layer was washed with saturated brine and dried by anhydrous sodium sulfate, and then concentrated. The titled compound (94mg) having the following physical data was obtained by purifying the obtained residue by silica gel column chromatography (chloroform:hexane=30:1).
TLC: Rf 0.51 (chloroform:methanol=9:1);
NMR (CDCl3): δ 7.85-7.79 (m, 1H), 7.58-7.22 (m, 12H), 3.87 (s, 2H), 3.86 (s, 2H), 3.65 (s, 3H). - Pentanoyl chloride (62µL) was added to the compound (85mg) prepared in Example 5 in pyridine solution (2mL) and stirred for 1.5 hours at room temperature. Further, water was added to the reaction mixture and extracted with ethyl acetate. The extract was sequentially washed with 1 mol/L hydrochloric acid, saturated sodium hydrogencarbonate solution and saturated brine and dried by anhydrous sodium sulfate, and then concentrated. The titled compound (101mg) having the following physical data was obtained by purifying the obtained residue by silica gel column chromatography (ethyl acetate:hexane=1:2).
TLC: Rf 0.55 (ethyl acetate:hexane=1:2);
NMR (CDCl3) : δ 7.89-7.80 (m, 1H), 7.60-7.16 (m, 12H), 4.65 (s, 2H), 4.50 (s, 2H), 3.68 and 3.66 (s, 3H), 2.50-2.40 (m, 2H), 1.80-1.64 (m, 2H), 1.48-1.26 (m, 2H), 0.96-0.87 (m, 3H). -
- 5 mol/L sodium hydroxide solution (0.3mL) was added to the compound (45mg) prepared in Example 6 in a mixed solution of dioxane (2mL) and methanol (1mL) and stirred for 2 hours at 80°C. To acidify, 1mol/L hydrochloric acid was added to the concentrated reaction mixture to be extracted with ethyl acetate. The organic layer was washed with saturated sodium and dried by anhydrous sodium sulfate, and then concentrated to obtain the titled compound (37mg) having the following physical data.
TLC: Rf 0.59 (chloroform:methanol=9:1);
NMR (CDCl3: δ 7.98-7.91 (m, 1H), 7.61-7,52 (m, 1H), 7.47-7.14 (m, 11H), 4.62 (s, 2H), 4.48 and 4.49 (s, 2H), 2.47-2.40 (m, 2H), 1.75-1.64 (m, 2H), 1.43-1.28 (m, 2H), 0.90 (t, J = 7.2 Hz, 3H). - Phenylamine (56mg) was added to the compound (120mg) prepared in Example 4 in methanol solution (3mL) and stirred for 4 hours at room temperature. The reaction mixture was added to sodium borohydride(37mg) and stirred for 1.5 hours. To alkalinize, 5 mol/L sodium hydroxide solution was added to the concentrated reaction mixture and then extracted with ethyl acetate. The organic layer was washed with saturated sodium and dried by anhydrous sodium sulfate, and then concentrated to obtain the titled compound (124mg) having the following physical data by purifying the obtained residue by silica gel column chromatography(diethyl ether:hexane=1:2). TLC: Rf 0.42 (ethyl acetate:hexane =1:4);
NMR (CDC13): δ 7.86-7.80 (m, 1H), 7.58-7.14 (m, 9H), 6.78-6.64 (m, 3H), 4.38 (s, 2H), 4.20-4.00 (br, 1H), 3.65 (s, 3H). -
- The titled compound having the following physical data was obtained by the same procedures as a series of Example 6 and Example 7 using the compound prepared in Example 8.
TLC: Rf 0.59 (chloroform:methanol =9:1);
NMR (CDC13): δ7.92 (dd, J = 7.6, 1.2 Hz, 1H), 7.60-7.51 (m, 1H), 7.46-7.16 (m, 9H), 7.00-6.93 (m, 2H), 4.90 (s, 2H), 2.06 (t, J = 7.6 Hz, 2H), 1.65-1.49 (m, 2H), 1.30-1.10 (m, 2H), 0.79 (t, J = 7.3 Hz, 3H). - Sodium borohydride (111mg) was added to the compound (400mg) prepared in Example 4 in methanol solution (10mL) and stirred for 1 hour at room temperature. The reaction mixture was concentrated and extracted with 1mol/L hydrochloric acid and ethyl acetate. The organic layer was washed with saturated sodium and dried by anhydrous sodium sulfate, and then concentrated to obtain the titled compound (400mg) having the following physical data.
TLC: Rf 0.33 (ethyl acetate:hexane =1:1);
NMR (CDCl3): δ 7.86-7.80 (m, 1H), 7.60-7.26 (m, 7H), 4.75 (s, 2H), 3.67 (s, 3H). - Sodium azide (650mg), triphenylphosphine (935mg) and carbon tetrabromide(1.18g) was added to the compound (345mg) prepared in Example 10 in N, N-dimethylformamide (15mL) solution and stirred for 2 hours at room temperature. Water was added to the reaction mixture, which was extracted with ethyl acetate. It was washed with saturated sodium and dried by anhydrous sodium sulfate, and then concentrated to the titled compound (380mg) having the following physical data by purifying the obtained residue by silica gel column chromatography (ethyl acetate:hexane=1:6).
TLC: Rf 0.53 (ethyl acetate:hexane =1:4);
NMR (CDCl3): δ 7.86 (dd, J = 7.7, 1.5 Hz, 1H), 7.60-7.30 (m, 7H), 4.40 (s, 2H), 3.64 (s, 3H). - 10% palladium-carbon (180mg) was added to the compound (370mg) prepared in Example 11 in methanol (6mL) solution and stirred overnight under hydrogen atmosphere at room temperature. The reaction mixture was substituted with argon gas and filtered with celite (trade name), and then concentrated. 4mol/L hydrochloric acid in ethyl acetate solution (1mL) was added to the obtained residue that was dissolved to ethyl acetate (10mL) and stirred, and then concentrated to obtain the titled compound (380mg) having the following physical data by washing the obtained residue with ethyl acetate and hexane.
NMR (CDCl3) : δ 8.40-8.10 (brs, 3H), 7.76 (dd, J = 7.6, 1.4 Hz, 1H), 7.68-7.59 (m, 1H), 7.55-7.31 (m, 6H), 4.14-4.02 (m, 2H), 3.61 (s, 3H). -
- The titled compound having the following physical data was obtained by the same procedures as a series of Example 6 and Example 7 using the compound prepared by Example 12 instead of the compound prepared by Example 5 and using phenylacetyl chloride instead of pentanoyl chloride.
TLC: Rf 0.57 (chlorofom methanol =8:2);
NMR (CDC13) : δ 7.94 (dd, J = 1.2, 7.6 Hz, 1H), 7.60-7.14 (m, 12H), 5.91-5.80 (br, 1H), 4.43 (d, J = 6.0 Hz, 2H), 3.63 (s, 2H). - The following experiments proved that the compound of the present invention has BLT2 binding activity and that BLT2 expresses in keratinocytes, and the function.
- All processes are based on basic and genetic engineering techniques, e.g., the preparation of gene high-expressing cells and routine procedures. Further, the measurement accuracy and/or snesitomety of the measuring method of the present invention were improved to evaluate the compound of the present invention as follows. The detailed experimental methods were shown as fallows.
- The receptor antagonist activity was evaluated by using human BLT2 gene-overexressing Chinese Hamster Ovar (CHO) cells (see J.Exp.Med. Volume 192, Number 3 2000, and 421-.). BLT2-expressing cells were cultured in Ham's F1 medium (GIBCO BRL and No. 11765-047) containing 10% FBS (fetal bovine serum), penicillin/streptomycin and blasticidin (5 µg/ml). First, to make the cells to take Fura2-AM (Dojindo and No.348-05831), the cells were incubated in 5µM Fura2-AM solution (Ham's F1 medium containing 10% FBS, 20mM HEPES buffer(pH7.4) and 2.5mM probenecid (Sigma and No. P-8761)) at 37°C for 60 minutes. Then, the cells were washed once with Hanks solution containing 20mM HEPES buffer (pH7.4) and 2.5mM probenecid, and soaked in Hanks solution until assay. The plate was sat up on fluorescent drug screening system (Hamamatsu Photonics FDSS-2000) and measured without any stimulation for 30 seconds, to which the compound solution of the present invention was added. LTB4 (final concentration: 3µM) was added to the plates 3 minutes later, of which the intracellular calcium ion concentration around the addition were measured at 3 seconds intervals (excitation wavelength 340nm, 380nm and fluorescent wave-length 500nm). The compound of the present invention was dissolved to dimethylsulfoxide (DMSO) and added in order that the final concentration is 1nM-10µM. BLT2 antagonistic activity was calculated by being compared the difference a value before addition of LTB4 and a value after the addition in cells processed with the compound with a peak value of LTB4 in a well containing DMSO as control value (A) (Inhibition ratio (%) = {(A-B)/A} × 100). IC50 value is a concentration of the compound of the present invention in which the inhibition ratio is 50%. Also, BLT1 antagonistic activity was measured by the same way. For example, IC50 value for BLT2 of the compound prepared in Example 1(32) is 1.8µM and the compound did not have BLT1 antagonistic activity.
- The compound of the present invention (final concentration: 1-10µM, dimethylsulfoxide(DMSO)) was added 3 minutes later, and the intracellular calcium ion concentrations around addition of LTB4 were measured at 3 seconds intervals (excitation wavelength 340nm, 380nm and fluorescent wave-length 500nm). BLT2 agonistic activity was calculated by being compared a rising value (D) of fluorescent ratio after addition of a subject compound from a value before addition with a peak value of LTB4 stimulation in a well containing DMSO instead of a subject compound as control value (C) (a rate of increase of intracellular Ca2+ concentration (%) = (D/C) × 100). The EC50 value was calculated by calculating the rate of increase in each concentration of the compound. Also, BLT1 antagonistic activity was measured by the same way. For example, IC50 value for BLT2 of the compound prepared in Example 13 is 0.045µM and the compound did not have BLT1 agonistic activity.
- mBLT2 ORF was amplified by PCR using a sense primer having BamHI restriction enzyme site (sense primer; 5'-CGGGATCCCGCATGTCTGTCTGCTACCGTC-3' (SEQ ID N0.1)) and an antisense primer having EcoRI restriction enzyme site(antisense primer; 5'-CGGAATTCTACCATTCTTGACTGTCTT-3 (SEQ ID N0.2)). The PCR product was digested with BamHI and EcoRI and inserted in expression plasmid (pcDNA3 Invitrogen). The inserted sequence was confirmed by the DNA sequence. Plasmid DNA (3µg) was transfected into CHO cells cultured in Ham's F-12 medium containing 10% fetal bovine serum and antibiotic (streptomycin (100µg/mL) and penicillin (100µg/mL)) in cell culture plates (6cm). The resistant strains were obtained by culturing for 2 weeks in the existence of antibiotic (G418 [Wako], 1mg/mL). The stable expressing strains were obtained by culturing 19 obtained resistant strains with limiting dilution method.
- Each mouse tissue BLT2 mRNA was northern-blotted to explore the expression pattern. First, total RNA of mouse tissue (C57B1/6J Jcl [Japan clea]) was extracted using RNA extraction reagent (Isogen [Wako]). Also, mouse peritoneal macrophages were collected 4 days later by injecting thioglycolate (4.05 w/v %, 2mL) into mouse peritoneal cavity. Mouse neutrophils were collected 7 hours later by injecting casein (2.0 w/v %, 2mL) into mouse peritoneal cavity. Poly(A)+ RNA was separated from total RNA(200µg) with mRNA extraction kit (µMACS mRNA isolation kit [Miltenyi Biotec]). Mouse tissue mRNA(5µg), total RNA(10µg) of macrophages and neutrophils was degenerated and transfered nylon membrane filter (Hybond N+ [Amersham Biosciences]) after 0.7% formaldehyde agarose gel electrophoresis. 32P-dCTP-labeled mBLT2 or glyceraldehydes-3-phosphate dehydrogenase(g.3PDH) ORF was hybridized for 2 hours at 65°C and washed with 2xSSC and 0.1% SDS. Then, it was washed for 20 minutes(at 65°C) with 0.2xSSC, 0.1% SDS and 1 hour(at 68°C) with 0.1XSSC, 0.1% SDS. Then, it was washed for 20 minutes (at 65°C) with 0.2XSSC and 0.1% SDS, and 1 hour (at 68°C) with 0.1XSSC and 0.1% SDS. It was autoradiographied for 7 days.
- The result of northern analysis revealed that mBLT2 mRNA was expressed in small intestine and skin. The main transcript was 1.5kb and 6.7kb. Figure 1 shows the result.
- Quantitative real-time RT-PCR was carried out to measure the expression of BLT2 mRNA in each mouse tissue. First, cDNA was synthesized (Superscript II [Invitrogen]) from mouse tissue mRNA(50ng), total RNA(50ng) of macrophages and neutrophils, and diluted 100 times with distilled water. Then, the cDNA was amplified in 20µL microcapillary as PCR solution containing diluted cDNA(5µL), 1xFastStart DNA Master SYBR Green I(Roche; Molecular Biochemicals), MgCl2(final concentration 4mM) and primers(0.5µM) by PCR (LightCyclerSystem[Roche Molecular Biochemicals]). Also, pCXN2-mBLT2 and pcDNA3.1 (containing mG3PDH cDNA) were used as controls and the following were used as a primer; mBLT2 820+, 5'-ACAGCCTTGGCTTTCTTCAG-3' (SEQ ID N0.3); mBLT2 1013-, 5'-TGCCCCATTACTTTCAGCTT-3' (SEQ ID NO.4); GAPDH-1013+, GTGGACCTCATGGCCTACAT-5'(SEQ ID NO.5); GAPDH-1226-, 5'-GGGTGCAGCGAACTTTATTG-3' (SEQ ID NO.6). Using the attached analytical software for LightCycler after PCR, each mRNA amount of BLT2 and G3PDH was calculated based on the signal and frequency of SYBR Green I as indicators.
- As the result of correcting the mRNA amount of BLT2 with the mRNA amount of G3PDH, it was revealed that BLT2 mRNA was extremely high-expressed in small intestine and secondary-expressed in skin, and low-expressed in large intestine and spleen. Figure 2 shows the result.
- Paraffin sections of mouse (C57B1/6J Jc1 [Japan clea]) skin sample were fixed by 10% formalin containing PBS, of which BLT2 mRNA expressions were observed by non-radioactive in situ hybridization. First, the paraffin-embedded mouse tissues were cut into 4µm thickness and mounted on silane coated glass, and deparaffinized. Afterwards, the samples were prepared by being processed by proteinase K (5 µg/mL in PBS) (for 10 minutes at room temperature) and being processed by glycine (2mg/mL in PBS) (for 15 minutes at room temperature.). The samples were acetylated in acetic anhydride (1mL in 400mL of 0.1M triethanolamine, pH8.0) for 15 minutes at room temperature and washed with PBS and soaked in 50% formamide containing 2×SSC, and then hybridized. mBLT2 ORF fragment (741-941) was amplified by PCR using a downstream primer containing HindIII restriction enzyme site and an upstream primer containing EcoRI restriction enzyme site and inserted into vector (pSPT18) by directional cloning system. An antisense probe was prepared by digesting them with HindIII and a sense probe was prepared by digesting them with EcoRI. These probes were digoxigenin-11-UTP-labeled with DIG RNA labeling kit (Roche Molecular Biochemicals). They were hybridized under humidification for 16 hours at 42°C. The samples were washed 3 times using 50% formamide containing 2×SSC for 20 minutes at 42°C. Non-hybridized probes were digested by enzyme (RNaseA(20µ g/mL) in NaCl(500mM), EDTA(1mM) and Tris-HCl(10mM, pH8.0)) for 30 minutes at 37°C. Further, the samples were visualized by digoxigenin-labeled probes prepared according to the attached manual using DIG nucleic acid detection kit (Roche Mollecular Biochemical). And, they were counterstained by methyl green.
- Figure 3 shows the result of In Situ hybridization. A, C and E show the result of hybridization with mBLT2 antisense probes and B, D and F show the result of hybridization with sense control probes (Magnification: A, B=140 times; C, D=240 times; E, F=430 times). These results revealed that mBLT2 is expressed in hair epidermal hair follicle keratinocytes and folicle keratinocyte.
- mBLT2-expressing CHO cells prepared by Biological Example 3 were cultured in modified Hepes-Tyrode's BSA buffer (Hepes-NaOH(25mM, pH7.4), NaCl(140mM), KCl(2.7mM), CaCl2(1.0mM), NaHCO3(12mM), D-Glucose(5.6mM), NaH2PO4(0.37mM), MgCl2(0.49mM), cremophour(0.01%), fatty acid-free BSA(fraction V, 0.1w/v%)) containing fluorochrome (Fura-2 AM [Dojin], 3µm) at 37°C for 2 hours to make to take fluorochrome. These cells were washed 2 times and resuspended (106cells/mL) in Hepes-Tyrode's BSA buffer. The cell suspension (0.5mL) was applied to fluorescent intensity meter (CAF-100 system [Jasco]). Dimethylsulfoxide (DMSO) solution (5µL) containing ligand was added to the cell suspension, of which the intracellular calcium concentration was monitored (excitation wavelength 340nm and 380nm and fluorescent wave-length 510nm).
- Figure 4 shows a graph of the rise of the intracellular calcium concentration using the compound prepared in Example 9 as a ligand (hereafter, it is abbreviated to compound A). Compound A (filed triangle) indicated EC50 value (compound A: 21nM; LTB4: 121nM) lower than that of LTB4(filed Diamond). The intracellular calcium concentration was not rised though compound A was added to mBLT1-expressing CHO cells (opened triangle) and mock(opened square).
- 4 weeks mouse (C57B1/6J Jcl [Japan clea]) skin sections were soaked at 4°C overnight in dispase solution (250PU/mL dispase in PBS). The epidermals were flaked off from the dermis and separated for 5 minutes using 0.05% trypsin-EDTA. Trypsin was inerted in 10% MEM medium (Sigma). After centrifugal separation, the cells were suspended to Defined keratinocyte-SFM medium containing E.G.F (10ng/mL) and cholera toxin (10pM).
- mBLT2-expressing CHO cells prepared in Biological Example 3 were cultured in 12 well-culture plate at cell density of 2.0×105 cell/well. The cells were transfered to F-12 medium containing 0.1% BSA 2 days later and cultured without serum for 12 hours. The cells were preincubated in F..12 medium containing 0.1% BSA for 10 minutes and exposed to various concentrations of ligand for 5 minutes. After removing the medium, the cells were digested by lysis buffer (Tris-HCl(20mM), β-glycerophosphate(50mM), EGTA(5mM), Na3VO3(1mM), DTT(2mM), PMSF(1µ M), NP-40(1%), 250µ L) and frozen at -80°C. After melting, they were dissolved by passing through 27
gauge needle 10 times. The cell lysate was heat-denatured for 10 minutes at 100 °C and transfered to nitrocellulose membrane(Hybond ECL) using semi-dry transfer cell (SEMI-DRY TRANSFER CELL [Bio-Rad]) after 12% acrylamide SDS-PAGE. The membrane was blocked at 4°C overnight using blocking liquid(Tween 20(0.1v/v%), tris-buffered saline containing skim milk(0. Iw/v% for ERK; 5w/v% for phospho-ERK)), Then, the membrane was incubated in blocking buffer containing 1000 times diluted primary antibody(anti-phospho-ERK antidbody(phospho-p44/p42 MAPK(Thr202/tyr204) antibody[Cell Signaling TECHNOLOGY]) and anti-ERK antibody(p44/p42 MAP Kinase Antibody[Cell Signaling TECHNOLOGY])) for 2 hours and reacted with 2000 times diluted second HRP-labeled antibody and then detected using ECL system(Amersham). - Figure 5 shows ERK phosphorylation when mBLT2-expressing CHO cells and mBLT1-expressing CHO cells were stimulated with LTB4 or compound A (upper row: mBLT2-expressing CHO cells; lower row: mBLT1-expressing CHO cells). ERK phosphorylations in mBLT2-expressing CHO cells and mBLT1-expressing CHO cells were induced by LTB4 and compound A. ERK phosphorylation in BLT1-expressing CHO cells was induced by compound A.
- The cells prepared in Biological Example 8 were cultured in chamber slide and fixed by fixative (methanol:acetone=1: 1). They were washed with PBS and blocked in PBS containing 10% goat serum and 3% BSA. Then, the specimens were dyed using antibody to mouse keratin 5(mouse keratin 5[Covance Research Products]) (1µg/mL) and second fluorescent-labeled antibody(Alexa Fluor R546 anti-rabbit IgG[Molecular probes], 10µg/mL) and observed with fluorescence microscope.
- Most cells prepared from mouse was mouse keratin 5-positive. Therefore, the result revealed that these cells are keratinocytes. Figure 6 shows the result.
- The primary culture keratinocytes prepared in Biological Example 8 were cultured in 12-well culture plate at cell density of 4.0 × 105 cell/well. They were transfered to Defined keratinocyte SFM medium (GibcoBRL) 1 day later from culture and cultured without serum for 12 hours. The cells were preincubated for 10 minutes in Defined keratinocyte SFM medium containing 0.1%BSA and stimulated as well as Biological Example 9, of which ERK phosphorylation was observed.
- Figure 7 shows ERK phosphorylation when mouse primary culture keratinocytes were stimulated with LTB4 or compound A. LTB4 and compound A induced ERK phosphorylation of mouse primary culture keratinocytes.
- 4'-{[pentanoyl(phenyl)amino]methyl}-1, 1'-biphenyl-2-carboxylic acid (100g), carboxymethylcellulose calcium, magnesium stearate and microcrystalline cellulose were admixed in conventional method and punched out to obtain 10,000 tablets each containing 10 mg of the active ingredient.
- 4'-{[pentanoyl(phenyl)amino]methyl}-1,1'-biphenyl-2-carboxylic acid, mannitol (2kg) and distilled water (50L) were admixed in a conventional method and filtered with dust removal filter and placed at 5 mL into ampoules. The ampoules were heat-sterilized by autoclave to thereby obtain 10,000 ampoules each containing 20 mg of the active ingredient.
- Since BLT2 is highly expressed in keratinocyte, a compound with BLT2 binding activity, salt thereof, solvate thereof or prodrug thereof is useful for prevention and/or therapy for skin disease. The compound represented in formula (I), salt thereof, solvate thereof or prodrug thereof is useful for prevention and/or therapy of BLT2 mediated diseases, e.g., dermatosis, intestinal disease, HIV infection, acquired immunodeficiency syndrome, rejection to transplant, transplant rejection, graft-versus-host disease, autoimmune disease, allergic disease, inflammation, infection, ulcers, lymphoma, malignant tumor, leucaemia, arterial sclerosis, hepatitis, hepatic cirrhosis or cancer, etc.
Claims (19)
- An agent for the prevention and/or treatment of skin diseases, which comprises a compound with BLT2 binding activity, a salt thereof, a solvate thereof or a prodrug thereof.
- The agent according to claim 1, wherein the compound with BLT2 binding activity is a compound with agonistic action on BLT2.
- The agent according to claim 1, wherein the compound with BLT2 binding activity is a compound with antagonistic action on BLT2.
- The agent according to claim 1, wherein the skin disease is psoriasis, eczema, skin cancer, keratosis, dyspigmentation or psilosis.
- The agent according to claim 1, wherein the compound with BLT2 binding activity is a compound represented by the formula (1)
X represents an acidic group,
Y represents a bond or a spacer in which the number of atom in the principal chain is one to three, and
E represents an amino group which may be substituted. - The agent according to claim 5, wherein the compound with BLT2 binding activity is a compound represented by the formula (I-1)
R1 and R2 each independently represent a hydrogen atom or a hydrocarbon group which may be substituted. - A pharmaceutical composition comprising a compound with BLT2 binding activity, a salt thereof, a solvate thereof or a prodrug thereof; in combination with one or more kinds of drugs selected from immunosuppressant, antibiotic, antihistaminic and drenocortical steroid.
- The agent according to claim 8, wherein the BLT2 binding agent is an agonist for BLT2.
- The agent according to claim 8, wherein the BLT2 binding agent is an antagonist for BLT2.
- The agent according to claim 8, which is an agent for the prevention and/or treatment of BLT2-mediated diseases.
- The agent according to claim 11, wherein the BLT2-mediated disease is rejection to transplant, transplant rejection, graft-versus-host disease, autoimmune disease, allergic disease, inflammation, infectious disease, ulcus, lymphoma, carcinoma, leukosis, arteriosclerotic, hepatitis, liver cirrhosis or cancer.
- The agent according to claim 11, wherein the BLT2-mediated disease is intestinal disease or human immunodeficiency virus infection.
- A pharmaceutical composition comprising the compound represented by the formula (I) according to claim 8, a salt thereof, a solvate thereof or a prodrug thereof; in combination with one or more kinds of drugs selected from nonsteroidal antiinflammatory drug, disease-modifying antirheumatic drug, drenocortical steroid, immunosuppressant, antiinflammatory enzyme drug, cartilage protective drug, T lymphocyte inhibitor, TNF-α inhibitor, prostaglandin synthase inhibitor, IL-6 inhibitor, interferon γ agonist, IL-1 inhibitor, EDG-1 agonist, EDG-6 agonist, prostaglandins, phosphodiesterase inhibitor, metalloproteinase inhibitor and chemokine receptor antagonist.
- A method for the prevention and/or treatment of skin diseases in mammal, which comprises administrating to a mammal an effective amount of a compound with BLT2 binding activity, a salt thereof, a solvate thereof or a prodrug thereof.
- Use of a compound with BLT2 binding activity, a salt thereof, a solvate thereof or a prodrug thereof for the manufacture of an agent for the prevention and/or treatment of skin diseases.
- A method for the prevention and/or treatment of BLT2-mediated diseases in mammal, which comprises administrating to a mammal an effective amount of a compound represented by the formula (I)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10150486A EP2172222A3 (en) | 2004-04-26 | 2005-04-25 | Novel BLT2-mediated disease, BLT2-binding agent and compound |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004129638 | 2004-04-26 | ||
JP2004219533 | 2004-07-28 | ||
PCT/JP2005/007765 WO2005102388A1 (en) | 2004-04-26 | 2005-04-25 | Novel blt2-mediated disease, and blt2 binding agent and compound |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1745800A1 true EP1745800A1 (en) | 2007-01-24 |
EP1745800A4 EP1745800A4 (en) | 2009-11-18 |
Family
ID=35196742
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05734600A Withdrawn EP1745800A4 (en) | 2004-04-26 | 2005-04-25 | Novel blt2-mediated disease, and blt2 binding agent and compound |
EP10150486A Withdrawn EP2172222A3 (en) | 2004-04-26 | 2005-04-25 | Novel BLT2-mediated disease, BLT2-binding agent and compound |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10150486A Withdrawn EP2172222A3 (en) | 2004-04-26 | 2005-04-25 | Novel BLT2-mediated disease, BLT2-binding agent and compound |
Country Status (4)
Country | Link |
---|---|
US (1) | US8673889B2 (en) |
EP (2) | EP1745800A4 (en) |
JP (1) | JP4793692B2 (en) |
WO (1) | WO2005102388A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008117970A1 (en) * | 2007-03-23 | 2008-10-02 | Korea University Industrial & Academic Collaboration Foundation | Use of inhibitors of leukotriene b4 receptor blt2 for treating human cancers |
WO2009009041A2 (en) * | 2007-07-06 | 2009-01-15 | Kinex Pharmaceuticals, Llc | Compositions and methods for modulating a kinase cascade |
US8518889B2 (en) | 2007-03-23 | 2013-08-27 | Korea University Research & Business Foundation | Method of treating cancer with antibodies against long-form leukotriene B4 receptor BLT2 |
WO2014008214A1 (en) * | 2012-07-02 | 2014-01-09 | Biogen Idec Ma Inc. | Biaryl-containing compounds as inverse agonists of ror-gamma receptors |
US9522873B2 (en) * | 2011-08-05 | 2016-12-20 | Dongguk University Industry-Academic Cooperation Foundation | Biphenyl derivative, pharmaceutically acceptable salt thereof, and methods for preventing or treating inflammatory diseases or autoimmune diseases |
US9926273B2 (en) | 2012-08-30 | 2018-03-27 | Athenex, Inc. | Composition and methods for modulating a kinase cascade |
CN108349875A (en) * | 2015-07-24 | 2018-07-31 | 东国大学校产学协力团 | Compounds with BLT inhibitory activity and include its composition for preventing or treating diseases associated with inflammation as active constituent |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7745477B2 (en) | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
JP2008031079A (en) * | 2006-07-28 | 2008-02-14 | Sigma Soyaku Kk | Medicine for suppressing symptom accompanying with pollinosis |
US7750027B2 (en) * | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
EP3017813A1 (en) | 2014-11-04 | 2016-05-11 | Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. | BLT2 agonists for the treatment of pain |
WO2017018751A1 (en) * | 2015-07-24 | 2017-02-02 | 동국대학교 산학협력단 | Novel compound having blt inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient |
CN105294458B (en) * | 2015-11-17 | 2017-07-11 | 中国人民解放军第四军医大学 | A kind of anti-tumor small molecular compound and its preparation method and application |
US10385007B2 (en) * | 2016-12-09 | 2019-08-20 | Celtaxsys, Inc. | Monamine and monoamine derivatives as inhibitors of leukotriene A4 hydrolase |
TWI683808B (en) | 2017-07-18 | 2020-02-01 | 德商菲尼克斯 Fxr有限責任公司 | Amine or (thio)amide containing lxr modulators |
JP6853406B1 (en) * | 2020-10-05 | 2021-03-31 | 昌也 片山 | Topical composition for antifolliculitis |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060875A1 (en) * | 2001-01-31 | 2002-08-08 | Pfizer Products Inc. | Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes |
WO2002060898A1 (en) * | 2001-01-31 | 2002-08-08 | Pfizer Products Inc. | Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes |
EP1270589A1 (en) * | 2000-03-21 | 2003-01-02 | Yamanouchi Pharmaceutical Co. Ltd. | Novel leukotriene b4 receptor |
US20040034064A1 (en) * | 2002-08-06 | 2004-02-19 | Kuduk Scott D. | 2-(biarylalkyl)amino-3-(alkanoylamino)pyridine derivatives |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3551414A (en) * | 1969-05-16 | 1970-12-29 | United States Steel Corp | 6,7-dihydro-5h-dibenz(c,e)azepin-7-ones |
DE122007000050I1 (en) | 1990-02-19 | 2007-11-08 | Novartis Ag | acyl compounds |
WO1996021456A1 (en) * | 1995-01-12 | 1996-07-18 | University Of Pittsburgh | Inhibitors of prenyl transferases |
CA2246356A1 (en) | 1996-02-13 | 1997-08-21 | G.D. Searle & Co. | Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist |
US5789441A (en) | 1996-02-15 | 1998-08-04 | Virocell Inc. | Leukotriene B4 as an antiviral and anti-neoplastic agent |
JP4926310B2 (en) | 1996-02-15 | 2012-05-09 | エルテーベー4・スウェーデン・アクチェボラーグ | Use of leukotriene B4 or analogs thereof as antiviral and antitumor agents |
US6228985B1 (en) * | 1998-05-21 | 2001-05-08 | Schering Corporation | Derivatives of aminobenzoic and aminobiphenylcarboxylic acids useful as anti-cancer agents |
WO2001034134A2 (en) | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
US6436987B1 (en) | 2000-06-08 | 2002-08-20 | Pfizer Inc. | Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid |
NZ526003A (en) * | 2000-10-20 | 2005-09-30 | Biocryst Pharm Inc | Biaryl compounds as serine protease inhibitors |
JPWO2002098840A1 (en) * | 2001-06-04 | 2004-09-16 | エーザイ株式会社 | Pharmaceuticals comprising carboxylic acid derivatives and their salts or esters |
EP1550461A1 (en) * | 2002-06-26 | 2005-07-06 | Ono Pharmaceutical Co., Ltd. | Remedy for chronic disease |
TW200408393A (en) | 2002-10-03 | 2004-06-01 | Ono Pharmaceutical Co | Antagonist of lysophosphatidine acid receptor |
JP2004182657A (en) * | 2002-12-04 | 2004-07-02 | Eisai Co Ltd | Agent for promoting elevation of hdl level |
BRPI0417543A (en) * | 2003-12-12 | 2007-03-27 | Wyeth Corp | quinolines useful in treating cardiovascular disease |
-
2005
- 2005-04-25 JP JP2006512614A patent/JP4793692B2/en not_active Expired - Fee Related
- 2005-04-25 EP EP05734600A patent/EP1745800A4/en not_active Withdrawn
- 2005-04-25 US US11/587,664 patent/US8673889B2/en not_active Expired - Fee Related
- 2005-04-25 WO PCT/JP2005/007765 patent/WO2005102388A1/en not_active Application Discontinuation
- 2005-04-25 EP EP10150486A patent/EP2172222A3/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1270589A1 (en) * | 2000-03-21 | 2003-01-02 | Yamanouchi Pharmaceutical Co. Ltd. | Novel leukotriene b4 receptor |
WO2002060875A1 (en) * | 2001-01-31 | 2002-08-08 | Pfizer Products Inc. | Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes |
WO2002060898A1 (en) * | 2001-01-31 | 2002-08-08 | Pfizer Products Inc. | Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes |
US20040034064A1 (en) * | 2002-08-06 | 2004-02-19 | Kuduk Scott D. | 2-(biarylalkyl)amino-3-(alkanoylamino)pyridine derivatives |
Non-Patent Citations (1)
Title |
---|
See also references of WO2005102388A1 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008117970A1 (en) * | 2007-03-23 | 2008-10-02 | Korea University Industrial & Academic Collaboration Foundation | Use of inhibitors of leukotriene b4 receptor blt2 for treating human cancers |
US8288357B2 (en) | 2007-03-23 | 2012-10-16 | Korea University Research & Business Foundation | Use of inhibitors of leukotriene B4 receptor BLT2 for treating human cancers |
US8518889B2 (en) | 2007-03-23 | 2013-08-27 | Korea University Research & Business Foundation | Method of treating cancer with antibodies against long-form leukotriene B4 receptor BLT2 |
WO2009009041A2 (en) * | 2007-07-06 | 2009-01-15 | Kinex Pharmaceuticals, Llc | Compositions and methods for modulating a kinase cascade |
WO2009009041A3 (en) * | 2007-07-06 | 2009-05-07 | Kinex Pharmaceuticals Llc | Compositions and methods for modulating a kinase cascade |
US8124605B2 (en) | 2007-07-06 | 2012-02-28 | Kinex Pharmaceuticals, Llc | Compositions and methods for modulating a kinase cascade |
US9522873B2 (en) * | 2011-08-05 | 2016-12-20 | Dongguk University Industry-Academic Cooperation Foundation | Biphenyl derivative, pharmaceutically acceptable salt thereof, and methods for preventing or treating inflammatory diseases or autoimmune diseases |
WO2014008214A1 (en) * | 2012-07-02 | 2014-01-09 | Biogen Idec Ma Inc. | Biaryl-containing compounds as inverse agonists of ror-gamma receptors |
US9926273B2 (en) | 2012-08-30 | 2018-03-27 | Athenex, Inc. | Composition and methods for modulating a kinase cascade |
US10106505B2 (en) | 2012-08-30 | 2018-10-23 | Athenex, Inc. | Composition and methods for modulating a kinase cascade |
CN108349875A (en) * | 2015-07-24 | 2018-07-31 | 东国大学校产学协力团 | Compounds with BLT inhibitory activity and include its composition for preventing or treating diseases associated with inflammation as active constituent |
EP3327001A4 (en) * | 2015-07-24 | 2019-02-06 | Dongguk University Industry-Academic Cooperation Foundation | Novel compound having blt inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient |
Also Published As
Publication number | Publication date |
---|---|
EP1745800A4 (en) | 2009-11-18 |
JP4793692B2 (en) | 2011-10-12 |
JPWO2005102388A1 (en) | 2008-03-06 |
WO2005102388A1 (en) | 2005-11-03 |
US8673889B2 (en) | 2014-03-18 |
US20080132574A1 (en) | 2008-06-05 |
EP2172222A2 (en) | 2010-04-07 |
EP2172222A3 (en) | 2010-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8673889B2 (en) | BLT2-mediated disease, BLT2 binding agent and the compound | |
EP2371811B1 (en) | Azetidinecarboxylic acid derivative and medicinal use thereof | |
US8653305B2 (en) | Compound having S1P receptor binding potency and use thereof | |
US7300917B2 (en) | Remedy for chronic disease | |
JP4792974B2 (en) | Azetidine ring compound and pharmaceuticals thereof | |
JPWO2005012221A1 (en) | Diphenyl ether compound, its production method and use | |
US20110052612A1 (en) | Spiropiperidine compound and medicinal use thereof | |
EP1616862A1 (en) | Nitrogenous heterocyclic compound and use thereof | |
RU2433121C2 (en) | Derivative of aminocarbon acid and application of said substances for medical purposes | |
JP2005132761A (en) | Nitrogen-containing heterocyclic compound and it use | |
JP2007015927A (en) | Heterocyclic bicyclo ring compound and heterocyclic tricyclo ring compound and medicine comprising the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20061026 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20091021 |
|
17Q | First examination report despatched |
Effective date: 20100217 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20111101 |